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Preface to ”Pleiotropic Action of Selenium in the
Prevention and Treatment of Cancer, and 
Related Diseases”
In recent years, proof of concept of the efficacy of biologically targeted therapies has been 
documented in several cancer types. Treatment-associated innate and/or acquired resistance, and 
dose-limiting toxicity and cost for chemo, radio, and target-directed therapies continue to represent 
major clinical challenges. Our advanced understanding of the molecular, immunological, and 
biological heterogeneity of tumor cells and their adjacent microenvironment has provided the 
opportunity for the development of new molecules that target commonly altered biomarkers that 
control tumor growth and angiogenesis. Selenium is a cheap natural product that exists in multiple 
forms and is expressed in differential metabolic actions, playing an important role in healthcare 
and maintenance. Dependent on the selenium types, dose, and schedule, selenium modulates 
target biomarkers associated with angiogenesis, drug resistance, and immune responses. Various 
forms of selenium-containing molecules have been extensively evaluated in clinical prevention trials. 
The potential use of specific types, dose, and schedule of selenium-containing molecules as a selective 
modulator of in vivo drug response in preclinical and clinical models has been introduced in recent 
years. The preclinical data generated indicate that to achieve an optimal therapeutic benefit, selenium 
must be sequentially combined with chemo and biologically targeted therapies. Thus, the dose and 
schedule of a drug modulator such as selenium in sequential combination with cytotoxic and biologic 
therapies should be optimized in several well-defined and clinically relevant preclinical models. 
The optimal therapeutic conditions documented in preclinical models should provide the basis for 
the design of future clinical trials. With the knowledge that hypoxia-inducible factors and specific 
microRNAs are altered in tumor cells and that their adjacent microenvironment are selenium targets, 
proof of concept should be carried out in tumors to significantly express the designated targets and 
to verify that the modulation of these targets would indeed predict treatment outcome.
It has been a privilege for me to assemble contributions from outstanding authors highlighting 
the therapeutic potential of selenium in cancer therapy. I must thank my collaborators, who were 
instrumental in the preclinical and clinical development of selenium, as without them, the progress 
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Abstract: Redox active selenium (Se) compounds have gained substantial attention in the last decade
as potential cancer therapeutic agents. Several Se compounds have shown high selectivity and
sensitivity against malignant cells. The cytotoxic effects are exerted by their biologically active
metabolites, with methylselenol (CH3SeH) being one of the key executors. In search of novel
CH3SeH precursors, we previously synthesized a series of methylselenoesters that were active
(GI50 < 10 μM at 72 h) against a panel of cancer cell lines. Herein, we refined the mechanism of action
of the two lead compounds with the additional synthesis of new analogs (ethyl, pentyl, and benzyl
derivatives). A novel mechanism for the programmed cell death mechanism for Se-compounds
was identified. Both methylseleninic acid and the novel CH3SeH precursors induced entosis by cell
detachment through downregulation of cell division control protein 42 homolog (CDC42) and its
downstream effector β1-integrin (CD29). To our knowledge, this is the first time that Se compounds
have been reported to induce this type of cell death and is of importance in the characterization of
the anticancerogenic properties of these compounds.
Keywords: selenium; methylselenoesters; entosis; anticancer agent
1. Introduction
Pancreatic ductal adenocarcinoma is an extremely aggressive neoplasm and one of the cancers
with the poorest prognosis, with a five-year survival of only 8% [1]. In addition, it is predicted to
become the second leading cause of cancer-related death by 2030 [2]. Late diagnosis in advanced cancer
stages due to a lack of prior symptomatology and the poor efficiency of actual therapeutics are the
main causes. Drug resistance in pancreatic cancer is largely caused by an active stroma contributing to
tumor progression [3]. Therefore, developing new therapeutic strategies has become an urgent need.
Modulation of redox homeostasis in cancer cells has emerged as a new opportunity for tumor
intervention. Induction of reactive oxygen species (ROS) by these compounds may affect all the
redox dependent pathways in the cell, which can be detrimental to cells. Antioxidant enzymes are
often induced to eliminate elevated ROS production. Due to metabolic transformation, cancer cells
have an increased and maximized antioxidant capacity in order to evade the ROS-induced cell death.
For instance, the expression of mutant oncogenic KrasG12D is commonly present in pancreatic ductal
adenocarcinoma (PDAC), resulting in an elevated basal state of the transcription factor, nuclear factor
E2-related factor 2 (NRF2) to mount an antioxidant response [4,5]. Therefore, even a slight additional
Int. J. Mol. Sci. 2018, 19, 2849; doi:10.3390/ijms19102849 www.mdpi.com/journal/ijms1
Int. J. Mol. Sci. 2018, 19, 2849
ROS induction, using redox modulators, would lead to the killing of cancer cells [6,7], and provides
an interesting therapeutic approach that has been established as a means of successful anti-cancer
therapy [8–11].
Redox modulating selenium (Se) compounds have gained substantial attention in the last decade
as potential cancer therapeutic agents [12]. Several Se compounds have shown high selectivity and
sensitivity in malignant cells [13]. Depending on the compound use, they have been reported to induce
different types of cell death, including apoptosis, autophagy, necrosis, or necroptosis.
Importantly, along with their active metabolites that execute their biological activity, the dosage
and chemical form of Se compounds highly determine their efficacy [12]. Methylselenol (CH3SeH)
is considered a key metabolite in the anticancer activity of Se compounds. However, the in situ
production or alternatively, the use of precursors, is required due to the high reactivity and volatility
of this molecule.
In search of novel CH3SeH precursors, we previously synthesized a series of methylselenoesters
that were active (GI50 < 10 μM at 72 h) against a panel of cancer cell lines [14]. Herein, we studied
the mechanism of action of the two lead compounds with the additional synthesis of new analogs
(ethyl, pentyl, and benzyl derivatives) (Figure 1). This study uncovers a novel cell death mechanism
for these Se-compounds as entosis inducers. Entosis was first described under anchorage-independent
conditions and the loss of β1-integrin (CD29) signaling [15]. However, it has also been described
in adherent cells [16–18] and recently, aberrant mitosis [16] and glucose deprivation [19] have been
identified as other possible triggers.
During entosis, the stiffer cell (hereafter target cell) actively participates in its own internalization,
via adherent junctions and the actin cytoskeleton that play a pivotal role in this process. Ultimately,
the target cell is killed through lysosomal enzyme-mediated degradation, using the autophagy
machinery, but independent of autophagosome formation [20]. The death subroutine might swift to
apoptosis in the absence of autophagy-dependent nutrient recycling, or eventually, the internalized
cell might divide or be released [21].
Methylseleninic acid (MSA) and the novel CH3SeH precursors induce cell detachment through
downregulation of cell division control protein 42 homolog (CDC42) and its downstream effector
CD29 [22]. Cell-cell adhesion molecules such as N-cadherin were upregulated after treatment and
facilitated cell clustering, which finally ended with cell-in-cell invasion and the degradation of the
inner cell. To our knowledge, this is the first time that Se compounds have been reported to induce
this type of cell death.
Figure 1. Chemical structures of the compounds. MSA, and compounds 1 and 2 were the primary focus
of this study, whereas remaining compounds were used for comparative analysis in some experiments.
MSA: methylseleninic acid; R: substituent; BznSeH: benzeneselenol; MeSeCys: methylselenocysteine.
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2. Results
2.1. MSA, and Compounds 1 and 2 Reduce Panc-1 Cell Viability Both in 2D and 3D Cultures
Initial characterization of the compounds was performed through viability assays in 2D and 3D
cultures of Panc-1 cells, given that 3D cultures have been demonstrated to mimic tumor behavior
more efficiently than traditional monolayer (2D) cultures. Panc-1 cells were treated with increasing
concentrations of MSA, and compounds 1 or 2 for 72 h. Cell viability was then determined. All three
compounds were cytotoxic, with compound 2 being the most potent compound in 2D cultures.
The compounds had IC50 values in the low micromolar range in 2D cultures (2.28, 3.31, and 1.43 μM
for MSA, and compounds 1 and 2, respectively). However, cells grown as spheroids (3D) were
consistent with previously reported data [23], and more resistant and higher doses of the compounds
were required to reduce cell proliferation and induce cell death (Figure 2A,B).
To further study the induced cell death in 3D cultures, spheroids were stained with Hoechst
and propidium iodide (PI) after 72 h treatment. While Hoechst stains the nucleus of all cells, PI only
penetrates and stains damaged membranes of dying cells. As shown in Figure 2C, the three compounds
were not only able to induce cell death, but the cell death was observed in the core of the spheroid,
suggesting that these compounds were able to reach to the core of the sphere.
The selenoester entity could be easily hydrolyzed by a nucleophile such as water, rendering the
corresponding carboxylic acids and releasing CH3SeH, which is believed to be a key molecule in Se
activity (Figure 2D). To exclude the possibility that the toxicity was from the linked moieties, the analog
carboxylic acids of compounds 1 (1’) and 2 (2’) were selectively tested as a proof-of-concept. As seen
in Figure 2E, they did not induce any cell death compared to the Se-containing molecules.
Figure 2. Cont.
3
Int. J. Mol. Sci. 2018, 19, 2849
Figure 2. Compounds 1 and 2 and MSA decrease cell viability in 2D and 3D Panc-1 cultures. (A) Panc-1
cells (2D cultures) were treated with different concentrations of the compounds for 72 h followed by
the determination of cell viability by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide) assay. Results represent mean ± SEM of at least three independent experiments performed
in quadruplicate. (B) Panc-1 spheroids (3D cultures) were treated with different concentrations of the
compounds for 72 h, after which cell viability was determined using the acid phosphatase (APH) assay.
Results represent mean ± SEM of at least three independent experiments performed in quadruplicate.
(C) Representative confocal images of Panc-1 spheroids stained with Hoechst 33342 and PI after 72 h
treatment with 7.5 μM and 25 μM of respective compounds. 10× objective magnification images were
acquired from the Operetta® High-Content Imaging System and processed by Colombus™ analysis
software. The adjacent graph represents a quantitative analysis of PI/Hoechst fluorescence. Results
represent mean ± SEM (n = 4). (D) Potential hydrolysis reaction of compounds 1 and 2. (E) 2D
cell viability after treatment with the corresponding carboxylic acid for 72 h. Statistical significance
compared to control: * p < 0.05, *** p < 0.001.
2.2. MSA, and Compounds 1 and 2 Induce Cell Detachment and Compromise Reattachment Abilities by
Promoting an Aberrant Adhesive Repertoire
In order to study the early effects of this particular cell death, a concentration of 5 μM of respective
compounds was chosen for further experiments in 2D cultures. Post 6 h treatment of Panc-1 cells,
morphological changes like rounding of the cells and cellular detachment from culture flasks were
observed. At 24 h, almost all the cells were detached, had acquired a refringent morphology, and
were grouped in a grape-like manner (Figure 3A). Trypan blue exclusion, however, indicated that
the floating cells were still alive at that particular time point (Figure 3B). To examine if the aberrant
cellular detachment was irreversible, an adhesion assay was performed wherein the floating cells
were washed to remove traces of the compounds and reseeded in fresh medium. The cells were then
allowed to reattach to culture flasks for 3 h. Nevertheless, their reattachment abilities after treatment
were observed to be compromised, with a clear loss of ability to re-adhere, especially in the case of
compound 2 (Figure 3C).
As a next step, the effect of respective compounds on different cellular adhesion markers was
analyzed. Post 24 h treatment, the expression of CD29, known to mediate adhesion to the extracellular
matrix [24], was significantly reduced, as observed after flow cytometry analysis (Figure 3D), explaining
the loss of cellular adhesion caused by these compounds. Moreover, the expression of N-cadherin,
a cell-cell adhesion marker [25], showed a considerable increase after treatment with respective
compounds, which explains the observed grape-like cellular clumping after detachment (Figure 3D).
In order to assess the fate of the detached cells, i.e., if they were able to recover or eventually go
into the cell death mode, a clonogenic assay was performed. As illustrated in Figure 3E, post 24 h
treatment with respective compounds, the cells displayed a significant decrease in colony formation
compared to the control.
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Figure 3. Compounds 1 and 2 and MSA induce loss of cellular adhesion prior to cell death and impair
the colony forming ability. Panc-1 cells were treated with 5 μM of MSA, or compounds 1 or 2 for
24 h. (A) Representative phase-contrast images of treatment-induced cell detachment with respective
compounds. (B) The viability of the floating cells was assessed using a trypan blue exclusion assay.
(C) Adhesion assay. After 24 h of treatment with respective compounds, the non-adherent but viable
cells, were collected and an adhesion assay was performed for 3 h, following which the adherent
cells were stained with Coomassie Brilliant Blue. Representative phase-contrast microscopic images
and graphical representation of percentage of non-adherent cells reattaching the tissue culture treated
plates. Error bars indicate mean ± SEM of three biological replicates. (D) The expression levels of
adhesion proteins, CD29, and N-Cadherin, post 24 h treatment with respective compounds as analyzed
by flow cytometry and its graphical representation. Error bars indicate mean ± SEM of three biological
replicates. (E) Clonogenic assay. Post 24 h treatment, with respective compounds, the non-adherent
cells were collected and re-seeded in 24 well plates to check for the colony forming ability of these
cells. Reduced colony forming ability indicates cell death. Error bars indicate mean ± SEM of three
biological replicates. Statistical significance as compared to control * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.3. MSA, Compounds 1 and 2 Induce Entosis.
Two well described cell death pathways that have been reported to be initiated by the loss of
cell adhesion are anoikis and entosis. Whereas anoikis is triggered exclusively upon adhesion loss
and is coursed through caspase activation, entosis is characterized by active cell invasion, leading
to endophagocytosis and the formation of cell-in-cell structures, and has been described both in
suspension and adherent cells.
To distinguish the programmed cell death mode, we analyzed the expression of total poly
(ADP-ribose) polymerase 1 (PARP) and cleaved PARP, wherein MSA and compounds 1 and 2 slightly
increased the 89 kD cleaved fragment at 72 h (Supplementary Figure S1A). PARP has been reported to
be cleaved by caspases, cathepsins, and calpains [26–29]. In order to rule out the possibility of apoptosis,
the expression of caspase 9 and cleaved caspase 9 (upstream marker for apoptosis) was analyzed after
48 h treatment with these compounds. We observed no expression of cleaved caspase 9, suggesting
that no activation of the caspase cascade was induced (Supplementary Figure S1A). Additionally,
cells were treated with the broad pancaspase inhibitor z-VAD-fmk, along with respective compounds.
Treatment with z-VAD-fmk did not prevent the cellular detachment, as well as cell death, induced
by these compounds, as observed by brightfield microscopy and the trypan blue exclusion assay,
respectively (Supplementary Figure S1B,C), suggesting a caspase-independent mechanism.
Furthermore, the expression of cathepsins, a structurally and catalytically distinguished class
of proteases, was checked. A context-depending role has been described for cathepsins, with either
tumor-promoting or suppressing activities. They have not only been reported to function as apoptotic
mediators, but also to be related to entosis [15] and cell cannibalism [30].
Both cathepsin B (CatB) and cathepsin D (CatD) have been reported to play an important
role in entosis [15,20,31]. Increased expression of CatB was observed, indicating that lysosomal
degradation is implied in cell death induced by these compounds. Unexpectedly, CatD levels were
downregulated (Figure 4A). Another family with a prominent role in entosis is the Rho family of
GTPases, master regulators of the actin cytoskeleton. Therefore, the protein levels of CDC42 and
RhoA were determined. Whereas CDC42 levels were decreased, RhoA levels remained unchanged
(Figure 4A). To further confirm entosis, cell fate was tracked once detached. Cells were labeled with
green or red fluorescent dyes, seeded, and treated with the compounds. Visualization by confocal
microscopy revealed cell-in-cell internalization (Figure 4B). A time-lapse experiment also recorded
live confirmed morphological changes during the formation of cell-in-cell structures and the ultimate
degradation of the target cell (Supplementary videos 1–3).
Figure 4. Cont.
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Figure 4. MSA, and compounds 1 and compound 2 induce entosis in Panc-1 cells. (A) Western blot
analyses of Cathepsin B, Cathepsin D, CDC42, and Rho A upon treatment with MSA or compound 1
or compound 2 for 24 h. Beta actin was used as a loading control. The corresponding graphs display
a quantitative analysis of western blots performed using the ImageJ program and GraphPad Prism
software. Error bars indicate mean ± SEM of three biological replicates. (B) Panc-1 cells stained with
CellTracker Red or Green and further mixed (1:1) were treated with MSA or compound 1 or compound
2 for 18 h, followed by live imaging using a confocal microscope, Zeiss LSM800. The arrows indicate
cell-in-cell formations i.e., cells undergoing entosis. Statistical significance as compared to control
* p < 0.05, ** p < 0.01, *** p < 0.001.
2.4. Cell Detachment Is Not Restricted to Selenomethylated Compounds and Does Not Correlate with the
Cytotoxic Potential of the Compound
In order to distinguish the type of Se compound that could cause this phenomenon, other
commercial Se derivatives together with other newly synthesized analogs of compounds 1 and 2 were
analyzed. To evaluate if this effect was exclusive to methylated forms of Se or unrestricted to other alkyl
or aromatic derivatives, the ethyl derivative for compounds 1 and 2 (1a and 2a, respectively), the pentyl
derivative for compound 1 (1b), and the benzyl analog for compound 2 (2c), were synthesized to cover
different alkyl lengths and additional substituents. Methylselenocysteine (MeSeCys) was also selected
as another CH3SeH precursor and benzeneselenol (BznSeH) as an additional aromatic selenol for a
comparative analysis. In addition, compound 3 was chosen, a previously synthesized selenide in our
laboratory, as a proof-of-concept compound without a labile bond between the core of the molecule
and the methylseleno residue [32], and therefore less prone to release it (Figure 1).
First, cell proliferation and cell death were evaluated. As illustrated in Figure 5A, all the
compounds were able to reduce cell proliferation. However, a longer chain or the substitution with a
benzyl residue impaired the cytostatic activity of the compounds. In general trends, and considering
the 72 h time point, the potency to reduce proliferation decreased according to the following order:
methyl > ethyl > pentyl or benzyl. Compound 2a stopped proliferation at 24 h, while the methylated
7
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analog (2) achieved a reduction at 72 h. BznSeH and compound 3 had the highest cytostatic potential,
with both of them inhibiting proliferation at 24 h of treatment.
Figure 5. Evaluation of the antiproliferative, cytotoxic, and de-adhesive properties of other Se
analogs. Cells were seeded and incubated for 24 h before starting treatments with the compounds.
Cell proliferation (A) and cell death based on Trypan blue exclusion (B) were analyzed after treatment
with a 5 μM dose. For MeSeCys, a 700 μM dose was used. For BznSeH and compound 2a, inducing
a floating and attached population, proliferation, and cell death were calculated without taking
into account the two populations in this case. (C) Cell detachment quantification after treatment.
(D) Procedure scheme to evaluate the attached and floating population. Floating cells were collected
with a pipette and remaining cells were considered as attached and slightly scrapped. (E) Cell death
comparison in the floating and adherent populations induced by compound 2a and BznSeH.
The methyl derivatives were more cytotoxic at 72 h than analogs with a longer alkyl chain or the
benzyl moiety (Figure 5B). Almost all the compounds showed similar activity at 24 and 48 h, with the
8
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exception of compound 1b, which was not cytotoxic. BznSeH, which was highly cytostatic, did not
induce noteworthy cell death, with only 15% of dead cells at 72 h. MeSeCys, which has been reported to
have a similar activity to MSA in vivo, required a considerably higher concentration to achieve similar
cell death induction in vitro, due to the need of metabolic processing to release CH3SeH, consistent
with previous reports [33]. Compound 3, on the other hand, was the most potent compound, inducing
cell death at 24 h treatment.
In addition to cell proliferation and cell death, the ability of the compounds to induce cell
detachment, and ultimately the same cell death mechanism as the methyl analogs, was analyzed. Most
of the compounds completely detached the cells or completely remained ineffective, as illustrated
in Figure 5C. However, some compounds induced two populations, and in this case, the procedure
schematized in Figure 5D was followed. Compounds 1a and 1b were unable to detach cells. whereas
compounds 2c and 3 had detached all the cells at 24 h. MeSeCys detached all the cells at 72 h, and a
concomitant increase in cell death was observed at that time point. However, cell detachment potential
was not correlated with cell death induction in the case of compound 2c, which was almost innocuous.
BznSeH and compound 2a induced mixed populations, with attached and floating cell fractions.
(Figure 5D,E). Nevertheless, they had considerably less detachment potential than the methylated
analogs, with only 16 and 24% of detached cells at 72 h, respectively.
3. Discussion
In this study, we demonstrate that MSA and two novel methylselenoesters induce entosis after
provoking cell detachment in Panc-1 cells, revealing a new and unexplored cell death mechanism for
Se compounds.
Compounds 1 and 2 and MSA reduced cell proliferation in both 2D and 3D cultures. Treatment
with the compounds led to a unique phenotype, characterized by changes in morphology and
cell detachment from the culture plate prior to cell death. Detached cells were alive at 24 h,
but their reattachment capability and the colony forming ability had been dramatically compromised.
We dismissed the possibility that the compounds were promoting anchorage-independent survival,
and instead induced cellular death, as confirmed by the MTT assay and the expression of cleaved
PARP in 2D cultures and PI staining in 3D spheroids.
Cell adhesion is gaining more attention due to its implication in cancer metastasis and progression,
in addition to drug resistance. Importantly, these results are in accordance with recent investigations
revealing that MSA targeted adhesion molecules in a leukemic cancer cell line, whereas inorganic
selenite affected other gene sets, indicating an interesting type-dependent effect of Se compounds [34].
To further confirm the compound-induced adhesion disturbance, levels of different adhesion molecules
were screened 24 h after treatment. We found that the expression of CD29 was significantly reduced.
This integrin has been linked to gemcitabine resistance and a poor outcome in pancreatic cancer [35].
Moreover, its knockdown has been reported to inhibit cell adhesion, migration, proliferation, and
metastasis of pancreatic cancer, unveiling CD29 as a potential therapeutic target [36].
The loss of CD29 signaling and consequent detachment from culture plate trigger entosis [16].
Entosis is primarily the engulfment of one live cell into another live cell. In our study, the detached
cells post 24 h treatment were observed to be viable. Also, the formation of adherent junctions has
been shown to be crucial for entosis initiation [15]. This kind of cell-cell contacts are mediated though
cadherins, which are calcium-dependent molecules that play central roles in cancer progression.
We found increased N-cadherin levels, which could explain cell clumping after detachment and the
ultimate invasion of one cell into another. Although E-cadherin usually forms adherens junctions
in epithelial cells, the coexpression of E- and N-cadherin has been reported in adherens junctions of
endoderm-derived epithelial tissues and tumors, such as pancreatic ducts [37]. In addition, Panc-1 cells
express very low basal levels of E-cadherin and, according to Cano et al. [38], it cannot be discarded
that pancreatic homotypic cell-in-cell formation might rely on N-cadherin-mediated cell contacts.
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Although N-cadherin is usually linked to a more aggressive phenotype, it has been reported as a tumor
suppressor in some types of cancers [39,40].
In addition, an upstream regulator of CD29 [22] and member of the Rho family of GTPases,
CDC42, was also observed to be downregulated after treatment. CDC42 is overexpressed by 21%
in pancreatic cancer [41] and the depletion of CDC42 enhances mitotic deadhesion and depends on
Rho A activation in human bronchial epithelial cells [16]. Although it plays a crucial role in adherent
entosis, it was reported to have no effect on suspension cells [16]. Consequently, treatment with the Se
compounds affects CDC42 expression and mediates cell detachment through CD29 regulation.
Entotic cells mainly die through lysosomal-dependent pathways, although a swift to apoptosis
can occur. In a floating population, different types of cell death have been reported to coexist [42].
Herein, we found that cell death induced by these Se compounds was caspase-independent,
with a slight increase in PARP cleavage. We found increased levels of CatB in cell-in-cell structures
undergoing entotic death, in concordance with previous reports [15]. By contrast, CatD, an interplayer
between autophagy and apoptosis, was clearly downregulated. CatD can function as an anti-apoptotic
mediator by increasing autophagy, revealing its two-faceted role [43]. In addition, CatD enhances
anchorage-independent cell proliferation [44], and it is therefore quite interesting that it becomes
down-regulated by compounds inducing cell detachment. Although cathepsins can mediate apoptosis,
high levels of cathepsins have also been related to cancer progression. Pancreatic cancer patients,
for instance, display a higher CatD concentration than healthy controls [45], and besides, elevated
levels have been shown to promote cell dissemination in pancreatic cancer in vivo [46].
Cell detachment could be caused by CH3SeH, one of the key metabolites in Se cytotoxicity, which
has been reported to cause cell detachment in different cancer cell lines [47,48], along with a decrease
in CD29 expression [48]. MSA is a penultimate precursor and compounds 1 and 2 bear this moiety.
However, we ruled out that this effect was exclusive to the methylated form of Se, given that other
compounds were able to induce the same phenotype. Lengthening the alkyl chain or the substitution
over an arylselenol in general dramatically decreased the percentage of detached cells. However,
the substitution of methyl for benzyl (compound 2c) induced similar deadhesive effects. Intriguingly,
despite induced cell detachment by this compound, it did not lead to cell death. The decreased
cytotoxic effects are consistent with previous reports, showing the impaired cytotoxic activity of
selenobenzyl derivatives with respect to their corresponding methylated analogs [49]. Hence, it is
clear that detachment per se does not trigger death signaling, and it will be interesting to investigate
the additional signaling pathways that the methyl and benzylseleno moieties are differentially able to
activate, in order to avoid anchorange-independent cell growth.
In summary, we report a novel mechanism of action for MSA and two methylselenoesters:
the induction of cell detachment through CDC42 and CD29 down-regulation leading to cell-in-cell
formation (entosis) and death of the inner cell. However, these compounds need to be further
evaluated in in vivo studies to gain an in-depth insight into their administration, hepatic metabolism
for bioavailability and absorption, distribution, metabolism, and excretion properties. Additionally,
the therapeutic potential of these compounds would be governed by the balance between their
toxicity and efficacy profiles. Therefore, further research to fully dissect the relationship between
structure, detachment abilities, and cell death induction of organic Se derivatives is required in order
to understand the complex Se biochemistry.
4. Materials and Methods
4.1. Cell Culture
Panc-1 cells were obtained from the American Type Culture Collection (ATCC) and cultured in
DMEM:F12 (Gibco™, ThermoFisher Scientific, Paisley, Scotland), 10% FBS (HyClone™, GE Healthcare
Life Sciences, Logan, UT, USA), and 1% glutamine (Gibco) at 37 ◦C under 5% CO2. The 3D spheroids
were cultured following the protocol described by Longati et al. [23]. Briefly, phenol red-free
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DMEM:F12 (Gibco™, ThermoFisher Scientific, Paisley, Scotland), 10% FBS (HyClone™, GE Healthcare
Life Sciences, Logan, UT, USA), and 0.24% methylcellulose were used. On day 0, 2500 Panc-1 cells in
50 μL volume were seeded in a low adherent 96-well round bottom microplate (Falcon™, ThermoFisher
Scientific, Stockholm, Sweden). On day 4, treatments were added, diluted in 50 μL of medium.
4.2. 2D Viability Assay
Cell viability after treatment was assessed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma Aldrich®, Stockholm, Sweden) assay. 6000 Panc-1 cells were
seeded in 96-well plates. Cells were treated with increasing concentrations of the compounds. Dilutions
of the compounds in cell medium were freshly prepared from a 0.01 M stock in DMSO. After 72 h
treatment, 50 μL of MTT solution in PBS (2 mg/mL) was added and cells were incubated at 37 ◦C under
5% CO2 for 4 h. Medium was removed and 150 μL of DMSO was added to dissolve the formazan
crystals. Absorbance was read at 590 nm in a VersaMax microplate reader (Molecular Devices, San Jose,
CA, USA). Viability is expressed as the percentage of untreated cells.
4.3. 3D Viability Assay
3D viability after 72 h treatment was analyzed with the acid phosphatase assay, following a
previously described protocol [23]. Briefly, 70 μL of medium was carefully removed and 60 μL of
PBS along with 100 μL APH buffer (1.5 M sodium acetate pH = 5.2, 0.1% TritonX-100) containing a
final concentration of freshly prepared 2 mg/mL p-nitrophenyl phosphate were added. Cells were
incubated for 5 h at 37 ◦C under 5% CO2 and then 10 μL of NaOH 1M was added to stop the reaction.
Absorbance was read at 405 nm in a VersaMax microplate reader (Molecular Devices, San Jose, CA,
USA). Viability is expressed as the percentage of untreated cells.
4.4. Fluorescent Staining
Spheroid formation was developed in a Gravity TrapTM ULA plate (InSphero Europe GmbH,
Waldshut, Germany), following the manufacturer’s protocols. Briefly, on day 0, the plate was
pre-wetted with 40 μL of medium before seeding 2000 Panc-1 cells in 75 μL phenol red-free DMEM:F12,
10% FBS, and 1% glutamine. The plate was centrifuged for 2 min at 250× g. On day 4, cells were
treated, adding 25 μL of the corresponding compound in medium. Dilutions were freshly prepared
from a 0.1 M DMSO stock. On day 7, cells were stained with 1 μM Hoechst 33342 (Molecular Probes®,
Life Technologies™, Eugene, OR, USA) for 2 h, and 2 μM PI (Molecular Probes®, Life Technologies™,
Eugene, OR, USA) for 1 h at 37 ◦C under 5% CO2. Spheroids were then carefully washed once with PBS
and fixed with paraformaldehyde (4%) at RT. Imaging was performed on the Operetta® High-content
Imaging System (PerkinElmer, San Jose, CA, USA) (confocal mode, 10× objective magnification,
0.3 objective NA, 35 μm focus height) and processed by the Colombus™ (PerkinElmer, San Jose, CA,
USA) analysis software.
4.5. Western Blotting
Protein lysate containing 20 μg of proteins was separated on a Bolt 4–12% Bis-Tris Gel (NovexTM,
ThermoFisher Scientific, Goteborg, Sweden) and transferred to a nitrocellulose membrane using the iBlot
Gel Transfer Device (ThermoFisher Scientific, Goteborg, Sweden). Incubation with primary antibody
(Cathepsin B (D1C7Y), Cell Signaling, Leiden, The Netherlands, Catalog no. 31718; Cathepsin D,
BD Biosciences, San Jose, CA, USA, Catalog no. 610800; CDC42, Abcam, Cambridge, UK, Catalog
no. ab155940; RhoA (67B89), Cell Signaling, Leiden, The Netherlands, Catalog no. 2117; PARP, Cell
Signaling, Leiden, The Netherlands, Catalog no. 9542; Caspase 9, Bioss, Nordic BioSite, Stockholm,
Sweden, Catalog no. bs-0049R; beta actin, Sigma-Aldrich, Stockholm, Sweden, Catalog no. A5441)
diluted in TBST containing 3.5% bovine serum albumin (BSA) was done overnight at 4 ◦C. Secondary
antibodies, goat anti-rabbit IgG HRP (Southern Biotech, Stockholm, Sweden Catalog no. 4030-05), or goat
anti mouse IgG HRP (Southern Biotech, Stockholm, Sweden Catalog no. 1030-05) were incubated for 1 h.
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Membranes were developed using the AmershamTM ECLTM Start Western Blotting Detection Reagent
(GE Healthcare Life Sciences, Logan, UT, USA) and bands were visualized using the Bio-Rad Quantity
One imaging system (Bio-Rad, Stockholm, Sweden). Images were quantified using ImageJ software.
4.6. Adhesion Assay
0.5 × 106 cells were seeded in 25 cm2 flasks and incubated at 37 ◦C under 5% CO2 24 h. Media
was changed and cells were treated with 5 μM of compounds, after which floating cells were collected,
centrifuged, and seeded at a density of 40,000 cells in 400 μL of fresh medium/well in a 24-well plate.
The control cells were scrapped and seeded at the same density in 24-well plates. The cells were
allowed to adhere to the surface of the plates. Cells were incubated at 37 ◦C, 5% CO2 for 3 h, when
95% of the control cells adhered to the plate, after which they were fixed using 4% paraformaldehyde
(PFA). The cells were further stained with 200 μL Coomassie blue staining solution (0.2% Coomassie
Blue Brilliant R-250, 10% Acetic Acid and 40% Methanol) for 1 h at room temperature. The cells
were then washed with PBS and further incubated for 1 h with 0.5 mL elution buffer (0.1 N NaOH
and 50% Methanol). Furthermore, 0.5 mL of developing solution containing 10% Trichloroacetic
acid (TCA) was added into the wells. Following this, 200 μL of the mix was transferred to a 96-well
plate and further absorbance was read at 595 nm using the plate reader Infinite® M200 Pro, Tecan,
Mannedorf, Switzerland.
4.7. Flow Cytometry
0.5 × 106 cells were seeded in 25 cm2 flasks and allowed to attach for 24 h. After that, medium was
replaced and cells were treated with the corresponding compounds or vehicle (DMSO) for 24 h. Cells
were collected, washed with PBS-staining buffer (1% BSA, 0.01% NaN3, 1% FBS), and stained for 30 min
at 4 ◦C and darkness in 50 μL PBS-staining buffer with the corresponding antibody: CD29/integrin
1-β (FITC conjugate, clone MEM-101A, Life Technologies, Eugene, OR, USA), CD325/N-cadherin
(PE conjugate, clone 8C11, Life Technologies, Eugene, OR, USA). Cells were washed once with
PBS-staining buffer and resuspended in fixation buffer (PBS, 1% paraformaldehyde, 2% FBS) until
being read in a BD FACSCalibur™ (BD Biosciences, San Jose, CA, USA).
4.8. Clonogenic Assay
0.5 × 106 cells were seeded in 25 cm2 flasks and incubated at 37 ◦C under 5% CO2 for 24 h.
Media was changed and cells were treated with 5 μM of compounds for 24 h, after which floating
cells were collected, centrifuged, and seeded at a density of 1000 cells in total volume of 2 mL/well
in a six-well plate. The control cells were checked for colony formation for five days. A group of
50 cells were considered as one colony. The plates were later stained with crystal violet according to
Franken et al. [50].
4.9. Chemical Synthesis
The NMR spectra (1H and 13C) were recorded on a Bruker 400 UltrashieldTM spectrometer
(Rheinstetten, Germany) and are provided in the supplementary material. The samples were solved
in CDCl3 and TMS was used as an internal standard. IR spectra were obtained on a Thermo Nicolet
FT-IR Nexus spectrophotometer (Thermo Nicolet, Madison, WI, USA) using KBr pellets for solids
or NaCl plates for oil compounds. The HRMS spectra were recorded on a Thermo Scientific Q
Exactive Focus mass spectrometer (Thermo Scientific™, Waltham, MA, USA) by direct infusion. For
TLC assays, Alugram SIL G7UV254 sheets (Macherey-Nagel; Düren, Germany) were used. Column
chromatography was performed with silica gel 60 (E. Merck KGaA, Darmstadt, Germany). Chemicals
were purchased from E. Merck KGaA (Darmstadt, Germany), Panreac Química S.A. (Montcada i
Reixac, Barcelona, Spain), Sigma-Aldrich Quimica, S.A. (Alcobendas, Madrid, Spain), and Acros
Organics (Janssen Pharmaceuticalaan, Geel, Belgium).
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4.9.1. Procedure for Compounds 1 and 2
Compounds 1 and 2 were synthesized as described in our previous work [14], under the references
5 and 15, respectively.
Procedure for Compounds 1a, 2a, 1b and 2c
The chemical synthesis was carried out following an already described procedure [51,52] with
some modifications. Briefly, the corresponding carboxylic acid was chlorinated by a reaction with
SOCl2. Se powder reacted with NaBH4 (1:2) in water or ethanol (1:1) and N2 atmosphere to form
NaHSe. The corresponding acyl chloride dissolved in N,N-dimethylformamide (2 mL) or chloroform
(2 mL) was then added and the reaction was stirred at room temperature until the reaction took place
(20 min–3.5 h). The reaction was followed by IR or TLC. The mixture was filtered and the intermediate
was further alkylated with the corresponding halide until discoloration of the mixture. The product
was extracted with methylene chloride and dried over Na2SO4. The solvent was eliminated under
rotatory evaporation and the residue was purified through column chromatography.
Ethyl 3-Chlorothiophen-2-Carboselenoate (1a)
From 3-chlorothiophen-2-carboxylic acid (1.5 mmol), Se powder (1.5 mmol), NaBH4 (3 mmol),
and ethyl iodide (1.5 mmol). A yellow oil was obtained, which was further purified through column
chromatography using methylene chloride as the eluent. Yield: 11%. 1H NMR (400 MHz, CDCl3):
δ 1.52 (t, 3H, –CH3, JCH3-CH2 = 7.5 Hz), 3.11 (q, 2H, –CH2–), 7.06 (d, 1H, H4 J4-5 = 5.3 Hz), 7.54 ppm
(d, 1H, H5). 13C NMR (100 MHz, CDCl3): δ 15.7 (–CH3), 20.5 (–CH2–), 128.0 (C4), 130.6 (C2), 131.0
(C5), 137.7 (C3), 184.3 ppm (–C=O). IR (KBr): ν 3105 (w, C−Harom), 2962–2867 (s, C−Haliph), 1649 cm−1
(s, −C=O). HRMS calculated for C7H8ClOSSe (M + H): 254.91441, found: 254.91418.
Diethyl 2,5-Furandicarboselenoate (2a)
From 2,5-furandicarboxylic acid (1.74 mmol), Se powder (3.48 mmol), NaBH4 (7.1 mmol),
and ethyl iodide (3.48 mmol). Conditions: 45 min reaction with NaHSe and 2 h reaction with ethyl
iodide. A yellow solid was obtained, which was purified through column chromatography using
ethyl acetate/hexane (1:10) as the eluent. Yield: 10%; m.p.: 35–36 ◦C. 1H NMR (400 MHz, CDCl3):
δ 1.5 (t, 6H, 2–CH3, J CH2-CH3 = 7.5 Hz), 3.11 (q, 4H, –CH2–), 7.17 ppm (s, 2H, H3 + H4). 13C NMR
(100 MHz, CDCl3): δ 15.8 (–CH3), 19.2 (–CH2–), 114.7 (C3 + C4), 153.5 (C2 + C5), 183.5 ppm (–C=O).
IR (KBr): ν 3143 (w, C−Harom), 2961–2860 (s, C−Haliph), 1649 cm−1 (s, −C=O). HRMS calculated for
C10H13O3Se2 (M + H): 340.91896; found: 340.91891.
Pentyl 3-Chlorothiophen-2-Carboselenoate (1b)
From 3-chlorothiophen-2-carboxylic acid (2 mmol), Se powder (2 mmol), NABH4 (2.15 mmol),
and pentyl iodide (2.15 mmol). Under N2 atmosphere, absolute ethanol (10 mL) was added to a
mixture of NaBH4 and selenium cooled by an ice bath, with magnetic stirring. After the formation
of NaHSe was achieved, the ice bath was removed and the following reactions were carried out at
room temperature. Before adding an excess of pentyl iodide, the mixture was filtered. Conditions:
20 min reaction with NaHSe and 20 min reaction with pentyl iodide. The solvent was eliminated under
rotatory evaporation. The product was purified through column chromatography using a gradient
elution of ethyl acetate: hexane. An orange oil was obtained. Yield: 53%. 1H NMR (400 MHz, CDCl3):
δ 0.83 (t, 3H, –CH3, JCH3-CH2 = 7.1 Hz), 1.27–1.35 (m, 4H, γ + δCH2), 1.66–1.77 (m, 2H, ßCH2), 3.02
(t, 2H, αCH2, JCH2-CH2 = 7.4 Hz,), 6.96 (d, 1H, H4, J4-5 = J5-4 = 5.3 Hz), 7.44 ppm (d, 1H, H5). 13C
NMR (100 MHz, CDCl3): δ 12.94 (−CH3), 21.19 (δCH2), 25.56 (αCH2), 28.89 (ßCH2), 31.18 (γCH2),
126.82 (C4), 129.50 (C2), 129.76 (C5), 136.56 (C3), 183.18 ppm (−CO). IR (KBr): ν 2922 −2852 (s, C−Halif),
1669 cm−1 (s, −C=O).
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Dibenzyl 2,5-Furandicarboselenoate (2c)
From 2,5-furandicarboxylic acid (1.74 mmol), Se powder (3.48 mmol), NABH4 (7.1 mmol),
and benzyl bromide (3.48 mmol). Conditions: 1.5 h reaction with NaHSe and 3.5 h reaction with
benzyl bromide. The product was extracted with methylene chloride, further washed with water,
dried over Na2SO4. The solvent was eliminated under rotatory evaporation. A yellow oil was obtained,
which was precipitated and washed with diethyl ether. A yellow solid was obtained. Yield: 25%; m.p.:
114–115 ◦C. 1H NMR (400 MHz, CDCl3): δ 4.34 (s, 4H, 2–CH2–), 7.2 (s, 2H, H3 + H4), 7.22–7.35 ppm (m,
10 H, Harom). 13C NMR (100 MHz, CDCl3): δ 28.5 (–CH2–), 115.0 (C3 + C4), 127.3 (C4’), 128.7 (C2’ + C6’),
129.1(C3′ + C5′ ), 138.21 (C1’), 153.2 (C2 + C5), 182.8 (−C=O). IR (KBr): ν 3123−3088 (s, C−Harom),
1677 cm−1 (s, −C=O). HRMS C20H16O3Se2Na (M + Na+): calculated 486.9322; found 486.9430.
4.9.2. Procedure for Compound 3
Compound 3 was synthesized in a previous work [32], under the reference 3c.
4.10. Timelapse
0.5 × 106 cells were seeded in 25 cm2 flasks and incubated at 37 ◦C under 5% CO2 24 h. Media
was changed and cells were treated with 5 μM of compounds for 24 h, after which floating cells were
collected, centrifuged, and seeded at a density of 50,000 cells in total volume of 100 μL/well in a
96-well plate. Post 48 h of treatment, the cells were imaged live for another 24 h in Operetta and images
were captured every 5 min.
4.11. Confocal
Monolayer cultures were stained with CellTracker Red or Green (Invitrogen) for 1 h at 37 ◦C in
the absence of serum. After this, 0.4 × 105 cells stained with each of the cell trackers were mixed (1:1)
and seeded onto 25 cm2 flasks for 24 h, followed by treatment with 5 μM of respective compounds for
18 h. Cells were imaged live using an LSM 800 confocal microscope (Zeiss, Oberkochen, Germany).
4.12. Statistical Analysis
One-way ANOVA followed by Dunnet’s test was performed using GraphPad 6.01 (GraphPad
Software, San Diego, CA, USA). (* p < 0.05, ** p < 0.01, *** p < 0.001).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/
2849/s1.
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Nrf2 nuclear factor erythroid 2 related factor 2
PDAC Pancreatic ductal adenocarcinoma
PI Propidium iodide
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Se Selenium
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Abstract: Hypoxia, or gradients of hypoxia, occurs in most growing solid tumors and may result in
pleotropic effects contributing significantly to tumor aggressiveness and therapy resistance. Indeed,
the generated hypoxic stress has a strong impact on tumor cell biology. For example, it may contribute
to increasing tumor heterogeneity, help cells gain new functional properties and/or select certain cell
subpopulations, facilitating the emergence of therapeutic resistant cancer clones, including cancer
stem cells coincident with tumor relapse and progression. It controls tumor immunogenicity, immune
plasticity, and promotes the differentiation and expansion of immune-suppressive stromal cells.
In this context, manipulation of the hypoxic microenvironment may be considered for preventing or
reverting the malignant transformation. Here, we review the current knowledge on how hypoxic
stress in tumor microenvironments impacts on tumor heterogeneity, plasticity and resistance, with a
special interest in the impact on immune resistance and tumor immunogenicity.
Keywords: hypoxia; tumor microenvironment; tumor heterogeneity; cancer; cancer stem cells; EMT;
cell plasticity; DNA damage and repair; immune evasion; HIF
1. Introduction
The tumor microenvironment (TME) is a complex system that consists of the extracellular matrix
(ECM) and numerous cell types including fibroblasts, adipose cells, immune cells, endothelial cells as
well as components of the blood and lymphatic vascular networks and the nervous system. TME plays
an important role in tumor development and progression [1–3]. It involves soluble factors and
metabolic changes. Among these metabolic changes, hypoxia plays a pivotal role in shaping the
TME [4,5]. In such a system, hypoxia appears as an essential metabolic element to control cellular
plasticity and tumor heterogeneity [6,7]. It is well established that hypoxic stress is a feature of
most solid tumors and is associated with poor clinical outcomes in various cancer types [2,8–11].
Hypoxia arises due to a combination of excessive oxygen consumption by growing tumor cells and the
disorganized tumor-associated vasculature [3]. Considerable evidence now suggests that hypoxia plays
an important role in tumor progression, affecting both metastatic spread and selection of cells with more
aggressive phenotypes [7,12,13]). This is at least partly explained by the fact that hypoxia can promote
cancer cell stemness, invasion or metastatic capacities via the activation of hypoxic cascades and
hypoxia-inducible factors (HIFs). To date, the mechanisms at play are still far from being understood.
The adaptive responses to hypoxia are regulated by HIFs. The master regulator of the hypoxic response
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is the hypoxia-inducible factor 1 (HIF-1). In mammalian cells, the response to hypoxia depends in large
part on the activation of HIF-1, a heterodimeric transcription factor consisting of a hypoxia-inducible
HIF-1α subunit and a constitutively expressed HIF-1β subunit [14]. HIF-1 transactivates target genes
containing cis acting hypoxia response elements that contain the HIF-1-binding site sequence. HIF-1α
protein levels are tightly regulated by the cellular pO2. Under hypoxic stress, hypoxia-dependent
stabilization of HIF dimers allows for the induction of numerous genes regulating various biological
processes and functions in cells, including angiogenesis, cell survival, proliferation, pH regulation,
and metabolism [4].
2. Hypoxia Induced Tumor Plasticity and Heterogeneity
Tumors contain distinct cell types that collectively create microenvironmental conditions
controlling the tumor growth and its evolution. Insufficient concentration of oxygen in
the growing tumor generates hypoxic stress, which can lead to metabolic, epigenetics and
phenotypic reprogramming of the cells coincident with fluctuations in the composition of the
microenvironment [15,16], while potentially affecting the functions, the phenotype and/or the number
of microenvironmental cell components [5,6]. As a corollary, hypoxia should be considered as a
driver of cell plasticity, since it can promote the capacity of a cell to shift from its original cellular
state to a distinct cellular state. One interesting unanswered question is the impact of hypoxic stress
on tumor heterogeneity. It is well established that tumors exhibit substantial heterogeneity with
potential consequences on their evolution in time and response to treatments [17–20]. So far, the
extent of this heterogeneity has been only partially explored, especially in relation to the diverse
mutational landscapes found in tumors [17]. Clearly, more work is now needed to explore and
define the phenotypic heterogeneity of the various cell types. The advent of single-cell approaches
offers a unique opportunity to gain insights into tumor heterogeneity [21–24]. Recently, using
breast tumors, Azizi and colleagues nicely showed that environmental factors, including hypoxia
present in the tumor, but marginal in the normal tissue, were linked to the increased diversity of
immune phenotypic states of T cells, myeloid cells and Natural killer (NK) cells [23]. Tumor-resident
T cells appeared to be particularly responsive to such regulation, as shown by the increased number
of gene signatures activated in highly hypoxic tumors. The findings also suggest that various
degrees of hypoxia, inflammation, and nutrient supply, or a combination of these factors in the
local microenvironment could lead to a spectrum of phenotypic states while promoting the enrichment
of certain subpopulations such as the Treg subset. The work of Palazon et al. recently revealed the
essential role of HIF-1α in regulating the effector state of CD8+ T cells [25]. Hypoxia stimulated
the production of the cytolytic molecule granzyme B in a HIF-1α- but not HIF-2α-dependent
fashion. Importantly, hypoxia through HIF-1α also increased the expression of activation-related
costimulatory molecules CD137, OX40, and GITR, and checkpoint receptors PD-1, TIM3, and LAG3.
This may have important implications for tumor immunology. Further experimental data from these
investigators already denote the importance of the HIF1/VEGF-A axis to promote vascularization and
T cell infiltration.
Aside from its impact on stromal components, the cell plasticity of cancer cells represents
a major source of phenotypic heterogeneity in the tumor. Here again, HIFs, angiogenesis and
inflammatory factors such as VEGF, or TGF-β (induced and activated under hypoxic conditions),
might exert important regulatory functions. A prime example of this notion comes from the numerous
studies demonstrating that all these factors can stimulate epithelial-mesenchymal transition (EMT)
and/or support a mesenchymal state [13,26,27]. It is also well established that certain cancer
cells have the capacity to transit between epithelial and mesenchymal phenotypes, or states, via
epithelial-mesenchymal transition (EMT), or the reverse process, mesenchymal-epithelial transition
(MET) [26]. In such a scenario, cancer cell plasticity is tightly regulated by signals perceived from
the TME and anatomic sites. Notably, hypoxic stress might enable other types of phenotypic
changes. For instance, HIF-1α and hypoxia could contribute to the neuroendocrine transformation of
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prostate tumors and adenocarcinoma cells through cooperation with the transcription FoxA2, reduced
Notch-mediated signaling, and induction of neuronal and neuroendocrine gene programs in the
cells [28–30]. Despite substantial evidence for a role of hypoxia in triggering EMT programs, the
exact mechanisms at play remain relatively unclear. Both promoting and suppressing roles of hypoxia
have been described in human and in mouse laboratory models [31–35]. In fact, our knowledge
of what really occurs in patient tumors is still fragmentary. In this regard, the study of Puram et
al. is particularly valuable [36]. These investigators profiled transcriptomes of ~6000 single cells
from 18 head and neck squamous cell carcinomas. This included the analysis of 2216 malignant cells
allowing the study of intra-tumoral phenotypic diversity of the cells. They found that malignant
cells varied within and between tumors in their expression of signatures related to cell cycle, stress,
hypoxia, epithelial differentiation, and partial EMT. One notable aspect of the findings was the strong
correlation found between hypoxia and EMT signatures in the individual tumors. Similarly, we recently
explored the relationship between hypoxia status and EMT-TF expression levels by analyzing lung
adenocarcinomas included in the TCGA-LUAD project [37]. In this large cohort, hypoxia signatures, as
well as HIF1A mRNA expression, were significantly and positively correlated with EMT-TF expression
levels. In an attempt to better model the impact of hypoxia in non-small cell lung cancer (NSCLC), we
exploited the primary NSCLC IGR-Heu cells and observed that EMT-related phenotypic changes were
particularly exacerbated when hypoxic stress was maintained for a prolonged period. Moreover, under
these experimental conditions, the shift towards a mesenchymal phenotype was only observed in a
fraction of stressed cells. While some cells undergo EMT, others do not shift towards the EMT spectrum.
Therefore, despite long-term exposure to hypoxic stress, a high proportion of clones retained epithelial
features contributing to expand the phenotypic diversity in the cancer cell population (Figure 1) [37].
It is also interesting to keep in mind that in vivo, cancer cells may be exposed to chronic or intermittent
hypoxic stresses, and depending on their location, to various hypoxia levels [38]. The propensity
of hypoxic stress to generate cancer cell heterogeneity was further illustrated by the recent study of
Lehmann and colleagues [39]. In their attempt to dissect how plasticity of tumor cell migration and
EMT is involved in the early metastatic steps, they identified the hypoxia/HIF-1 axis as an inducer
of amoeboid detachment and the production of heterogeneous cell subsets whose phenotype and
migration were dependent or independent of Twist-mediated EMT. Taken together, these reports
underscore the importance of hypoxic stress in mediating tumor plasticity and heterogeneity.
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Figure 1. Tumors contain distinct cell types that collectively enable tumor growth and progression.
Hypoxic stress can contribute by increasing cell plasticity, genomic instability and phenotypic
heterogeneity of certain carcinoma cells, leading to intra-tumor heterogeneity and the emergence
of cancer clones resistant to therapies and anti-tumor immunity.
3. Impact of Plasticity and Heterogeneity on Tumor Immune Escape
Evidence is accumulating that tumor plasticity and heterogeneity might be key determinants
in the emergence of therapy resistant cancer clones (Figure 1) [19,40]. Considering the relationship
between tumors and the immune system, it becomes quite clear that EMT or dedifferentiation can turn
even highly immunogenic cancer clones into poorly immunogenic cancer variants resistant to T cell
immune attacks through various mechanisms accompanying their phenotypic reprogramming [41–43].
This includes defects in the antigen-presentation machinery involving major histocompatibility
complex (MHC) class I molecules, defects in immune recognition following loss of adhesion molecules,
gain or loss of immune-modulatory factors and secretion of immunosuppressive substances, or gain of
anti-apoptotic properties by the cancer cells against cytotoxic immune effectors. Thus, the acquisition
of a more mesenchymal phenotype by cancer cells has been associated with deficiencies in the MHC I
antigen presentation pathway [44–47], downregulation of E-Cadherin [37], which could be critical for
the recognition of cancer cells by tumor infiltrating lymphocytes (TILs) expressing [48,49], hyperactivity
of TGF-beta signaling [45], or increased expression of programmed death-ligand 1 (PD-L1) [46,50,51].
Such immune resistant phenotypes are not only relevant for resistance to T-cell-mediated killing.
Numerous reports showed evidence of a link between acquisition of mesenchymal features by
cancer cells and their relative protection from NK-cell-mediated lysis [37,52,53], or phagocytosis
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through direct or indirect mechanisms [54]. Ricciardi and colleagues observed that exposing carcinoma
cells to inflammatory cytokines not only promotes EMT in these cells but also confers a number of
immunomodulatory properties, including interference with proliferation, differentiation and apoptosis
of NK, T and B cell populations [55]. On the other hand, immune cells such as macrophages and NK
cells can also mediate EMT of cancer cells, and presumably, could influence immune resistant states of
carcinoma cells [56–58].
A study by Huergo-Zapico et al. recently showed that NK-cells could mediate EMT programs
in melanoma cells, simultaneously potentiating the immune resistance capacity of the latter. On the
contrary, data from at least two studies using various model systems have raised the possibility that
EMT induction could increase cancer cell susceptibility to NK cells through up-regulation of NKG2D
ligands or cell adhesion molecule 1 (CADM1) [59,60]. This further highlights the contextual nature of
the events. For a better understanding of these discrepancies, we suggest that special attention should
be paid to the dynamic and the continuum of EMT states, as well as on the timing and the nature of
the EMT inducers used to manipulate laboratory models. Considering the role of hypoxic stress in our
recent study, we demonstrated that a prolonged hypoxic stress (1% O2) promotes EMT in the NSCLC
IGR-Heu population in a manner that depends on the hypoxia effector HIF-1-α [37]. As mentioned
above, while some cells experienced profound phenotypic changes toward mesenchymal states, others
do not, thus generating cancer cell heterogeneity in the cancer cell population. This was reflected by the
presence of a mixture of cells moving along the EMT spectrum with more epithelial or mesenchymal
phenotypes. Among the cancer subclones emerging from this hypoxic stress, those with a more
mesenchymal phenotype had an increased propensity to resist attacks by cytotoxic lymphocytes as
compared to the more epithelial counterpart. This was illustrated by their reduced susceptibility to
both cytotoxic T cells (CTL) and NK cell-mediated lysis [37]. In another study, hypoxia-induced EMT
of hepatocellular carcinoma cells promoted an immunosuppressive TME by stimulating expression of
indoleamine 2,3-dioxygenase (IDO) in monocyte-derived macrophages [61].
Work by Zhang indicates that HIF-1α can stimulate CD47 expression, an important factor for
maintaining plasticity of the cells, which also enables breast cancer cells to avoid phagocytosis by
macrophages [62]. CD47 hampers the “eat me signal” on cancer cells by interacting with SIRP on
macrophages impairing phagocytosis. More recently, Noman and colleagues identified CD47 as a
direct target of SNAI1 and ZEB1 [54]. They observed that the CD47 blockade sensitized cancer cells to
phagocytosis, particularly in breast cancer cells with Mesenchymal features. In Triple-negative breast
cancers (TNBCs), a heterogeneous group of breast tumors that can present many of the salient features
found during EMT, the recent report by Samanta et al. revealed that several immuno-modulatory
molecules including CD47, PD-L1 and CD73 are direct HIF target genes in TNBC cells [63]. Thus, CD47
expression could reduce killing by macrophages, whereas CD73 and PD-L1 mediate independent
mechanisms to inhibit the T-cell effector functions. The coordinate transcriptional induction of
these factors was especially observed in cells exposed to certain chemotherapeutic agents such as
carboplatin, doxorubicin, gemcitabine, or paclitaxel. Taken together, this data gives great insight into
how plasticity of the cancer cells can be linked to a multi-resistant phenotype involving resistance
to chemotherapy and immune resistance. The high amount of TGF-β (another HIF target gene)
produced by certain carcinoma cells, or the stromal compartment, could also be crucial in dampening
the immune response in tumors [20,64–67]. Moreover, interactions between the different contingents
should be highlighted. For instance, carcinoma cells with a mesenchymal or a partial EMT features
could cooperate and interact with cancer associated-fibroblasts to regulate their phenotype, and
presumably immune suppression [36]. Substantial evidence also indicates the role of HIF-mediated
immune plasticity in shaping anti-tumor immunity [5,6,68]. As mentioned above, HIF1 could be a
major regulator of effector CD8+ T cell functions [25]. An interesting study by Hatfield and colleagues
reported that hypoxia reversal via supplemental oxygenation had significant anti-tumor effects in
mouse models, resulting in long-term survival of the mice [69]. Importantly, the observed effects
were mainly attributed to the presence of T and natural killer cells. Investigators further showed
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an association with increased intratumoral infiltration, reduced immunosuppression by regulatory
T cells and inhibition of tumor-reactive CD8 T cells concomitant with increased pro-inflammatory
cytokines and decreased immunosuppressive substances including TGF-β. It is known that dendritic
cell differentiation and maturation is impaired under hypoxia, with negative effects on their T-cell
activating functions [70]. The work of Facciabene and colleagues invoked the role hypoxia in the
recruitment of Tregs through inducing expression of chemokine CC-chemokine ligand 28 (CCL28),
which in turn, promotes angiogenesis and tumor tolerance [71]. Further research also indicates the
direct role of HIF-1α in regulating the functionality and plasticity of T-regs [72,73]. Myeloid-derived
suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are also known to contribute
to tumor-mediated immune escape [74]. Eubank and colleagues showed evidence for a role of HIF-1
and HIF-2 in the promotion of macrophage angiogenic property [75]. HIF-1α could also regulate
their inhibitory functions on T cells [4,5]. Interestingly, the study of Corzo et al. showed that hypoxia
via HIF-1α could somehow extend the suppressive function of tumor MDSCs while redirecting their
differentiation toward macrophages in the TME [76]. Finally, we showed that hypoxia could regulate
the tumor MDSC functions by direct transcriptional induction of the programmed death-ligand 1
(PD-L1) in these cells, resulting in increased MDSC-mediated T cell tolerance [77].
4. Mechanisms of Hypoxia-Induced Cancer Stem Cells
CSCs are a subpopulation of cancer cells that have the ability to self-renew, to divide, to give
rise to another malignant stem cell and to drive tumor growth and heterogeneity [78,79]. Hypoxia is
a significant culprit for the development of tumor cell resistance to therapy, which is in part due
to the generation of cancer stem cells (CSCs) [80–82]. Both HIF-1α and HIF-2α have been found to
contribute to the mechanisms involved in mediating stemness [80,82–84]. Despite numerous studies
in cancer model systems, the molecular mechanisms underlying the CSC generation, downstream
of HIFs have not yet been completely elucidated. So far, they have been explored in various cancer
models. HIF proteins can directly or indirectly regulate the expression of genes involved in the
initiation and maintenance of stem cells such as (OCT4, SOX2, KLF4, MYC, NANOG, CRIPTO, Wnt
or NOTCH) [80,85–88]. In addition to their essential functions during embryonic development, these
genes could exert diverse functions in cancer. In certain human tumors, they might represent valuable
tools to predict recurrence and tumor plasticity, although such prognostic value is far from being
established [79,89–94].
In response to hypoxia, HIF-2α was shown to upregulate OCT4 and SOX2 expression resulting in
an increase in the migratory capacity of glioma cells [95,96]. In the study of Tang et al., increased levels
of HIF-1α in colorectal cancer cells was associated with increased chemoresistance through the GLI2
transcription factor, which coincides with an increase in cancer stem cells [97]. Similarly, HIF-1α and
HIF-2α have been shown to increase the expression of the stem cell marker CD133 in glioblastoma cells
concurrent with increased chemoresistance [98]. In breast cancer cells, HIF-1α and HIF-2α increased
NANOG mRNA by stimulating expression of AlkB homolog 5 (ALKBH5), an m(6)A demethylase able
to demethylate NANOG mRNA [99]. HIF-1 was required for the activation of the p38 MAP kinase
pathway and inhibition of ERK signaling resulting in stabilization of NANOG, KLF4, and enrichment
of breast cancer stem cells [100]. Clearly, understanding how these different signaling mechanisms
interact to drive tumor progression and therapy resistance under variable oxygenation conditions will
be critical to the efforts to develop more effective cancer therapies.
5. EMT at the Crossroad of Stemness
EMT has been proposed to drive invasion, resistance to therapy, and spreading of cancer to distant
sites [13,26,27]. Cells that are committed to EMT also exhibit numerous attributes that are known
to be characteristics of stemness [101]. Although cancer stem cells account for only a small part of
the tumor bulk, they are assumed to be the main players involved in therapeutic resistance, cancer
relapse, and distant metastasis. Hypoxia and HIF proteins likely contribute to the molecular link
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between EMT and stemness (Figure 1). Indeed, HIFs are not only involved in the regulation of stem cell
factors, in response to hypoxic stress HIF1 protein activates the expression of EMT-transcription factors
TWIST1 or ZEB1, which ultimately promotes EMT [31,102]. HIF1 can also help cells transition to a
more mesenchymal phenotype by regulating the lysyl oxidases LOX and LOXL2, leading to repression
of E-cadherin [34,103]. Other studies have reported that Notch signaling and the EMT-TF SNAIL could
be involved in this network as well [35]. It is important to note that cancer cells undergoing EMT in
response to hypoxia will not only gain mesenchymal properties, but also may acquire stem cell-like
features [104]. Signaling pathways leading to EMT involves TGF-β, STAT3, miR-210 among others
(Notch, Nanog) [26,104–106]. TGF-β expression is regulated by HIF-1, and in turn, TGF-β plays an
important role in stabilizing HIF-1 [37,107]. TGF-β has been described as having a dual function both
in suppressing as well as promoting cancer stem cell populations [108]. The effect of TGF-β has also
been correlated with the stage of the cancer; at early stages TGF-β has anti-growth effects, whereas at
late stages, it promotes the development of aggressive growth [109]. Interestingly, in breast cancer, stem
cell-like cells obtained after TGF-β exposure showed resistance to radiation therapy [110]. Likewise,
renal cell carcinoma cells having acquired a stem-like phenotype after TGF-β-induced EMT showed an
increase in chemoresistance [111]. In gynecologic cancer patients, the use of chemotherapy can induce
TGF-β signaling resulting in reduced chemosensitivity [112]. In primary lung cancer cells, TGF-β
exposure led to an increase in cancer stem cell population through repression of miRNA138 [113] while
in colon cancer, TGF-β seems to play a key role in angiogenesis, tumor growth and metastasis [114].
On the other hand, in the context of hepatocellular carcinoma, TGF-β resulted in a decrease in cell
survival of stem-like side populations [115]. Collectively, these studies highlight the importance of
HIFs and TGF-β in the regulation of EMT, and provide support for the development of strategies
exploiting these pathways to overcome therapy resistance.
It should be noted that STAT3 also plays an important role in the regulation of cancer stem cells
and therapy resistance [116,117]. STAT3 has been demonstrated to be a potent stabilizer of HIF-1 in
multiple cancer cell models [118–121]. Moreover, at the molecular level, STAT3 signaling is complex
and cooperates with several other pathways implicated in cancer growth. This has recently been
reviewed by Galoczova et al. [116]. There is currently a need and ample room to better explore STAT3
implications in EMT, cancer stem cells and tumor resistance to therapy. Of particular interest is the
development of strategies for STAT3 inhibition, which has been shown to induce apoptotic cell death
of STAT3 dependent cancer cells [122]. MicroRNAs also deserve particular attention. They are small
non-coding RNAs that function in post-transcriptional regulation of gene expression and in mRNA
silencing. Recent studies unraveled the role of hypoxia in the regulation of microRNA machinery
components Drosha and Dicer in cancer cells with important consequences for miRNA biogenesis and
tumor progression [123,124]. In particular, this work points to the role of hypoxia in promoting EMT
and stem cell phenotypes through mechanisms involving oxygen-dependent H3K27me3 demethylases
KDM6A/B or HIF-1 target ETS1/ELK1, which ultimately may lead to derepression of certain EMT-TFs
such as the miR-200 target ZEB1. On the other hand, miR-210 is highly induced in response to hypoxic
stress and it regulates HIF expression [125,126]. miR-210 is known to have important functions during
cancer progression, with both promoting and suppressive roles [127]. Inhibition of miR-210 through
small molecules results in inhibition of tumorigenesis in a mouse model for triple negative breast
cancer [128]. In ovarian cancer cells, it was found to be a promoter of EMT by causing a decrease in
E-cadherin, and increase in vimentin [129]. In lung cancer cells, miR-210 was found to regulate the
susceptibility of cancer cells to lysis by cytotoxic T cells [126].
6. Hypoxia, DNA Repair and Genomic Instability
Hypoxic regions are heterogeneous within tumors and the hypoxic phase can vary with time
and intensity (acute and/or chronic). Accumulating evidence demonstrates that this component of
the TME can be associated with an increase in genomic instability of tumor cells, covering a wide
range of alterations, from point mutations to chromosomal instability. The magnitude of genetic
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aberrations such as increases in gene mutations and gene amplifications due to variation in severity of
hypoxia can be 5–1000-fold [130]. Indeed, several studies have suggested that hypoxia can induce DNA
damage, alter cell cycle checkpoints and/or the sensing and repair of DNA damage, and consequently
favor genetic instability (Figure 1) [131–133]. In this regard, several teams have documented an
increase in the rate of DNA mutations in cells exposed to in vitro or in vivo hypoxic conditions, mostly
using reporter assays [134–136]. The origins of these hypoxia-induced DNA mutations are probably
multiple, emerging from hypoxia-mediated oncogene amplification, induction of DNA damages or
DNA replication stress, deregulation of DNA damage checkpoint signaling, interference with DNA
repair or escape from cell death [132]. Importantly, cycles of hypoxia and re-oxygenation are common
phenomena seen in solid tumors and characterized by an increase in the intracellular free radical
species [133,137,138], which are also strongly associated with accumulation of DNA damage [133].
However, in the absence of re-oxygenation (chronic hypoxia), hypoxia-induced genetic instability
mostly arises from the influence of hypoxic conditions on DNA-damage repair pathways or the
induction of a replicative stress, without detectable induced DNA damage [131]. It will be important
to further investigate this intriguing possibility, especially in vivo.
In the case of DNA damage, the G1/S and the G2/M checkpoints kinases ataxia telangiectasia
mutated [139], ATM-Rad3-related (ATR) and CHK2/CHK1, respectively, transmit signals to the effector
molecules such as p53, p21 and CDC25 to prevent cell cycle progression or to initiate programmed cell
death. Interestingly, emerging evidence suggests that different severities and durations of hypoxia
may have different effects on cell cycle checkpoint controls. For example, oxygen levels such as 0.2%
can bypass ATM or ATR and cell cycle checkpoint signaling allowing the propagation of tumor cells
with potentially altered DNA that can contribute to genomic instability [140]. Furthermore, it has been
proposed that hypoxia can exert selective pressure that leads to expansion of tumor cells with reduced
apoptotic capacity due to, for example, TP53 mutations [141], which is considered as the guardian of
genome integrity. As mentioned above, DNA repair pathways, especially homologous recombination
(HR), mismatch repair (MMR), non-homologous end joining (NHEJ) and base-excision repair (BER)
have also been shown to be compromised under hypoxic conditions [131,132]. For example, it was
demonstrated that hypoxia can decrease the expression of the HR-related protein RAD51 in a HIF-1α
independent manner [142]. Similarly, reduced expression of the NHEJ-related proteins DNA-PKcs,
Ku70, Ku80 and DNA-ligase IV has been observed in hypoxic conditions [143]. Hypoxia has been
also shown to transcriptionally downregulate the MMR genes MLH1, MSH2 and MSH6 [144] and a
hypoxia driven microsatellite instability (MSI) has been proposed [132]. This hypoxic modulation of
DNA repair pathways is thus thought to be of major importance in the genomic instability induced by
chronic hypoxic conditions.
The induction of DNA damage, the alteration of DNA-damage cell cycle checkpoints and a
functional decrease in the DNA repair pathways under hypoxic conditions probably contribute to
“mutator” phenotypes in hypoxic cells and to genomic instability, which might have important effects
on the anti-tumor immune response and tumor immunogenicity. For example, recent studies have
provided new insights into how specific genomic alterations deriving from genome instability can
impact on immune evasion of antitumor immunity [43]. Moreover, recent findings demonstrate
the role of double strand break repair pathway in up-regulation of PD-L1 expression by cancer
cells [145]. However, the influence of hypoxia-induced DNA-damages in PD-L1 expression is currently
unknown. Importantly, a potential mutational burden in hypoxic cells could also be linked to
their immunogenicity. Indeed, during the past few years, several groups have identified cancer
rejection antigens formed by peptides that are entirely absent from normal human tissues, so-called
“neo-antigens”. Such neo-antigens are solely created by tumor-specific DNA alterations/mutations
that result in the formation of novel protein sequences. As compared with non-mutated self-antigens,
neo-antigens are thought to be of particular relevance to tumor control, as the quality of the T cell pool
that is available for these antigens is not affected by central tolerance [146]. As a result, neo-antigens
appear to represent ideal targets for T cell-based cancer immunotherapy [147]. In this regard, tumors
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harboring deleterious mutations in the DNA repair pathways were found to carry a high number of
candidate neo-antigens, which is associated with a clinical benefit from immune checkpoint inhibitor
therapy (anti-PD1) (Le, 2015 #2213), indicating that a high burden of tumor neo-antigens correlates with
a durable response to anti-immune checkpoint-based immunotherapy. Two recent studies revealed
that mutations and/or loss of the DNA repair mechanism leads to increased mutational load, thus
resulting in enhanced neo-antigen generation in cancer cells [148,149]). Nevertheless, the hypothesis
that hypoxia-induced DNA damages/genomic instability can lead to a high mutational burden and
high numbers of neo-antigens, increasing the potential immunogenicity of hypoxic cells, has never
been validated.
7. Therapeutic Targeting of Hypoxia in Cancer
In view of the importance of the link between cancer stem cells, cell plasticity and therapeutic
implications in cancer development, targeting the hypoxic niches may offer a great advantage in
anti-cancer therapy. This is because targeting hypoxic niches results in eliminating diverse cell
populations including cancer stem cells, and preventing the commitment of certain highly plastic cells
to an EMT program [27,150].
In support of this idea, it was shown that oxygen administration to patients does transiently
relieve tumor hypoxia, and as a result, improve therapy [151]. As such, detection of hypoxic areas
in vivo is an essential first step. Recent development of two-photon molecular probes in detecting
hypoxia in tissue in vivo and in vitro recently demonstrated some efficacy in detecting hypoxia in deep
tumor tissue [152]. However, its effective use in the human situation needs to be established. Another
important issue to be addressed is for the drugs to be targeted to the hypoxic zones. Several approaches
for targeting hypoxic tumor cells are being explored including hypoxia-activated prodrugs, gene
therapy, recombinant anaerobic bacteria and specific targeting of HIFs, or targeting pathways important
in hypoxic cells such as the mTOR and UPR pathways [27,153,154]. Hypoxia activated prodrugs are
drugs that are converted to their active state under a hypoxic environment. These have been developed
and used in combination with chemotherapy or targeted therapy [155]. Recombinant anaerobic
bacteria have been considered as gene delivery vehicles to cancer cell sites and spare normal tissue.
The Clostridium strain that expresses prodrug-converting enzymes has been used, allowing for high
therapeutic doses in the tumor [156]. A combination of hypoxia-activated drugs with nanotechnology
can be used to enhance tumor specific delivery of anti-cancer agents to the hypoxic tumor zone.
HIF1, being presumably the most powerful factor in the hypoxic response represents an ideal
target for therapy. In this regard, the development of selective HIF-1α antagonists remains an
important clinical challenge [157,158]. Nonetheless, molecule inhibitory drugs reducing HIF-1α
levels, or targeting HIF1 stability/activity may provide interesting benefits in anti-cancer therapy.
Nanoparticle formulations containing amino bisphosphonate zoledronic have been successfully used
in combination with doxorubicin to sensitize cancer cells to multidrug resistance through inhibiting
HIF-1 [159,160]. Inhibitors affecting HIF protein translation include cardiac glycosides, PX-478 or
topoisomerase I inhibitors [161–167]. Translation of HIF1 mRNA is known to be controlled by the
PI3K/AKT/mTOR pathway. Inhibition of this pathway could decrease HIF expression and the
resultant tumorigenesis [168–170]. As an alternative, targeting pathways downstream of HIF signaling
includes the use of anti-VEGF therapy (monoclonal antibodies targeting VEGF (bevacizumab) or small
molecule inhibitors targeting the VEGF receptor), which has been used for anti-angiogenic/vascular
normalization effects in certain medical indications including ovarian, renal, lung or colorectal cancers,
in combination with chemotherapy [171]. Finally, recent studies give promise to our ultimate ability
to design specific inhibitors of HIFs. A new class of HIF antagonists are currently being tested and
have already proven to selectively target HIF-2α with relatively low toxicity compared to current
anti-angiogenic drugs [158,172–174].
26
Int. J. Mol. Sci. 2018, 19, 3044
8. Conclusions
Expansion of resistant cancer cell clones during cancer treatment is a major issue for cancer
therapy. It reflects a clonal evolution resulting from genomic instability, cellular plasticity and
activation of stemness pathways, as well as complex regulatory networks orchestrated by the TME.
Tumor microenvironmental hypoxia is a relevant example that demonstrates how microenvironmental
parameters can interfere and neutralize immune cell functions. Converging evidence now suggests its
potential value as a prognostic factor as well as a predictive factor owing to its multiple contributions to
chemoresistance, radio resistance, angiogenesis, resistance to cell death, altered metabolism, genomic
instability, cell plasticity and various immune-related aspects. There is a clear rationale to develop
efficient ways to target microenvironmental hypoxia to prevent tumor evolution and the emergence
of therapy resistance. However, information on the mechanisms at play is still fragmentary and may
vary in a contextual manner. Despite insightful experimental studies using in vitro or in vivo models,
the challenge remains for scientists and clinicians alike to gain a better understanding of how human
tumors respond to hypoxia. It will also be critical to develop specific agents for targeting hypoxia
and associated pathways. This has the potential to provide innovative cancer therapies that can
enhance antitumor immunity and overcome the barriers of treatment resistance, tumor tolerance and
escape from immune surveillance. In the era of cancer immunotherapy, current strategies such as
immune checkpoint blockade have focused on attempting to target immune cells directly to boost the
immune system of the host. Is it possible to use therapeutic targets derived from the hypoxic TME and
associated pathways as new therapeutic solutions for immunotherapy of cancer? This question merits
further investigation. An important challenge will be to determine the best combination strategies as
well as the optimal timing and sequence of these combinations.
We are still at the beginning of an exciting period of discovery, and integrating the manipulation
of hypoxic stress in cancer immunotherapy may lead to more durable and effective cancer
immunotherapy approaches in the future.
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Abstract: Selenium, a trace element with anticancer properties, can reduce harmful toxicities of
chemotherapy and radiotherapy without compromising efficacy. However, the dose-response
relationship in normal versus malignant human cells is unclear. We evaluated how methylseleninic
acid (MSA) modulates the toxicity and efficacy of chemotherapy and radiation on malignant and
non-malignant human mononuclear blood cells in vitro. We specifically investigated its effects on
endoplasmic reticulum stress induction, intracellular glutathione concentration, DNA damage and
viability of peripheral blood mononuclear cells and THP1 monocytic leukaemia cells in response
to radiation, cytosine arabinoside or doxorubicin chemotherapy. MSA, at lower concentrations,
induced protective responses in normal cells but cytotoxic effects in malignant cells, alone and in
conjunction with chemotherapy or radiation. However, in normal cells higher concentrations of MSA
were directly toxic and increased the cytotoxicity of radiation but not chemotherapy. In malignant
cells higher MSA concentrations were generally more effective in combination with cancer treatments.
Thus, optimal MSA concentrations differed between normal and malignant cells and treatments.
This work supports clinical reports that selenium can significantly reduce dose-limiting toxicities of
anticancer therapies and potentially improve efficacy of anticancer treatments. The optimal selenium
compound and dose is not yet determined.
Keywords: selenium; glutathione; malignant; viability; DNA damage; ER stress
1. Introduction
Selenium (Se) is an essential trace element that is extensively studied in the prevention of
numerous malignancies [1], although the majority of research on Se has focused on providing adequate
nutritional intake in populations that have inherently low Se intake [2]. However, substantial preclinical
data suggests that Se compounds, in supranutritional doses, have direct anticancer effects, mediated
by various mechanisms including oxidative capability and modulation of immunological responses,
angiogenesis, protein confirmation and DNA repair pathways [3,4]. These same mechanisms allow
selenium compounds to act in synergy with cancer therapies and increase the efficacy of these
treatments while reducing their normal tissue toxicities, as reviewed by Evans et al. [4]. Se compounds,
when added to chemotherapy, resulted in improved tumour response rates and cures in human tumour
xenograft animal models and reduced organ-specific toxicity [5–7]. Some aspects of these findings have
Int. J. Mol. Sci. 2018, 19, 3167; doi:10.3390/ijms19103167 www.mdpi.com/journal/ijms37
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been replicated in clinical trials, with various Se compounds ameliorating the toxicity of chemotherapy
or radiotherapy [8–17], although the trials were not powered to evaluate overall treatment efficacy.
These promising results argue for the initiation of larger clinical trials that can definitively assess
the contributions of Se compounds to modulating both efficacy and toxicity of chemotherapy and
radiation [4,18].
There is unquestionably a major unmet need in this regard. Despite many advances in supportive
care, the toxicities of chemotherapy and radiotherapy still limit their efficacy, utility and acceptability
to patients and clinicians, and result in poor quality of life for patients, treatment-related deaths
and inadequate outcomes [19]. Apart from antiemetics and haemopoietic growth factors, few agents
substantially prevent these toxicities, many are poorly-tolerated, and some reduce toxicities while
compromising anticancer efficacy [20–22]. In contrast, Se compounds offer the potential, at optimum
doses, of being well-tolerated agents that can improve both cancer outcomes and treatment toxicities.
In one study, Se-methyl-selenocysteine was more effective and dose-potent than seleno-l-
methionine or sodium selenite in reducing cytotoxic chemotherapy-related mortality and augmenting
its anticancer activity [6]. This may relate to the in vivo ability of Se-methyl-selenocysteine to directly
generate methylselenol, a compound that is considered the active moiety for the observed effects
of Se compounds in cancer cells [23–27]. In preclinical models Se-methyl-selenocysteine dosed at
0.2 mg/mouse/day optimises the mechanisms that mediate protection of normal tissues while
enhancing tumour cytotoxicity [5,6,28]. In humans, however, this dose-response relationship has
not been well-characterised, and thus the optimal type and dose of Se for use in clinical trials has
not yet been determined [4]. Therefore, there is a need to provide a framework for characterising the
divergent biological effects of Se in normal and malignant cells in humans, to inform future trials
evaluating Se compounds in conjunction with anticancer treatments.
This investigation was undertaken to evaluate whether peripheral blood mononuclear cells
(PBMCs) from healthy blood donors and a comparable malignant human cell line, THP1 monocytic
leukaemia, could serve as an in vitro model to investigate the differential effects of Se on normal and
malignant human mononuclear cells. Se has been previously shown to enhance apoptosis through
the induction of endoplasmic reticulum (ER) stress in cancer cells [29], therefore we evaluated the
induction of ER stress in both normal and malignant cells in response to Se treatment. Given that ER
stress signalling can be induced in response to oxidative triggers, we also investigated the impact of Se
on intracellular glutathione levels [30–32], a key component in maintaining redox homeostasis in the
cell, and how this influences DNA damage and viability of normal and malignant cells to cytotoxic
chemotherapy or radiation [33–35].
Instead of Se-methyl-selenocysteine, which does not generate methylselenol in vitro, we used
methylseleninic acid (MSA), which directly provides methylselenol through non-enzymatic reduction,
and enabled us to directly evaluate the impact of this active metabolite of Se compounds [25,27].
We used MSA at Se concentrations (2.5, 5 and 15 μM) that could be achieved in plasma in subsequent
clinical trials, and were comparable to plasma levels in mice at effective doses [6]. MSA was used
alone or in combination with cytotoxic chemotherapy drugs or gamma radiation to evaluate their
interactions in normal and malignant cells.
We demonstrate that Se has divergent effects in normal and malignant human mononuclear cells,
protecting normal cells from chemotherapy and radiation toxicity while enhancing their therapeutic
effects against malignant cells. In this model we were also able to use analytical methods to
demonstrate changes in biological pathways that mediate these effects of Se compounds, which
could be incorporated into future clinical trials.
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2. Results
2.1. Methylseleninic Acid (MSA) Induces Endoplasmic Reticulum (ER) Stress in Normal and Malignant Cells
But Differentially Modulates Apoptosis
To investigate the induction of ER stress in normal and malignant cells we measured the cellular
expression of 78 kDa glucose-regulated protein (GRP78) and phosphorylated eukaryotic initiation
factor 2-alpha (phospho-EIF2α), and splicing of X-box binding protein 1 (XBP1), in response to exposure
to increasing concentrations of MSA for 6 h. MSA induced ER stress in both normal and malignant cells,
which was seen through an increase in the expression of GRP78, as well as an increase in the splicing
of XBP1 (spliced: S-XBP1; unspliced: U-XBP1) and phosphorylation of EIF2α (Figure 1). Interestingly,
when we assessed the effect of MSA on the apoptotic response induced by ER stress we found different
patterns between normal and cancer cells (Figure 1). Caspase-8 was down-regulated by MSA in a
concentration-dependent manner in normal PBMCs yet was upregulated in malignant THP1 cells at
the same concentrations, with the maximal differential impact between normal and malignant cells at
5 μM MSA (Figure 1).
 
Figure 1. Selenium induces endoplasmic reticulum (ER) stress response in normal and malignant
cells. (a) Concentration-dependent increase in ER stress proteins and decrease in caspase-8 in
peripheral blood mononuclear cells (PBMCs) with 2.5, 5 and 15 μM methylseleninic acid (MSA)
at 6 h; (b) Concentration-dependent increase in both ER stress proteins and caspase-8 in THP1 cells;
(c,d) Quantification of protein expression in PBMC and THP1 cells.
2.2. MSA Has a Divergent Impact on Glutathione (GSH) Levels in Normal and Malignant Cells
To investigate the link between ER stress and generated oxidative stress we measured intracellular
total GSH levels in normal and malignant cells. At 6 h we observed differential effects of MSA in normal
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and malignant cells (Figure 2a). MSA significantly increased total GSH levels in PBMC (Figure 2a)
after 6 h in a concentration-dependent manner (a protective response). Conversely, THP1 cells had a
baseline GSH level approximately 40-fold higher than PBMCs that was significantly reduced by MSA
in a concentration-dependent manner after 6 h (Figure 2b).
We then tested the duration of the MSA-induced alteration on GSH levels in normal and malignant
cells. The increase in GSH observed in PBMCs after 6 h of MSA treatment at 2.5 and 5 μM was
maintained at 24 h but returned to baseline levels at 48 h (Figure 2c). However, at 15 μM MSA, the GSH
concentration was less elevated at 24 h than at 6 h and also returned to baseline levels at 48 h. In THP1
cells, the depletion of GSH at 24 h was still significant but not concentration-dependent, whereas at
48 h the return of GSH levels towards baseline values was greater with 2.5 and 5 μM compared with
15 μM MSA (Figure 2d).
Figure 2. MSA has divergent impact on glutathione (GSH) levels in normal and malignant cells.
(a,b) GSH quantification in PBMC and THP1 cells demonstrates that MSA significantly reduces
GSH levels in THP1 cells and significantly increases GSH levels in PBMCs after 6 h (n = 5, ± SEM);
(c,d) Timeline of GSH levels in PBMCs and THP1 cells after MSA treatments demonstrates GSH
alterations are maintained for up to 24 h. n = 3, ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001, ns,
not significant.
Next, we investigated if the MSA-induced GSH response in cells was maintained at 24 h after
radiation and chemotherapy treatment. The GSH increase in normal PBMCs was maintained at 24 h
when cells were also treated with 2 Gy radiation, cytosine arabinoside (AraC) or doxorubicin (Dox),
though the maximum benefit was achieved with 2.5 μM MSA (Figure 3a–c). Furthermore, the depletion
of GSH by MSA in malignant THP1 cells was still significantly reduced at 24 h after radiation and
chemotherapy treatment, again without the advantage of higher MSA concentrations (Figure 3a–c).
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Figure 3. MSA-induced GSH alterations are maintained in the presence of therapeutic treatments.
(a–c) GSH levels are significantly elevated in PBMCs at 24 h after radiation, AraC or Dox treatment,
whereas GSH levels are significantly reduced in THP1 cells 24 h after treatment. n = 3, ± SEM, ** p < 0.01,
*** p < 0.001.
2.3. MSA Reduces DNA Damage in Normal Cells While Increasing DNA Damage in Malignant Cells
Given the divergent effects of MSA on apoptosis induction and GSH expression in normal and
malignant cells, we investigated if MSA would protect normal cells from DNA damage due to radiation
or chemotherapy, while potentiating the DNA-damaging efficacy of these treatments in malignant
cells. Using the comet assay (Figure 4a), this differential effect was pronounced with chemotherapy
but not radiation. Treatment with MSA alone at the highest concentration, 15 μM, slightly increased
DNA damage levels in normal cells but not in malignant cells, though the lower concentrations had no
such effect (Figure 4b).
 
Figure 4. Selenium protects normal cells from DNA damage while enhancing DNA damage in
malignant cells. (a) Representative image of comet assay (400× magnification) in PBMCs and THP1
cells treated with MSA alone or MSA in combination with radiation, AraC or Dox; (b) Quantification
of DNA damage in PBMCs and THP1 cells: treatment with MSA 15 μM, but not lower concentrations,
slightly increased DNA damage levels in normal but not in malignant cells; (c) DNA damage is
increased in both PBMCs and THP1 cells exposed to 2 Gy radiation; (d,e) MSA is significantly protective
against DNA damage in PBMCs while significantly increasing DNA damage in THP1 cells treated with
AraC or Dox. n = 3, ± SEM, ** p < 0.01, *** p < 0.001, ns, not significant.
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As expected, when PBMCs and THP1 cells were exposed to 2 Gy radiation DNA damage
was elevated compared to controls (Figure 4c). While MSA at 2.5 μM reduced radiation-induced
DNA damage in PBMC but not THP1 cells, higher concentrations of MSA progressively increased
radiation-induced DNA damage in both normal and malignant cells (Figure 4c). DNA damage was
significantly increased in PBMCs and THP1 cells when treated with AraC, however adding MSA
protected the normal cells while increasing DNA damage in the malignant cells, without a clear
concentration dependency (Figure 4d). Dox-induced DNA damage in PBMCs was not potentiated by
MSA, while in contrast MSA increased Dox-induced DNA damage in THP1 cells (Figure 4e). However,
this effect on THP1 cells was maximal at 2.5 μM MSA, and diminished at higher concentrations
(Figure 4e).
2.4. MSA Treatment Protects Normal Cells While Potentiating Cell Death in Malignant Cells
We next investigated if the differences in DNA damage culminated in differences in cell viability.
MSA alone significantly reduced the viability of THP1 cells with increasing MSA concentrations
compared to PBMCs (Figure 5a). Although 2 Gy radiation alone did not affect viability of THP1 cells,
adding MSA to radiation significantly reduced THP1 cell viability (Figure 5b). In agreement with
the DNA damage induced by radiation, the addition of MSA to this treatment further reduced the
viability of PBMCs (Figure 5b). However, when we assessed the combination of MSA with AraC or
Dox we found significant differences (Figure 5c,d). Treatment with MSA at all concentrations provided
significant protection of PBMCs while progressively increasing toxicity in THP1 cells in response to
AraC or Dox treatment (Figure 5c,d).
Figure 5. MSA protects normal cells and results in elevated cell killing of malignant cells after 48 h.
(a) MSA treatment alone significantly reduces cell viability of malignant THP1 cells compared to
normal PBMCs; (b) MSA does not significantly alter cell viability of PBMCs compared to THP1 cells in
response to radiation; (c,d) MSA significantly protects normal PBMCs from cell death while enhancing
the therapeutic activity of AraC or Dox in THP1 cells. n = 3 ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001,
ns, not significant.
3. Discussion
The toxicity of anticancer therapies is a major ongoing clinical issue and developing agents that
usefully modulate the toxicity and efficacy of chemotherapy and radiotherapy without compromising
their efficacy is important. Preclinical work and some clinical trials suggest that Se compounds can
achieve this, though the Se compounds and doses used have varied widely [4,6]. In the present study,
we used an in vitro model of normal and malignant human mononuclear blood cells to investigate the
dose-response relationship of Se in modulating the efficacy and toxicity of cancer treatments. We have
shown important differences between normal and malignant cells in the dose-response relationship of
Se to biological mechanisms that mediate cell survival and response to cancer treatments.
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Se compounds have previously been shown to induce ER stress in a concentration- and
time-dependent manner in prostate cancer cell lines, which leads to apoptosis in malignant cells [29].
In this study, we found that MSA induced apoptosis through caspase-8 expression in THP1 cells while
reducing caspase-8 in PBMCs, in agreement with previous studies that have shown Se compounds
induce apoptosis through caspase-8 activation [36]. Moreover, caspase-8-mediated apoptosis has been
demonstrated to mediate the therapeutic synergy of Se compounds and chemotherapy treatment
in various cancer settings [37,38]. The reduction in caspase-8 induced by MSA in PBMC in this
study is consistent with the clinical data that Se compounds, at tested doses, are protective of normal
tissues [10,16].
ER stress has been demonstrated to induce reactive oxygen species generation [39]. This results in
the depletion of intracellular GSH, causing the cellular environment to become more oxidized, which
is associated with increased apoptosis and necrosis [40–42]. GSH contributes to cellular resistance to
anticancer treatments through covalent binding and inactivation of drugs [43–47]. Thus the 40-fold
higher initial concentration of GSH present in THP-1 cells compared to PBMCs would protect the
malignant cells against cytotoxic therapies, whereas the MSA-induced severe depletion of GSH in
malignant cells shown in this study may contribute to the increased sensitivity to these treatments with
MSA. These results are consistent with work showing that Se compounds inhibit the cisplatin-induced
increase in GSH in ovarian cancer cells, thereby preventing chemoresistance [32]. These malignant
cells may also have been sensitised to the effects of MSA due to their high concentrations of GSH,
as GSH is a cofactor in the metabolic reduction of MSA to methylselenol [31]. This may not be relevant
to Se compounds that generate methylselenol through other mechanisms.
Contrary to the effect of MSA seen in malignant cells, it induced a significant increase in GSH in
normal cells, which is expected to protect them against cancer therapies. The simultaneous increase
in GSH in normal cells and depletion of GSH in malignant cells may contribute to improving the
therapeutic ratio of cancer treatment by reducing normal tissue toxicities while increasing the anticancer
efficacy. This effect on GSH may mediate, at least in part, the observed ability of Se compounds to
reduce the toxicity of chemotherapy and radiation in normal tissues [10,16].
Previous in vitro and in vivo studies have shown that DNA damage and inducible DNA damage
is reduced with Se [33,34]. While we demonstrated that MSA reduced chemotherapy-induced DNA
damage in normal cells, it was ineffective in protecting them against radiation-induced DNA damage
and cytotoxicity. Of particular concern, at the highest concentration tested (15 μM), MSA significantly
increased DNA damage from radiation in PBMC. In contrast, all concentrations of MSA increased the
DNA damage and cytotoxicity of radiation and chemotherapy in the malignant cells.
This study supports previous work that demonstrated the potential therapeutic benefit of
using Se in conjunction with cancer therapeutics, due to its differential effects on chemotherapy-
or radiation-treated normal cells relative to malignant cells [48]. It is encouraging in this study that
MSA generally protected normal cells while sensitising malignant cells to cytotoxic therapies, and
that it informs about mechanisms that plausibly contribute to the reduction of clinically-significant
toxicities seen in clinical trials with Se supplementation during cancer treatments [10–12,14].
A very important concern, however, has been raised by this study: in PBMCs the highest
concentration of MSA proved toxic, and increased the cytotoxicity and DNA damage from radiation.
This could increase the potential for second malignancies and other late complications of radiation,
especially if using inorganic forms of Se that are associated with increased genotoxicity compared to
several organic forms [49]. These outcomes have not been mentioned in clinical trials to date but the
numbers evaluated have been small and follow-up is limited.
There is always a tension in cancer treatment between maximising efficacy while managing
toxicities [19]. While Se has considerable and important potential to widen this usually narrow
therapeutic window, data from this study strongly suggests that following the traditional cytotoxic
therapy paradigm of using the maximum tolerated dose [50,51] may be inappropriate with Se
compounds. However, our data also suggests that these interactions are treatment-specific,
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with greater vulnerability of normal cells when using the highest concentrations of MSA with
radiation, but continued protection of normal cells from chemotherapy by MSA at all concentrations.
Furthermore, there were marked differences in the concentration-dependence of the improved
anticancer effects of chemotherapy or radiation with MSA on malignant THP1 cells. More modest
concentrations of MSA proved equally effective to the highest one in terms of inducing ER stress
and reducing GSH levels from radiation or chemotherapy, and at inducing DNA damage with
chemotherapy drugs. The highest MSA concentration, however, was most effective at inducing
DNA damage with radiation and at augmenting the cytotoxicity of radiation or chemotherapy.
4. Materials and Methods
4.1. Mononuclear Cell Isolation
PBMCs were isolated from buffy coats obtained from blood donations given by healthy
individuals, and supplied by the New Zealand Blood Service at Waikato Hospital, Hamilton,
New Zealand. Ethical approval for their use was granted by the Northern Y Health and Disability
Ethics Committee (reference NTY/10/08/065/AM01, 16 August 2011). The mononuclear cell fraction
was isolated via density gradient centrifugation using Histopaque® (St. Louis, MO, USA).
4.2. Cell Culture
PBMCs and THP1 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 1%
penicillin (10,000 units/mL) and streptomycin (10,000 μg/mL) at 37 ◦C in 5% CO2. Both cell lines were
incubated either in the presence of MSA (2.5, 5 and 15 μM), cytosine arabinoside (AraC; 5 ng/mL),
or doxorubicin (Dox; 20 nM) alone, as well as the combination of MSA and AraC or Dox. To assess
the response to radiation, cells were irradiated with a total of 2 Gy with or without MSA. Cells were
incubated with MSA for 6 h prior to treatment with chemotherapy or radiation.
4.3. Western Blot Analysis
Western blotting was carried out as previously described [52]. Briefly, total cell protein
was isolated using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 1% Triton-X-100, 1% Na-deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM
ethylenediaminetetraacetic acid (EDTA), phosphatase inhibitors and protease cocktail inhibitors
(Sigma Aldrich, St. Louis, MO, USA), and 1 mM phenylmethanesulfonylfluoride). Proteins were
resolved by SDS-polyacriliamide gel (PAGE), transferred to nitrocellulose membranes, blocked in 5%
non-fat powdered milk in tris-buffered saline-tween (TBS-T) and probed with antibodies. Protein
bands were detected using a FUJIFILM Intelligent dark box II LAS-1000 system.
4.4. Measurement of GSH
Glutathione (GSH) assay kit was purchased from Sigma-Aldrich (St. Louis, MO, USA).
The assay was carried out according to the manufacturer’s directions. Total GSH was determined
using a kinetic assay that measures the reduction of 5,5′-dithiobis-(2-nitrobenzoic) acid (DTNB) to
5-thio-2-nitrobenzoic acid (TNB) at 412 nm.
4.5. Comet Assay
DNA damage was assessed with the comet assay as previously described [53]. Preparation of
slides was carried out by coating a pre-agarose-coated slide (1% normal melting point in PBS), with
approximately 1000 cells in 0.5% low melting point agarose in PBS. Slides were lysed at 4 ◦C in a
solution containing 1% Triton X-100, 2.5 M NaCl, 100 mM EDTA, and 10 mM Tris pH 10.0 for two hours.
Slides were incubated for 20 min in an alkaline buffer (300 mM NaOH and 1 mM EDTA (pH > 13)) and
electrophoresed for 20 min at 20 V and 300 mA at 4 ◦C in the same buffer. Slides were then neutralized
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and dried in 70% ethanol before being stained with SYBR Gold (Thermo Fisher Scientific, Waltham,
MA, USA) and scored using the tail moment [53].
4.6. MTT Assay
Viability was measured with a tetrazolium salt as previously described [52]. The MTT
(methyl-thiazol-tetrazolium) assay was used to assess the impact of treatments on cell viability in
THP1 cells and PBMCs after 48 h. Cells were incubated with MTT for two hours, lysed in 20% SDS
(w/v), 50% dimethylformamide (v/v) pH 4.7, and the absorbance was measured at 570 nm.
4.7. Statistical Analysis
GraphPad Prism version 6.0 (La Jolla, CA, USA) was used for all calculations. Multiple
comparisons were controlled for using the Sidak-Bonferroni method. All experiments were
performed at a minimum of 3 independent repeats. Differences with p-values less than 0.05 were
considered significant.
5. Conclusions
Overall this study suggests that doses of Se compounds that achieve plasma Se concentrations in
the range of 2.5–5 μM might achieve the optimal balance between enhancing efficacy and reducing the
toxicity of radiation. It is possible that higher doses of Se might safely be used with some chemotherapy
drugs. It is noteworthy that dosing to achieve plasma Se levels determined by this in vitro study
would not apply to seleno-l-methionine, as it is non-specifically incorporated into the general protein
pool, especially albumin, which gives disproportionately high plasma Se levels compared to dosing
with equivalent elemental Se doses of sodium selenite or Se-methylselenocysteine [54,55].
The potential of Se to improve the efficacy and reduce toxicities of cancer treatments is
important and deserves careful examination in clinical trials. However, when designing these
trials, we need to be cognizant of the genotoxicity dose-dependence of the Se compounds to be
used, with the potential for increased serious late toxicities of cancer treatments such as secondary
malignancies, and evaluate this in our trials. Importantly, this study has demonstrated several
laboratory methods that can be incorporated into clinical trials to enable investigators to evaluate the
pharmacokinetic-pharmacodynamic relationship of the Se compounds being used in cancer patients.
This will assist us in rationally determining the optimal dose and form of Se for use in combination
with various cancer treatments in clinical trials; such trials are already underway [4,28].
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Abstract: Durable response, inherent or acquired resistance, and dose-limiting toxicities continue to
represent major barriers in the treatment of patients with advanced clear-cell renal cell carcinoma
(ccRCC). The majority of ccRCC tumors are characterized by the loss of Von Hippel–Lindau tumor
suppressor gene function, a stable expression of hypoxia-inducible factors 1α and 2α (HIFs), an
altered expression of tumor-specific oncogenic microRNAs (miRNAs), a clear cytoplasm with dense
lipid content, and overexpression of thymidine phosphorylase. The aim of this manuscript was to
confirm that the downregulation of specific drug-resistant biomarkers deregulated in tumor cells by
a defined dose and schedule of methylselenocysteine (MSC) or seleno-L-methionine (SLM) sensitizes
tumor cells to mechanism-based drug combination. The inhibition of HIFs by selenium was necessary
for optimal therapeutic benefit. Durable responses were achieved only when MSC was combined
with sunitinib (a vascular endothelial growth factor receptor (VEGFR)-targeted biologic), topotecan
(a topoisomerase 1 poison and HIF synthesis inhibitor), and S-1 (a 5-fluorouracil prodrug). The
documented synergy was selenium dose- and schedule-dependent and associated with enhanced
prolyl hydroxylase-dependent HIF degradation, stabilization of tumor vasculature, downregulation
of 28 oncogenic miRNAs, as well as the upregulation of 12 tumor suppressor miRNAs. The preclinical
results generated provided the rationale for the development of phase 1/2 clinical trials of SLM in
sequential combination with axitinib in ccRCC patients refractory to standard therapies.
Keywords: methylselenocysteine; seleno-L-methionine; clear-cell renal cell carcinoma microRNAs;
hypoxia-inducible factor; antitumor activity
1. Introduction
Despite advances in the treatment of patients with advanced clear-cell renal cell carcinoma
(ccRCC) with anti-angiogenic agents, checkpoint inhibitors, and mammalian target of rapamycin
(mTOR) inhibitors alone and in combination, durable responses are seen in about 30% of treated ccRCC
patients [1–13]. A systematic review of the first line for metastatic renal carcinoma reported an average
progression-free survival of 8.4 months with a range of 6.5 to 12.3 months, and an average overall
survival of 24.4 months with a range of 18.5 to 32.9 months [14]. Based on the clinical data generated
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in patients with advanced cancer, resistance and the associated dose-limiting toxicities remain major
clinical challenges. There is an unmet clinical need to identify a new treatment modality that is
patient-centric, selective, and efficacious for metastatic ccRCC patients. Both primary and metastatic
ccRCC tumors are uniquely characterized by the expression of altered biomarkers associated with
increased angiogenesis, metastasis, and drug resistance, including deletion and/or mutation of the von
Hippel–Lindau (VHL) tumor suppressor gene in the majority of ccRCC tumors, resulting in the stable
expression of hypoxia-inducible factors 1α and 2α (HIFs), and vascular endothelial growth factor
(VEGF) [15–33]. Programmed death 1 (PD-1) is expressed in the membrane and cytoplasm of activated
T cells, B cells, and dendritic cells. Programmed death ligand 1 (PD-L1) is expressed in 21–75% of
ccRCC tumors, and allows cancer cells to evade immune response [34–47]. Although multiple signaling
and epigenetic pathways regulate the expression of PD-L1, interferons γ and α (INF-γ and INF-α) and
specific oncogenic micro RNAs (miRNAs) are also known to induce PD-L1 [48–53]. PD-L1 incidence
and intensity vary among different tumor types. The analysis of melanoma tumors revealed that
38% of them express both PD-L1 and tumor-infiltrating lymphocyte (TIL), while 41% are negative
for both, and 1% are PD-L1-positive, and 20% are TIL-positive [38,54,55]. PD-L1 was expressed in
69 out of 98 (70.9%) ccRCC tumors expressing mutant VHL. In all wild-type VHL tumors, 11.2%
express PD-L1 [16]. HIFs and PD-L1 are co-expressed in cancer cells. Under hypoxic conditions, HIFs
regulate the expression of PD-L1 by binding to the hypoxia response element in the PD-L1 proximal
promoter to activate its transcription [47,48,56]. PD-L1 expression in cancer cells may, therefore, be
regulated transcriptionally by HIF and post-transcriptionally by miRNAs. It is likely that the effective
downregulation of HIFs would lead to the downregulation of PD-L1, resulting in an increased tumor
response to subsequent treatment with anti-PD-1/PD-L1 therapies.
Thymidine phosphorylase (TP), an angiogenic protein and an enzyme required for the activation
of several 5-fluorouracil (FU) prodrugs, is overexpressed by approximately 30–40% of cancers [57–63].
TP may function as an independent prognostic factor for increased tumor vascularity, and a target for
the activation of 5-FU prodrugs. Utilizing TP to activate 5-FU prodrugs may also reduce its angiogenic
activity, and may synergize with VEGF-targeting drugs. The reported overexpression of TP in ccRCC
provided the opportunity to evaluate 5-FU prodrugs, such as S-1, in combination with tyrosine kinase
inhibitors (TKIs) targeting VEGF/VEGF receptor (VEGFR).
Morphologically, ccRCC tumors are characterized by extensive lipid accumulation.
Hypoxia-inducible protein 2 (HIG-2) is highly expressed in tumors expressing HIF1α, but not
HIF2α [22,64]. Results generated indicate that HIG-2 is a direct target of HIF1α, but not HIF2α.
Carnitine palmitoyltransferase (CPT1A), a fatty-acid transporter in the mitochondria, was recently
reported to be a direct target of HIFs [65]. Clear-cell RCC cells transfected with VHL led to the
downregulation of CPT1A, resulting in fatty-acid transport into the mitochondria, and forcing the
formation of lipid droplets from fatty acids. Recent published reports indicated that ccRCC tumor cells
expressing mutant VHL and the stable expression of HIFs participate in lipid deposition. However,
HIF2α, but not HIF1α, controls the expression of perilipin 2, resulting in lipid storage [66]. In cells with
a co-expression of HIFs, miRNA-155, and miRNA-210, it is possible that HIG-2, CPT1A, and perilipin
2 may also be regulated by miRNAs through HIF-dependent or -independent pathways. Since both
HIFs are involved in the regulation of lipid droplets in ccRCC, agents that target HIF2α, but not HIF1α,
may express limited antitumor activity. Agents that target both HIFs may have greater therapeutic
impact and could avoid the need to regulate or target individual pathways regulated by HIFs.
2. Results
2.1. Hypoxia-Inducible Factors 1α and 2α (HIFs) and VHL Tumor Suppressor Gene
The molecular profiles of ccRCC tumors are summarized in Figure 1 and Table 1. HIFs are
transcriptional factors that regulate the expression of over 200 genes involved in angiogenesis, tumor
metastasis, and drug resistance. Unlike colorectal and head-and-neck tumors, ccRCC tumors feature
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a high incidence and intensity of constitutively expressed HIFs, as well as lower levels of VEGF
and prolyl hydroxylase 2 (PHD2), with no detectable prolyl hydroxylase 3 (PHD3), as assessed by
immunohistochemistry (Table 1).
Figure 1. Hypoxia-inducible factors (HIFs, ‘+’ indicates presence and ‘−’ means absence), vascular
endothelial growth factor (VEGF), high-intensity thymidine phosphorylase (HTP), and programmed
death ligand 1 (PD-L1) biomarker expression in clear-cell renal cell carcinoma (ccRCC) tumors. The
data for HIFs and VEGF were generated by our laboratory [20,22], while others are from published
reports [13,63].
Our laboratory was the first to report that constitutively expressed HIF1α and HIF2α (Table 1,
Figure 2) are selenium targets (adopted from References [20,32]). The data in Figure 2 show that the
inhibition of constitutively expressed HIF1α and HIF2α in RC2 and 786.0 Clear-cell RCC cells, and
HIF1α in FaDu head and neck [32], A548 lung carcinoma cells, and HT29 colorectal tumor cells is
selenium dose-dependent and independent of the disease site/cell type. Unlike other HIF-targeting
agents, selenium inhibits HIF expression via PHD-dependent degradation [20,32].
Table 1. Molecular profile of tumor biopsies.
Incidence of HIF-α and PHDs Protein Expression in Primary Human ccRCC, Head & neck (H/N) and Colorectal Cancer
(CRC) Tumor Biopsies:
Tumors HIF-1α HIF-2α HIF-1α and/or HIF-2α PHD2 PHD3
ccRCC 45% (40/88) 78% (69/88) 92% (81/88) 35% (31/88) 0% (0/88)
H/N 23% (40/173) 16% (23/146) 38% (46/122) 86% (180/210) 21% (32/153)
CRC 13% (8/62) 15% (10/65) 26% (17/64) 90% (55/61) 50% (31/62)
VEGF(A)
Tumors Incidence of Positions Average Immunoscope
ccRCC 54% (48/88) 2.3 (weak)
H/N 79% (136/173) 4.24 (moderate)
CRC 97% (60/62) 5.68 (strong)
51




Figure 2. Constitutively expressed HIFs are selenium targets [20,32]. Effects of methylseleninic
acid (MSA), the active moiety of methylselenocysteine (MSC) or seleno-L-methionine (SLM), on the
expression levels of constitutively expressed HIFs in RC2 and 786.0 renal cell carcinoma, and on HIF1α
head and neck in FaDU, lung carcinoma, A549, and colorectal carcinoma cell lines. RC2 and 786.0 cells
(adopted from Reference [20]) were exposed to 10 μM MSA for 24 h, while other cells—FaDu (adopted
from Reference [32]), A549, and HT29—were exposed to 0.5% O2 for 24 h and treated with different
MSA concentrations. Cells were lysed rapidly on ice and analyzed for HIF expression by Western
blot [20,32].
2.2. Tumor Vasculature
To accommodate survival, growth, and metastasis, tumor cells promote the formation and
development of new blood vessels [36,39]. Tumor-associated blood vessels within the tumor
microenvironment are unstable and leaky, and they could represent a barrier to the delivery of effective
therapies to tumor cells [67,68]. Thus, for the development of efficacious therapy, treatment should
include drugs targeting biomarkers that induce the normalization of tumor-associated vasculature.
Our laboratory was the first to report that the stabilization of tumor vasculature by MSC is dose- and
schedule-dependent. We previously reported that the therapeutic dose and schedule of MSC/SLM
exert dual effects. Firstly, anti-angiogenic effects were achieved via the inhibition of new vessel
formation and a reduction in microvessel density. Secondly, tumor vascular maturation was achieved
through an increase in pericyte recruitment. Collectively, these effects were associated with an increase
in drug delivery and distribution to tumor cells. As shown in Figure 3, in vivo treatment with
therapeutic doses of MSC resulted in a selective increase in vascular maturation index in tumors, but
not in normal liver mouse tissues. The data generated demonstrate that tumor cells and their associated
vasculature can be successfully and selectively modulated in vivo by a therapeutic, non-toxic dose and
schedule of MSC. These results are consistent with the data generated by Jain et al., demonstrating
normalization of the tumor microenvironment by Avastin, an anti-angiogenic agent [69].
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Figure 3. MSC selectively stabilizes tumor vasculature [68,70]. Effects of MSC treatment on the
stabilization of tumor vasculature. Xenografts bearing FaDU tumors were treated orally with 10 mg/kg
MSC daily for seven days, at which point the vascular maturation in tumor and normal liver tissues
was assessed histologically [68,70].
2.3. Oncogenic miRNA-155 and miRNA-210
Non-coding miRNAs are small molecules involved in the post-transcriptional regulation of genes,
and are often associated with increased angiogenesis and drug resistance. Micro RNAs function as
either tumor suppressors or promoters, and they act by targeting the 3’ untranslated region (3’-UTR)
of targeted genes [71,72]. Micro RNAs reduce the gene expression of mRNAs by inhibiting translation
or via degradation of the transcript. Oncogenic miRNA-155 and miRNA-210 are highly overexpressed
in ccRCC tumors expressing HIF1α, HIF2α, VEGF, and PD-L1 [73–81].
To identify a possible link between HIF-α protein expression levels and tumor-associated miRNAs,
three primary ccRCC biopsies and two ccRCC cell lines expressing a similar incidence and distribution
of HIF-α were analyzed using a microarray for miRNA expression. Microarray analysis using an
Exiqon microarray chip of RC2 cells treated with methylselenic acid (MSA), an inhibitor of HIF1α,
revealed that 28 miRNAs were downregulated and 12 miRNAs were upregulated (Figure 4A).
Although several miRNAs were altered, selected miRNAs which were upregulated and downregulated
by MSA treatment are shown in Figure 4B. These results suggest that these miRNAs are likely regulated
by HIF1α and can be effectively modulated by therapeutic doses of selenium.
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Figure 4. Oncogenic and tumor-suppressor micro RNAs (miRNAs) expressed in ccRCC are selenium
targets. Effects of MSA on the expression levels of oncogenic and tumor-suppressor miRNAs altered in
RC2 cells expressing HIF1α: (A) microarray analysis of miRNAs regulated by the treatment of RC2
cells with 10.0 μM MSA for 24 h, and (B) selected miRNAs shortlisted for further analysis.
The data in Figure 5 indicate that the miRNAs that were significantly altered by MSA treatment
of RC2 cells expressing HIF1α and of 786.0 cells expressing HIF2α were also altered in primary
ccRCC biopsies.
 
Figure 5. Selected miRNAs expressed in primary ccRCC biopsies are also expressed in ccRCC cell
lines and can be modulated by selenium. Modulation of miRNAs expressed in ccRCC patient tumor
biopsies, and in RC2 and 786.0 cells lines treated with MSA. Quantitative RT-PCR analysis of selective
hypoxia-regulated microRNA in human RCC patient tumors (n = 3), and in RC2 and 786.0 cells treated
with MSA. MicroRNAs downregulated in human tumors (miR let7b and miR328) (left panel) found
to be upregulated with MSA treatment in RC2 and 786.0 cells. MicroRNAs which were upregulated
(right panel: miR106b, miR155, and miR210; left panel: miR185) in RCC patients were found to be
downregulated with MSA treatment in RC2 and 786.0 cells. Log fold changes are shown compared to
matched normal kidney tissues for patients and untreated RC2 and 786.0 cells.
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Two miRNAs, Let-7b, and -328, which were upregulated, and miRNA-106b, -155, and -210, which
were downregulated by MSA treatment of RC2 and 786.0 cells, were randomly selected to perform
qRT-PCR analysis along with four primary ccRCC tumor biopsies and their paired normal kidney cells.
The results presented in Figure 5 confirmed the microarray data that these selected miRNAs
which were altered in RC2 and 786.0 cells were similarly altered in the patient biopsies, and their
expressions could be modulated in vitro and in vivo by selenium. Collectively, the data generated
demonstrate that a defined dose and schedule of selenium can effectively modulate the expression
levels of specific oncogenic and tumor-suppressor miRNAs altered in ccRCC tumor cells.
2.4. Selenium: A Selective Modulator of Anticancer Therapies
2.4.1. Nude Mice Bearing HIF1α
The data in Figure 6A demonstrate the antitumor activity of MSC in sequential combination
with two representative cytotoxic drugs, irinotecan (an approved drug for the treatment of colorectal
cancer) and docetaxel (used in head-and-neck cancers among others), and radiation therapy. Oral
daily administration of 10 mg/kg/day MSC for seven days prior to and concurrent with the
administration of cytotoxic or radiation therapies beginning on day seven was associated with
enhanced therapeutic efficacy.
 
Figure 6. Antitumor activity of MSC in combination with irinotecan and docetaxel in nude mice
bearing human head-and-neck cancer cells, FaDU and A253 (A), and radiation-treated A549 lung
carcinoma (B). MSC was administered orally daily for seven days and concurrently with anticancer
therapies administered on day seven [82].
The data in Figure 6B demonstrate the antitumor activity of MSC in sequential combination with
radiation therapy of mice bearing A549 lung carcinoma tumors expressing HIF. Collectively, MSC
was found to significantly enhance the therapeutic efficacy of chemotherapy and radiation in different
human cancer xenografts from different disease sites. The results generated suggest that the action of
selenium in tumor cells expressing HIFs is a universal phenomenon, irrespective of the cancer type or
disease site.
2.4.2. Nude Mice Bearing Tumor Xenografts That Constitutively Expressed HIF2α
Figure 7A,B depict tumor growth inhibition by MSC, SLM, axitinib, sunitinib, and topotecan. The
dose and schedule of MSC and SLM that inhibited HIF exhibited limited but similar tumor growth
inhibition. Sunitinib exerted greater antitumor activity than Avastin, axitinib, and topotecan [83]. The
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order of antitumor activity is sunitinib > Avastin ≥ axitinib > topotecan > MSC or SLM. The data in
Figure 7C depict the antitumor activity of tyrosine kinase inhibitors (TKIs) that target VEGF/VEGFR,
and topotecan alone and in combination with either MSC or SLM. The combination of topotecan and
sunitinib in sequential combination with MSC or SLM had the most therapeutic efficacy and achieved
long-term and durable responses not observed with these drugs administered individually. The data
in Figure 7D indicate that MSC and SLM similarly potentiate the antitumor activity of axitinib, a
Food and Drug Administration (FDA)-approved VEGFR-targeting agent for the treatment of relapsed
ccRCC patients. The data in Figure 7E confirm that HIFs are a critical therapeutic target of MSC.
MSC potentiates the antitumor activity of topotecan, a topoisomerase 1 poison which targets HIF
synthesis, as well as that of Avastin, axitinib, and sunitinib, which target VEGF/VEGFR. In comparison,
the antitumor activity of irinotecan, a topoisomerase 1 poison with no demonstrable effects on HIF
protein expression, was not potentiated by MSC. In this model, S-1 exhibited significant antitumor
activity, perhaps due to overexpression of TP. Collectively, the data in Figure 7E indicate that optimal
therapeutic benefit was obtained with MSC in sequential combination with topotecan and sunitinib.
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3. Discussion
Clear-cell RCCs and their associated microenvironment express a unique molecular and
morphological profile including a variety of tumor-suppressor and oncogenic miRNAs. However,
miRNA-155 and miRNA210 are extensively characterized and overexpressed in multiple tumor
types [75–78]. Although VHL may be regulated by multiple biomarkers expressed in tumor cells and
their adjacent microenvironment, miRNA-155 and -210 emerged as key modulators of VHL function,
and may offer an alternative mechanism for stable expression of HIFs in ccRCC tumors [17,77]. Loss of
VHL in ccRCC tumors may mimic the upregulation of HIFs by hypoxia. In recognition of the critical
role of VHL in the pathogenesis of ccRCC tumors, efforts are underway to develop anti-VHL chemical
agents [84,85]. Similarly, recognizing that HIFs are upregulated by hypoxia-dependent and -independent
pathways and that they are critical therapeutic targets, a number of HIF inhibitors are presently under
preclinical and clinical development. A recent phase 1 clinical trial of PT2385, a synthetic small-molecule
HIF2α antagonist, demonstrated clinical activity in previously treated ccRCC patients [86].
Tumor microarray analysis demonstrated that HIF1α and HIF2α are individually and jointly
co-expressed in a majority of primary and metastatic ccRCC biopsies [20]. In addition, it was reported
that, although HIF1α and HIF2α are structurally similar, they functionally regulate different target
genes in different cell types [25]. Furthermore, under hypoxia, the expression of VEGF is regulated
by HIF1α, but not by HIF2α [33]. It is possible that the inhibition of one HIF isoform may induce the
activation of the other in support of tumor growth. The data to date suggest that optimal therapeutic
benefit may require targeting both HIF1α and HIF2α.
HIFs and PD-L1 are co-expressed in cancer cells. Under hypoxic conditions, HIFs regulate
the expression of PD-L1 by binding to the hypoxia response element in the PD-L1 proximal
promoter to activate its transcription [42,47]. PD-L1 expression in cancer cells may, therefore, be
regulated transcriptionally by HIF and post-transcriptionally by miRNAs. It is likely that effective
downregulation of HIFs would lead to the downregulation of PD-L1, resulting in an increased tumor
response to subsequent treatment with anti-PD-1/PD-L1 therapies.
Micro RNA-155 and miRNA-210, amongst others, were reported to modulate the tumor
microenvironment [74,75], regulate glucose metabolism [87], and target transcription factor E2F2
in ccRCC tumor cells [88]. Neal et al. reported that the VHL/HIF axis regulates the expression of
several types of miRNAs in ccRCC tumors, including miRNA155 and miRNA-210 [53]. Increasing
evidence suggests that oncogenic miRNA-155 and miRNA-210 are regulators of immune response
biomarkers, including forkhead box P3 (FoxP3) regulatory T cell, myeloid-derived suppressor cell
(MDSC) T-cells, and immune checkpoint PD-1/PD-L1 [56,80,81,89,90]. Despite the progress made in
our understanding of the biology and therapeutic potential of miRNAs, their clinical use as a prognostic
and as a predictor of therapeutic outcome is yet to be determined. Efforts to develop miRNA inhibitors
fall short of clinical expectations [91–93]. The limited clinical benefits were attributed, in part, to their
limited bioavailability, instability, and dose-limiting toxicities, in addition to an inability to demonstrate
in vivo modulation of expression of intended targets. Our laboratory was the first to demonstrate that
specific types, doses, and a schedule of MSC in ccRCC xenograft models can selectively modulate
specific types of miRNAs.
Clear-cell RCC tumors are highly vascular with clear, large cytoplasms expressing perilipin 2,
hypoxia-inducible lipid-droplet protein 2, which represses fatty-acid metabolism, and is a target
gene of HIF1α [22,64,65]. Molecularly, the majority of ccRCC tumors express high incidence and
intensity of HIF1α, HIF2α, and oncogenic miRNA-155 and -210, which target genes involved in
ccRCC tumorigenesis, including VEGF and PD-L. The tumor microenvironment associated with
ccRCC is leaky and unstable, expressing the common biomarkers that regulate tumor cell growth and
metastasis commonly seen in many cancers. Thus, ccRCC tumors provide the opportunity to test the
hypothesis and rationale for a mechanism-based treatment combination with selenium that may offer
the potential for the development of novel treatment in patients with ccRCC and other cancers with
similar expression of Se targets.
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Resistance and dose-limiting toxicities continue to represent major clinical challenges for
both cytotoxic chemotherapy and biological targeted therapies. In general, in vivo resistance is
regulated by multiple molecular and immunological biomarkers expressed in tumor cells and their
surrounding microenvironment. These two tumor compartments are functionally interactive. The
tumor microenvironment could promote tumor growth while impeding optimal drug delivery and
the distribution of effective tumor drug concentrations. Thus, the tumor microenvironment may be
considered as the gatekeeper, while tumor cells are the ultimate targets. In order to achieve durable
antitumor activity, treatment should include a combination of drugs that enable targeting both the
tumor microenvironment and the tumor cells.
In ccRCC, HIFs, miRNA-155, and miRNA-210 are commonly co-expressed and were reported
earlier to regulate the expression of gene targets implicated in enhanced angiogenesis, tumor metastasis,
and resistance. While considerable efforts are underway to develop miRNA- and HIF-based strategies,
in vivo toxicity, tumor instability, and limited drug delivery in effective concentrations continue to
plague efforts to have a more clinically effective outcome [93]. In addition, an increased activation of
5-FU prodrugs by TP should result in increased antitumor activity [94–96].
During the last several years, our laboratory determined that SLM, an FDA-approved drug
for clinical trials, and MSC (under development) exert several effects that are not shared by other
selenium compounds and HIF-targeting compounds that are currently under preclinical and clinical
evaluation [20,23,70,83–90]. We were the first to demonstrate [97,98], in several tumor xenograft
models, that (1) therapeutic and nontoxic doses and a schedule of organic selenium compounds,
SLM and MSC, potently enhance constitutively expressed HIF1α and HIF2α degradation; (2) SLM
and MSC downregulate VEGF, which is regulated by HIF1α, but not by HIF2α; (3) SLM and MSC
stabilize tumor vasculature resulting in the selective enhancement of drug delivery to tumor cells,
consistent with results reported by Jain [69]; (4) SLM and MSC modulate the expression of a number of
tumor-suppressor and oncogenic miRNAs altered in ccRCC tumors; (5) SLM and MSC offer selective
protection against toxicity induced by toxic and often lethal doses of cytotoxic drugs in preclinical
models [83]; and (6) treatment with MSC and SLM was associated with significant enhancement
of the efficacy and selectivity of anticancer therapies in head-and-neck, colorectal, and renal cancer
xenografts. The antitumor activity of VEFG/VEGFR-targeted therapies alone and in combination with
topotecan and S-1 can be further enhanced by MSC in mice bearing VHL-deficient 786.0 ccRCC tumors
expressing HIF2α, VEGF, miRNA-155, and miRNA-210. Taken together, non-toxic doses of selenium
may offer the potential for the development of novel therapeutic modality. Chart 1 is an outline of the
approach used in the translational development of selenium in combination with anticancer drugs
in preclinical models to phase 1 and 2 clinical trials. The data generated in several xenograft models
provided the rationale for the development of a phase 1 clinical trial in ccRCC patients. The aim was
to confirm that the SLM dose used to yield blood selenium concentrations similar to those determined
therapeutically, synergistic with anticancer drugs in the preclinical model, could be achieved clinically
without toxicity. The optimal SLM dose defined in the phase 1 trial [99] was used to design a phase 2
trial of SLM in sequential combination with axitinib, aimed at assessing the efficacy and modulation of
relevant molecular correlates.
 
Chart 1. “Bench-to-bedside” therapeutic development of SLM from preclinical models to phase 1 and
2 clinical trials in patients with advanced clear-cell renal cell carcinoma (ccRCC).
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Based on the preclinical results generated, a mechanism-based combination therapy is proposed,
as outlined in Chart 2. In order to achieve optimal therapeutic benefit with the proposed
mechanism-based drug combination, the dose, schedule, and sequence of MSC and SLM are critical
parameters. Pretreatment with selenium prior to and concurrent with the administration of anticancer
therapy is necessary for the optimal modulation of relevant selenium biomarkers in tumor cells
and for the optimal stabilization of tumor vasculature. To maintain the optimal and sustained
inhibition of HIFs and associated gene targets, it is recommended that topotecan be administered
in combination with MSC or SLM. Since therapeutic doses and the schedule of selenium partially
downregulate the expression levels of VEGF in tumor cells expressing HIF1α but not HIF2α [20,23],
we propose, therefore, adding TKI inhibitors to the combination regimen in order for maximum
downregulation of VEGF/VEGFR. This proposed mechanism-based combination was evaluated in
786.0 xenografts and was determined to be highly selective and therapeutically effective. The dose and
schedule of the SLM/MSC used were selected based on their molecularly effective dose instead of
the maximum tolerated dose. Furthermore, since the expression level of PD-L1 is regulated by HIFs
and miRNAs, it is reasonable to expect that SLM/MSC will also modulate the therapeutic efficacy of
checkpoint inhibitors. Proof of principle in ccRCC could provide the basis for the verification of this
mechanism-based treatment combination in other tumors expressing these molecular targets similarly
affected by SLM/MSC.
Chart 2. Schematic representation of targetable markers expressed in ccRCC. Methylselenocysteine
(MSC) targets hypoxia-inducible factors (HIFs) and micro RNAs (miRNAs). Topotecan targets
HIF synthesis, while tyrosine kinase inhibitors (TKIs) target vascular endothelial growth factor
(VEGF)/VEGF receptor (VEGFR) and 5-fluorouracil (5-FU) prodrugs are the substrate for activation by
thymidine phosphorylase.
4. Conclusions and Future Perspectives
The aim of this paper was to determine that the levels of specific biomarkers altered in the majority
of ccRCC tumors, such as HIFs, oncogenic miRNA-155 and miRNA-210, and VEGF, can be selectively
downregulated by therapeutic nontoxic doses and a schedule of MSC and SLM. In addition, the aim
was also to confirm that downregulation of these biomarkers would translate into therapeutic synergy
with anticancer therapies. The results in several xenograft models and with multiple cytotoxic and
biologic agents demonstrated that the dose- and time-dependent downregulation of constitutively
expressed HIFs, miRNA-155 and -210, and VEGF-A by selenium was associated with enhanced
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therapeutic efficacy and selectivity of anticancer therapies. Preclinical data generated provided the
rationale for the development of a phase 1 clinical trial in ccRCC patients treated with escalating doses
of SLM in sequential combination with a fixed dose of axitinib [99,100]. Unlike the 200 μg/day SLM
dose used in prevention clinical trials, the SLM doses used in combination therapy were 10 mg/kg in
nude mice, and 8000 μg/day in ccRCC patients, which was the dose recommended for the ongoing
phase 2 clinical trial for efficacy assessment and for the monitoring of the effects of SLM on relevant
biomarkers. The plasma selenium concentrations achieved clinically with the recommended SLM
dose were comparable with those achieved with SLM doses determined therapeutically synergistic
with anticancer drugs in preclinical models. The mechanism-based drug combination proposed
in Chart 2 warrants expanded preclinical investigation and clinical verification. Proof of concept
that enhanced therapeutic efficacy and selectivity of axitinib in refractory ccRCC patients are SLM
dose- and schedule-dependent will be highly innovative and significant. Furthermore, the ability
of selenium to downregulate specific biomarkers associated with drug resistance may provide the
opportunity for the clinical development of SLM in sequential combination with other clinically
available targeted therapies.
5. Material and Methods
5.1. Cell Culture and Drug Treatments
Clear-cell RCC cell lines 786.0 and RC2 were cultured in Rosewell Memorial Park Institute
(RMPI-1640) medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (PenStrep,
Sigma-Aldrich, St. Louis, MO, USA) at 37 ◦C in an incubator with 5% CO2. Cells were routinely tested
for mycoplasma contamination. Cells were seeded in T75 and/or T150 flasks, and were allowed to
grow overnight. Cells were treated with MSA for 24 to 48 h, and were processed to isolate total RNA.
Untreated control cells were maintained without treatment.
5.2. Animals
Female athymic nude mice (Envigo, nu/nu, 20–25 g body weight), 8–12 weeks of age, were
used for the tumor xenograft experiment as previously described [97]. All studies were carried out
as approved by the Institutional Roswell Park Comprehensive Cancer Center Animal Care and Use
Committee (207M, 2009).
Tumor Xenografts
Clear-cell RCC 786.0 cells were cultured in RMPI-1640 and transplanted into nude mice to establish
xenografts. Tumors were harvested, and ~50 mg of non-necrotic tumor tissue was transplanted into
nude mice and randomized to groups of 5–10 mice each. Treatment with drugs alone or in combination
was started when tumors reached ~200 mg, and the tumor volume and response were measured
as described previously [97]. Drug toxicity was evaluated by measuring the weight loss of the
mice biweekly.
5.3. Drugs
MSC and SLM (Sigma-Aldrich, St. Louis, MO, USA) were given at 0.2 mg/kg for 35 days
starting seven days prior to the start of drug treatment. Axitinib (AdooQ Bioscience, Irvine, CA,
USA), sunitinib (LC laboratories, Woburn, MA, USA), and topotecan (Selleckchem, Houston, TX, USA)
were administered orally at 25 mg/kg, 80 mg/kg, or 2 mg/kg five days per week for four weeks,
either as a single drug or in combination. Avastin (Genentech, South San Francisco, CA, USA), was
given at 5 mg/kg via intraperitoneal injection for five days/week for four weeks either by itself or in
combination with selenium.
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5.4. Total RNA Isolation from ccRCC Cells Treated with and without MSA
Cells were treated with MSA for 24–48 h and processed for isolation of total RNA using Trizol
reagent as per the instructions of the manufacturer (Invitrogen, Liverpool, NY, USA). RNA quantity
and quality was measured using Nanodrop (Thermo-Fisher Scientific, Liverpool, NY, USA), and then
used for microRNA microarray analysis and quantitative PCR analysis of microRNA.
5.5. Total RNA from ccRCC Patient Tumors and Their Matched Normal Tissues
Total RNA of de-identified ccRCC patient tumors and their matched normal kidneys were
obtained from the RPCI Pathology core facility. RNA samples were isolated using Trizol reagent
(Thermo-Fisher Scientific, Liverpool, NY, USA) from the non-necrotic tissues selected by the pathologist,
and purity was determined before use for detecting microRNA expression by qRT-PCR.
5.6. Reverse Transcription (RT) and miRNA qPCR
Complementary DNA (cDNA) was prepared using the following quantities of each reagent and
RNA: 4 μL (20 ng) of RNA, 9 μL of H2O, 1 μL of Spike-In, 4 μL of reverse transcription (RT) buffer,
and 2 μL of enzyme in a total volume of 20 μL. Immediately after the RT reaction was finished, a 1:80
dilution was made on the cDNA, and ROX was added. The reaction mix for qRT-PCR was prepared
using 400 μL of SYBR® Green Master Mix (Thermo-Fisher Scientific, Liverpool, NY, USA) and 320 μL
of cDNA (from the above diluted RT reaction). Then, 9 μL of this mix was added to a 384-well plate
pre-loaded with specific miR primers in triplicate using an electronic multichannel pipette. Plates were
sealed with optical tape and shaken on a plate shaker for 30 s, before being centrifuged for one minute
and run on the ABI7900 qPCR machine (Applied Biosystem, Foster City, CA, USA). Quantitative PCR
machine cycling conditions and parameters were set exactly the same for every plate.
Normalization of Exiqon miRNA Panels (http://www.exiqon.com/mirna-pcr-panels) Excerpt
from Exiqon Manual: Inter-Plate Calibrator (IPC). Since each assay was present only once on each
plate, replicates were performed using separate plates. This raises the issue of run-to-run differences.
To allow for simple inter-plate calibration, we designed a calibration assay with an accompanying
template (annotated as UniSp3 or IPC in the plate layout files). Three wells were assigned for inter-plate
calibration to provide triplicate values with the possibility for outlier removal. In each of these wells,
both the primers and the DNA template were present, giving high reproducibility. The inter-plate
calibrator requires only the addition of the SYBR® Green master mix in order to give a signal and can,
therefore, be used for quality control of each plate run.
GenEx Software (ver 6.1, Thermo-Fisher Scientific, Liverpool, NY, USA: http://www.exiqon.com/
qpcr-software.
Plates were imported into the GenEx software (ver 6.1, Thermo-Fisher Scientific, Liverpool, NY,
USA) and the IPCs (in triplicate on each plate) were used to normalize the plates helping to eliminate
run-to-run variation when comparing multiple plates. All Ct values above 38 were set to 38 as the
maximum value (this is arbitrary and may even be left blank to denoted non-amplification). All
miRNAs were listed in an excel file regardless of whether or not they were expressed in the samples,
with normalized Ct values for each sample. Data were represented as individual triplicate runs and as
averages of triplicates (with outliers excluded). Expressions of miRNA were normalized to untreated
controls, and fold changes with the selenium treatment were determined. In ccRCC patient tumors,
microRNA expression was normalized to normal tissue and fold changes were determined.
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Abbreviations
ccRCC Clear-cell renal cell carcinoma
HIF Hypoxia-inducible factor
HIG-2 Hypoxia-inducible protein 2
IFN Interferon
MSC Se-methylselenocysteine
PD-1 Programmed death 1 receptor
PD-L1 Program death ligand 1
SLM Seleno-L-methionine
TP Thymidine phosphorylase
TNF Tumor necrosis factor
TKI Tyrosine kinase inhibitor
TIL Tumor-infiltrating lymphocyte
VEGF Vascular endothelial growth factor
VHL von Hippel–Lindau
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Abstract: Selenium-binding protein 1 (SBP1) is a highly conserved protein that covalently binds
selenium. SBP1 may play important roles in several fundamental physiological functions, including
protein degradation, intra-Golgi transport, cell differentiation, cellular motility, redox modulation,
and the metabolism of sulfur-containing molecules. SBP1 expression is often reduced in many cancer
types compared to the corresponding normal tissues and low levels of SBP1 are frequently associated
with poor clinical outcome. In this review, the transcriptional regulation of SBP1, the different
physiological roles reported for SBP1, as well as the implications of SBP1 function in cancer and other
diseases are presented.
Keywords: selenium-binding protein 1; SBP1; SELENBP1; hSP56; cancer; disease
1. Introduction
Selenium (Se) is a non-metallic, essential trace element for many organisms, including humans.
Se has long been recognized for its potential in cancer prevention as evidenced by multiple animal,
and human epidemiological studies that have reported an inverse association between Se status
and cancer risk [1–8]. Many mechanisms have been suggested for the chemopreventive effect of
Se [9–11], including DNA hypomethylation [12], blocked cell cycle progression, enhanced cell death,
decreased cell proliferation, increased glutathione peroxidase or thioredoxin reductases activities [13],
modulated ER stress response [14], and enhanced DNA repair [15]. Furthermore, Se has been
found to play a key role in mammalian development [16] and immune function [17,18]. Low
levels of Se may be a contributing factor to several pathologies, including male infertility [19], heart
disease [20], inflammation [21,22], and neuromuscular disorders [23]. It is generally recognized that
important cellular and organismal functions of Se are likely mediated by the action of selenoproteins
constituting the mammalian selenoproteome [24]. While the functions of many selenoproteins are still
unknown, they likely have a significant role in human health and disease. Human selenoproteins
are generally classified into three categories [11,25]. The first category includes proteins in which
Se is cotranslationally incorporated into the elongating peptide as the amino acid selenocysteine
in response to an in-frame UGA codon in the corresponding messenger RNA [26]. The human
selenoproteome contains 25 genes [25]. The second category consists of proteins in which Se is
incorrectly substituted for sulfur in sulfur-containing amino acids due to the similarity in structure
between these two elements. The third category is composed of selenium-binding proteins which bind
Se by an unknown mechanism. This review will be primarily focused on one member of the latter
category, selenium-binding protein 1 (SBP1, SELENBP1, hSP56).
2. SBP1 Discovery
SBP1 was first discovered in mouse liver in 1989 by Bansal et al. using 75Se labelling. Normal
6-week old female BALB/c mice were given a single intraperitoneal injection of 75Se in the form of
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Na2SeO3. After 40 h, animals were euthanized and livers were harvested for preparation of liver
cytosols which were then used for a combination of gel filtration, ion-exchange chromatography
and SDS-PAGE techniques. This led to identification of four selenium-binding proteins of apparent
molecular weights of 12, 14, 24, and 56 kDa [27]. The 56-kDa protein was designated as SBP1, whereas
the 24-kDa protein was identified as glutathione peroxidase 1 (GPX1), an enzyme that detoxifies
hydroperoxides using reducing equivalents from glutathione [28]. The full-length human SBP1 cDNA
clone was first described by Chang et al. in 1997 and determined to be 1668 base pair (bp) long with an
open reading frame encoding 472 amino acids [29]. SBP1 is abundantly expressed in various human
tissues, including liver, lung, prostate, colon, and pancreas, while moderate levels were detected
in spleen, heart, and ovary. In contrast, its expression was barely detectable in thymus, testis, and
peripheral blood leukocytes [30]. SBP1 is a highly-conserved protein. Flemetakis et al. reported that
the predicted amino acid sequence of SBP1 is conserved in both plants and animals, ranging from 77
to 88% in plants, while the identity between the plants and mammalian proteins ranged from 57 to
60% [31]. By comparison, this degree of homology is higher than other conserved proteins, such as
HSP60, γ-tubulin, apoptotic cell death 1 protein, and elF4E whose identities of the plant and human
proteins are 44, 49, 48, and 52%, respectively [31]. The homology between the mammalian SBP1 of mice
and humans is 86% [31], indicating that the potential fundamental cellular and molecular functions for
SBP1 are also conserved across different species. SBP1 is very similar to another selenium-associated
protein, selenium liver binding protein (AP-56, SBP2), whose sequence differs by only 14 residues from
SBP1 and is encoded by a distinct gene [32]. AP-56 is implicated in the detoxification of acetaminophen
in the liver [32]. Although these genes are regulated differently, their similarity may indicate a role for
SBP1 in detoxification.
3. The Role of Se in SBP1
The form of Se in SBP1 is currently unknown. Se is stably associated with SBP1, probably through
a selenosulfide bond (perselenide), as indicated by the binding of Se to SBP1 being reversed by the
addition of a reducing agent during SDS-PAGE [33]. Based on structural and functional studies, it was
suggested that one cysteine in SBP1 was the likely binding site for the Se molecule, the cysteine at
position 57 [34]. Converting cysteine 57 in SBP1 to a glycine and ectopically expressing that protein in
human HCT116 cells that do not express detectable SBP1 levels indicated that the loss of the cysteine
reduced the half-life of the protein, induced mitochondrial damage, and attenuated the degree of
phosphorylation of signaling proteins such as p53 and GSK3β compared to the native protein expressed
at similar levels [35].
The Se in SBP1 may facilitate its interaction with other proteins. SBP1 physically interacts with
von Hippel–Lindau protein–interacting deubiquitinating enzyme 1 (VDU1), which plays a role in
proteasomal protein degradation [33,36]. This indicates that SBP1, via its interaction with VDU1,
may have a role in ubiquitination/deubiquitination-mediated protein degradation and detoxification
pathways. When the Se moiety was dissociated from SBP1 by the addition of ß-mercaptoethanol, the
interaction with VDU1 was completely blocked, indicating that Se may be essential for the interaction
of these two proteins [33]. While the Se moiety is likely required for its interaction with VDU1,
the inclusion of Se in SBP1 does not appear to be essential for functioning as methanethiol oxidase
(MTO), a recently-discovered novel human SBP1 enzyme activity that metabolizes sulfur-containing
molecules [37].
As a non-selenocysteine containing protein, SBP1 is not considered as a part of the “selenium
hierarchy” that describes the relative response of selenoproteins to the availability of Se [38]. Initial
studies feeding rats varying amounts of Se led to the conclusion that SBP1 levels were not likely
dependent upon dietary Se supplementation [39]. However, there may be indirect regulation of SBP1
by Se due to its interaction with GPX1, a member of the selenocysteine-containing selenoproteins.
GPX1 is a highly conserved and ubiquitously expressed enzyme that detoxifies hydrogen and lipid
peroxides and is implicated in several diseases by human genetics [40]. There is a reciprocal regulatory
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relationship between SBP1 and GPX1. Ectopically expressing SBP1 in HCT116 human colon cancer
cells that do not express endogenous SBP1 resulted in the inhibition of GPX1 enzyme activity without
affecting protein levels [28], indicating a likely physical interaction. Consistent with this possibility
was data indicating that knocking down SBP1 in human liver cells resulted in a 4–5 fold increase in
GPX activity, also without altering protein levels [41].
Expressing GPX1 in MCF7 human breast cancer cells that do not exhibit detectable GPX1 levels
resulted in a decline in both SBP1 mRNA and protein levels [28]. The reciprocal relationship between
SBP1 and GPX1 has also been established in mouse colon and duodenum epithelial cells [28], as well
as human prostate and liver tissues [41,42]. This raises the possibility that SBP1 can be indirectly
downregulated by Se because GPX1 is high on the Se hierarchy, being among the selenoproteins
most responsive to Se availability. Support for the indirect regulation of SBP1 by GPX1 comes
from experiments showing that increasing Se in the culture media of MCF7 cells caused a dramatic
reduction in SBP1 levels only when GPX1 was present and GPX1 levels were increased by the Se
supplementation [28].
4. SBP1 Levels Are Reduced in Cancer and Low Levels Are Predictive of Clinical Outcome
One of the striking observations about SBP1 is the diversity of the types of cancers in which
SBP1 was found to be reduced compared to normal or benign tissues (reviewed in [43]), including
cancers of the thyroid [44], lung [45], stomach [46,47], liver [41], kidney [48], ovary [49–51], breast [52],
prostate [53,54], colon [55,56], head and neck [57], and malignant melanoma [58]. In addition to
being lower in cancers, the degree of reduction of SBP1 in resected tissues is often predictive of how
long a patient will be cancer free and survive their disease [43]. Reduced SBP1 levels have been
correlated with poor survival in several types of carcinomas, including colorectal [55,59], gastric [47],
nasopharyngeal [57], pulmonary [45], renal [48], and prostate [53] cancers. Recently, a search for
genetic variations in selenoprotein genes revealed that a polymorphism in the gene for SBP1, along
with variations in the genes of selenocysteine encoding genes, were associated with prostate cancer
aggressiveness at diagnosis [60]. The exception to this pattern is ovarian cancer where higher levels of
SBP1 were associated with poor survival [50].
In addition to its levels, the distribution of SBP1 between cellular compartments may be relevant
to cancer etiology. The associations between prostatic SBP1 levels, tumor grade, and disease recurrence
following prostatectomy were investigated using a tissue microarray containing tissue from more than
200 prostate cancer patients who experienced biochemical (PSA) recurrence after prostatectomy and
matched control patients whose cancer did not recur [53]. Reduced SBP1 levels were associated with a
higher likelihood of prostate cancer recurrence, as has been seen in other cancer types. The subcellular
localization of SBP1 was both nuclear and cytoplasmic, with nuclear staining being sporadic (Figure 1).
However, a lower nuclear-to-cytoplasmic distribution of SBP1 was associated with a higher tumor
grade (Gleason score) [53]. These results indicate that sequestration of SBP1 in a particular cellular
compartment may restrict access to relevant substrates or the protein has different functions at
these locations.
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Figure 1. Localization of SBP1 in prostate cancer. Human prostate cancer tissue showing cells that
express SBP1 (magenta) mostly in the cytoplasm and several cells that express SBP1 in the nucleus.
Nuclei are highlighted with DAPI (blue).
4.1. Is SBP1 a Tumor Suppressor?
The frequent loss of SBP1 in cancer and the association of reduced SBP1 levels with greater
mortality could imply that SBP1 is a tumor suppressor. Alternatively, its loss or downregulation
may be a consequence of cancer development and progression, and the reduced levels represent
a mere “bystander effect”. Data supporting the direct role of SBP1 in cancer comes from studies
where its levels are altered in cells and consequences relevant to transformation and tumorigenesis
are revealed. Over-expressing SBP1 in colon, gastric, and prostate cancer cells have generally yielded
results consistent with a tumor suppressor function, including reduced growth in semi-solid media
and decreased tumorigenicity in xenograft studies using immune-deficient mice [46,53,54,61,62].
When over-expressed in lung cancer cells, SBP1 reduced proliferation and induced greater apoptosis
compared to control cells only when the cells were challenged with H2O2 [41]. Some of the
phenotypic consequences of over-expressing SBP1 may be due to the downstream activation of
the p53 tumor suppressor protein. Over-expression of SBP1 in HCT116 human colon cancer cells
resulted in the increased phosphorylation of p53 [53]. In addition to the phosphorylation of p53, SBP1
over-expression in the same cells resulted in the differential expression of 132 proteins, many are
associated with energy metabolism and MAPK, Wnt, NF-κB, and Notch signaling [61]. This same
study reported that the expression of SBP1 resulted in the reduction of TWIST1, a critical regulator of
the epithelial-mesenchymal transition and metastasis.
Consistent with over-expression data, either knocking down SBP1 or inactivating the gene
using CRISPR/Cas9 editing in mouse lung cancer cells and injecting these cells into syngeneic hosts
increased the size of tumors obtained compared to controls, although the number of tumors was not
increased [63]. Knockout mice that are null for SBP1 exhibit very limited pathology and do not develop
tumors [64]. However, examining the ovaries from these animals by gene expression microarrays
indicated the increased expression of several genes associated with ovarian carcinogenesis, including
Notch1 and Fas1 [64]. Less clear is why tumor suppressor genes such as Apc, RB1, and Trp53 were
also enhanced in the ovaries from these mice. Collectively, studies altering the levels of SBP1 provide
substantial evidence that SBP1 serves as a tumor suppressor and its loss or downregulation during
cancer development contributes to disease development or progression.
4.2. Is SBP1 Downregulation an Early or Late Event in the Process of Tumorigenesis?
Given the data presented above indicating the frequent downregulation of SBP1 in cancers and
its association with poor outcomes, it raises the issue of whether SBP1 loss occurs early in cancer
development or late in the process, contributing to cancer progression. This issue was investigated
by Zhang et al. who examined SBP1 levels in tissues classified as gastric cancer, precursor lesions,
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and matched controls of corresponding non-neoplastic epithelial tissues [65]. SBP1 was reduced in
most of the gastric cancer tissues compared to its abundant expression in matched non-neoplastic
controls and precursor lesions, including tissues obtained from gastric ulcers, gastric polyps, as well
as tissues presenting with chronic atrophic gastritis, intestinal metaplasia and dysplasia [65]. SBP1
expression was similar in tissues with different levels of intestinal metaplasia or dysplasia indicating
that the reduction of SBP1 levels may be a late event associated with gastric carcinoma progression from
normal gastric epithelium or premalignant lesions [65]. These results are consistent with those of Kim
et al. who observed much lower levels of SBP1 in colorectal carcinomas compared to matched controls
of normal tissues and colon adenomas, supporting the notion that SBP1 loss is a late event during
tumorigenesis [59]. In addition, changes in the levels of proteins that occur during the progression
of human squamous lung cancer were investigated using isobaric tags for relative and absolute
quantitation labeling combined with 2D LC-MS/MS [66]. SBP1 levels were determined by western
blotting and immunohistochemistry and shown to be progressively lost during bronchial epithelial
cancer progression [66].
In contrast to the data obtained examining gastric, bronchial, and colonic tissues, results have also
been reported indicating that the reduction in SBP1 expression may be an early event in the evolution
of some tumor types, including ovarian cancer [50] and uterine leiomyoma [67]. Huang et al. identified
SBP1 to be the most significantly reduced protein in ovarian cancer cell lines, including DOV13,
OVCA429, OVCA882, TOV112D, and SKOV3 using a membrane proteome profiling analysis [50].
However, relatively low levels of SBP1 were also observed in the immortalized human ovarian cell
line, HOSE2089, indicating that the reduction of SBP1 may have occurred during the immortalization
process [50]. SBP1 expression was also approximately 4-fold lower in leiomyoma samples compared
to normal myometrium, as determined by western blotting and immunohistochemistry [67]. However,
SBP1 levels were similar in tissues obtained from patients with proliferative secretory and atrophic
endometrium in either leiomyoma or normal myometrium. These contrasting results may indicate
distinct roles of SBP1 in the development of cancers of different origins.
5. Physiological Roles for SBP1
The impact of SBP1 on normal biological processes and pathologies other than cancer may be
due to roles in the modulation of cellular redox homeostasis. The SBP1 amino acid sequence contains
two bis (cysteinyl) sequence motifs, Cys-X-X-Cys, at Cys5-X-X-Cys8 and Cys80-X-X-Cys83 shown
to be a characteristic feature among several proteins which are involved in modulating the cellular
redox state in vivo [68]. In addition, SBP1 may also modulate the redox state of the extracellular
environment. Experimental data in support of this comes from a study where the knockdown of
SBP1 in MCF-7 breast cancer and HC116 colon cancer cells by siRNA resulted in increased levels of
H2O2 and superoxide ion, leading to enhanced apoptosis when cells were exposed to selenite [69].
The authors attributed this effect to the significant increase in extracellular glutathione in the culture
media. Changes in either the intracellular or extracellular environment can potentially impact a broad
range of biological processes responsive to reactive oxygen in signaling pathways and contribute to
the pathology associated with SBP1 dysregulation.
SBP1 has also been implicated in the late stages of intra-Golgi transport. Using an in vitro
intra-Golgi cell-free transport assay, both endogenous and recombinant SBP1 (rSBP1) exhibited
transport activity in the cell-free assay and the addition of antibodies directed against SBP1 abolished
this activity [70]. This data indicates that SBP1 may be regulating vesicular intra-Golgi transport,
particularly at the docking or fusions stages [70]. The reported roles for SBP1 are summarized
in Figure 2.
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Figure 2. The potential roles of SBP1 in human health and disease. Illustration of the different potential
functions reported for SBP1 in the published literature.
Tissue-Specific Roles for SBP1
Several studies have indicated a potential role for SBP1 in neurobiology. SBP1 has been localized
at the tips of rapidly extending protrusions in T98G glioblastoma multiforme cells in vitro [71]. Cell
protrusive motility, which is tightly associated with actin filament polymerization, is an essential
function for multiple cellular processes, including cell proliferation and migration. Monomeric G-actin,
but not filamentous F-actin, was shown to be recruited to the SBP1-positive tip, indicating that the
recruitment of SBP1 and G-actin at the cell margin precedes actin polymerization [71]. In addition,
SBP1 recruitment to the cell margin was observed to precede that of G-actin. The extension of the
protrusion will stop when G-actin polymerizes to F-actin at the protruding edges, hence, SBP1 and
G-actin disappear from these margins. SBP1 also localized to the growing tips of neurites in SH-SY5Y
neuroblastoma cells in vitro [71], possibly indicating a role for SBP1 in neuronal cell outgrowth.
Changes in the levels of SBP1 in neuronal tissues may implicate the protein in several
neuropathologies. SBP1 mRNA has reported to be elevated in the frontal cortex of patients with
schizophrenia, indicating a potential specialized role in the pathophysiology of schizophrenia and the
central nervous system [72–74]. Genetic data has also implicated SBP1 in the risk of schizophrenia as
two single nucleotide polymorphisms in the SBP1 gene (rs2800953 and rs10788804) have been identified
as susceptibility loci for schizophrenia in a family-wide association study [75]. This, and a report
of plasma SBP1 protein levels being decreased in patients with recent-onset schizophrenia [76],
collectively indicate a potential specialized role for SBP1 in the pathophysiology of this disease.
Whether these data indicate a role for SBP1 in the proper functioning of the central nervous system or
the potential neuroprotective effect of Se against oxidative and excitatory brain damage [77] remains
to be determined.
SBP1 may also be involved with the pathogenesis of glaucoma. Elevated levels of SBP1 have
been associated with elevated ocular pressure [78]. It was also identified as a differentially expressed
gene in datasets comparing transcripts in glaucoma to normal control tissues, which has been verified
in a rat model of acute elevated intraocular pressure [79]. SBP1 was also identified as a novel target
antigen in patients with Behçet’s disease (BD) with uveitis, where an autoimmune response to retinal
antigens is considered to be involved in the pathogenesis of the uveitis in those patients [80,81]. What
if any role SBP1 plays in these diseases has not yet been investigated.
6. The Transcriptional Regulation of SBP1
A greater understanding of the biological roles of SBP1 could be gained by examining how its
expression is regulated. A subtractive hybridization approach was used to identify transcripts that
were more abundant in the relatively fast growing PC-3 human prostate cancer cells compared to slow
growing LNCaP cells [30]. The low levels of SBP1 mRNA in LNCaP cells was shown to be due to
the down regulation of SBP1 transcription as treatment with of androgen-sensitive LNCaP cells with
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dihydrotestosterone (DHT, active form of androgen) reduced the levels of SBP1 mRNA in a reversible,
concentration-dependent manner [30]. A more complicated picture was revealed by the analysis of the
effect of androgen on normal ovarian epithelial cells obtained from the scraping of the ovary surface of
patients with benign disease, an immortalized cell line, and ovarian cancer cell lines [50]. Treatment of
the primary and immortalized cells with DHT reduced the levels of SBP1 mRNA while SBP1 levels
were increased in four tumor-derived cell lines by DHT treatment. The mechanism accounting for the
differential response of these cell lines to DHT has not been resolved.
In addition to androgens, SBP1 expression is also downregulated by estrogen treatment (17-β
estradiol) in estrogen receptor (ER)-positive breast cancer cells, but not in ER-negative cells [52].
The suppression of SBP1 expression by transforming growth factor beta (TGF-β) was also observed
using a rhesus monkey renal allograft model to identify molecules involved in the pathogenesis
of chronic allograft nephropathy (CAN) [82]. SBP1 was absent or markedly reduced in vascular
smooth muscle cells in monkey kidney allografts with CAN. Testing growth factors previously
associated with graft rejection, including IFNγ, TNFα, and PDGF, only TGF-β blocked the expression
of SBP1 in the normal human vascular smooth muscle cell line, CRL-1999 [82]. It is unlikely that the
effects of androgens or estrogens on SBP1 transcription is a direct consequence of the binding of the
corresponding receptor to the SBP1 promoter as there does not appear to be a consensus binding
sequence for the receptor/transcription factor.
The mouse Sbp1 gene has been identified as a direct target gene of the hypoxia-inducible
factor-1α (HIF-1α) transcription factor in primary keratinocyte cell cultures [83]. Scortegagna et al.
examined HIF-1α gain of function during multistage murine skin chemical carcinogenesis in
K14-HIF-1αPro402A564G transgenic mice. They concluded that HIF-1α was functioning as a tumor
suppressor, most likely by upregulating target genes, including Sbp1. Four hypoxia response elements
were located within 1400 bp of the transcription start site of the human promoter region of SBP1,
although the demonstration that these were bona fide response elements was not provided [83].
HIF-1α is a central mediator of the cellular response to environmental stresses, such as hypoxia [84].
It is overexpressed in many types of human cancer [85–87] and its overexpression is associated with
treatment failure and increased mortality in some cancers including cancers of the cervix [88,89],
breast [90,91], ovary [92], uterus [93], stomach [94], and brain [95]. It is also associated with
decreased mortality in other cancers, including those of the head and neck [96] and non-small-cell
lung cancer [97]. The consequences of the changes of HIF-1α levels are cancer-type specific and the
accompanying molecular alterations, such as SBP1 reduction/loss, can affect the balance between pro-
and anti-apoptotic factors. A study by Huang et al. demonstrated that the decreased expression of
SBP1 could lead to a higher GPX1 activity and reduced HIF-1α expression in hepatocellular carcinoma,
indicating that SBP1 might exert its tumor suppressive function as a regulator of the tumor redox
microenvironment [41].
In addition to the putative HIF-1α response elements in the SBP1 promoter, two potential
antioxidant response elements (ARE) with strong homology to the consensus ARE recognition motif
are present in promoter region of SBP1 [28], although the functionality of these sequences as AREs has
yet to be established. The presence of functional AREs in the promoter region of SBP1 may account
for the repression of transcription observed when the anti-oxidant selenoprotein GPX1 is ectopically
expressed in colon carcinoma cell lines [28], as well as the reciprocal relationship observed in cells and
tissues [43]. The factors potentially regulating SBP1 and some downstream targets are summarized
in Figure 3.
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Figure 3. The molecular regulation of SBP1. Illustration of the different proteins that can potentially
interact, be regulated by, or regulate SBP1 according to the literature. TGF-β: transforming growth
factor beta; HIF-1α: hypoxia-inducible factor-1α; H2S: hydrogen sulfide; VDU1: von Hippel–Lindau
protein–interacting deubiquitinating enzyme 1; TWIST1: Twist Family BHLH Transcription Factor 1;
TP53: tumor protein p53.
In some cases, epigenetic silencing by promoter methylation may be a mechanism by which the
expression of SBP1 is reduced in human colon cancers. Comparing DNA obtained from colon cancer
samples to DNA obtained from matched normal tissue indicated significantly more methylation in the
promoter region of samples from the cancers [56]. Hypermethylation of the SBP1 promoter region was
demonstrated in the human colon cell lines SW480, Caco-2, HT-29, and HCT1161 in which the extent
of promoter methylation was associated with the degree of SBP1 protein levels. Moreover, treatment
of these cells with 5-aza-deoxycytidine, a demethylation agent, decreased promoter methylation and
resulted in increased promoter activity and protein levels [56]. In contrast, treatment of three different
human colon cancer cell lines, LOVO, SNU-C4, and A549, with 5-aza-deoxycytidine did not result in
increased SBP1 expression, nor was there any evidence of genetic loss at the SBP1 locus [59]. There was
also a lack of evidence for either hypermethylation or genetic deletion accounting for the low levels of
SBP1 observed in lung cancers [98]. While there is consistent loss of SBP1 in many cancer types, there
may be a multitude of ways in which tumor cells can achieve the reduction in SBP1 expression.
7. SBP1 Is a Methanethiol Oxidase
The enzymatic function of SBP1 was recently revealed by investigators examining the genetic
determinants of extraoral halitosis, bad breath [37]. The authors analyzed breaths and body fluids of
five affected individuals with extraoral halitosis from three unrelated families using NMR spectroscopy
and gas chromatography with a sulfur-specific detector. All patients exhibited elevated levels of
methanethiol (MT), dimethylsulfide (DMS), dimethylsufoxide, and dimethylsulfone in breaths and
body fluids [37]. The authors postulated that the accumulation of these compounds was due to a defect
in a protein which oxidizes MT, leading to its accumulation in affected individuals. Methanethiol
oxidases (MTOs) have not previously been reported in humans, but SBP1 was identified as a candidate
gene for extraoral halitosis by searching for human sequences that were similar to the gene encoding
an MT-metabolizing protein previously recognized in methylotropic bacteria, the mtoX gene. This
effort revealed a 26% identity and a 54% sequence similarity between the two genes [37]. Subsequent
sequencing of SBP1 in patients DNAs revealed four different biallelic mutations in the five patients
(1039G>T, 481+1G>A, 673G>T, and 985C>T) that were predicted to be pathogenic. Fibroblasts from
these patients had significantly reduced SBP1 protein levels and undetectable MTO enzymatic activity,
compared to the control cells [37].
MTO converts MT to H2O2, formaldehyde, and hydrogen sulfide (H2S), the latter is a gaseous
signaling molecule with distinct functions at different cellular concentrations [99,100]. At low
concentrations, H2S stimulates mitochondrial electron transport in mammalian cells, increasing oxygen
consumption [101]. At high concentrations, H2S is toxic through the inhibition of mitochondrial
respiratory-chain complex IV, and consequently reduces oxygen consumption [101]. H2S has been
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proposed as a therapy for multiple disorders by suppressing inflammation, affecting apoptotic
pathways, increasing anti-oxidant defenses, and vasodilatation [99,102,103]. It is quite conceivable that
many of the consequences of SBP1 expression can be due to the effects on H2S levels as well as the
other products of the MTO-mediated reaction, on a broad spectrum of physiological endpoints.
8. Conclusions
Among the selenium-associated proteins, SBP1 is relatively less studied, but is a highly-conserved
protein that may be critical for a variety of physiological functions, including cell differentiation,
protein degradation, intra-Golgi vesicular transport, cell motility, and redox modulation. The variety
of processes where SBP1 has been implicated to have a role is suggestive that there may be cell
type-specific functions that are yet to be identified. The only enzymatic function of SBP1 identified
to date is MTO activity and it is possible that different levels of both its substrates and products
provide differential signals, resulting in distinct intracellular and extracellular environments for the
SBP1-expressing cells. With a better understanding of the function of SBP1 in these tissues, its role
in diseases such as cancer may be resolved and SBP1 may become a novel therapeutic target for
interventions to control it levels and/or activity.
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Abstract: In the last two decades, the discovery of various pathways involved in renal cell carcinoma
(RCC) has led to the development of biologically-driven targeted therapies. Hypoxia-inducible
factors (HIFs), angiogenic growth factors, von Hippel–Lindau (VHL) gene mutations, and oncogenic
microRNAs (miRNAs) play essential roles in the pathogenesis and drug resistance of clear cell renal
cell carcinoma. These insights have led to the development of vascular endothelial growth factor
(VEGF) inhibitors, Mechanistic target of rapamycin (mTOR) inhibitors, and immunotherapeutic
agents, which have significantly improved the outcomes of patients with advanced RCC. HIF
inhibitors will be a valuable asset in the growing therapeutic armamentarium of RCC. Various histone
deacetylase (HDAC) inhibitors, selenium, and agents like PT2385 and PT2977 are being explored in
various clinical trials as potential HIF inhibitors, to ameliorate the outcomes of RCC patients. In this
article, we will review the current treatment options and highlight the potential role of selenium in
the modulation of drug resistance biomarkers expressed in clear cell RCC (ccRCC) tumors.
Keywords: clear cell renal cell carcinoma; hypoxia-inducible factors (HIFs); selenium; PD-L1; miRNA;
VEGF; mTOR inhibitors
1. Introduction
Clear cell renal cell carcinoma (ccRCC) is the most common malignancy in the kidney. Over
65,000 new kidney cancer cases and 14,000 deaths were estimated in the United States in 2018 [1].
Renal cell carcinoma (RCC) is the most lethal genitourinary cancer, given that its disease course
is largely asymptomatic and incidentally found in more than half of new cases [2,3]. Established
modifiable risk factors for RCC include obesity, smoking, and hypertension [4]. Other studies link
alcohol use, type 2 diabetes, and occupational or environmental exposures to increased risk of RCC [5].
RCC is categorized into three major histological subtypes: ccRCC, comprising 70% of cases;
papillary and chromophobe RCC, which together comprise 25% of cases; and tumors of the medullary
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and collecting systems, which comprise 5% of cases [6,7]. These subtypes arise from distinct genetics
and therefore are treated differently [8].
Localized RCC is often managed surgically with a partial or radical nephrectomy, with tumor
ablation or active surveillance for small tumors. Systemic therapy is primarily reserved for metastatic
RCC. Current evidence for adjuvant systemic therapy after complete resection of the tumor has shown
no survival benefit [9]. For stage IV disease, cytoreductive nephrectomy in addition to systemic
therapy has not shown improvement in overall survival [9,10]. In the last two decades, there has been
significant improvement in our knowledge of renal cell carcinogenesis that has, in turn, led to the
development of biologically-driven targeted therapies.
2. Role of Hypoxia-Inducible Factors in Renal Cell Carcinogenesis
Adaptation to a hypoxic environment is a key attribute of cancer cells. This is mediated
via transcription factors called hypoxia-inducible factors (HIFs). These factors are heterodimers
with an α-subunit (HIF1α, HIF2α, or HIF3α) and a β-subunit (HIF1β) [11]. Previously, HIF1α
was considered to be a predominant oncogenic driver, but recent evidence shows HIF2α as a key
player in renal cancer progression [12]. Along with hypoxia, the von Hippel–Lindau (VHL) gene
and other oncogenic signaling pathways (e.g., PI3K, RAS) are known to regulate HIF activation.
Once activated, HIF transcription factors translocate to the nucleus and bind to the hypoxia response
elements, which leads to transcription of several target genes involved in angiogenesis (vascular
endothelial growth factor (VEGF)), oxygen transport and metabolism (erythropoietin), glycolysis
(LDH), glucose transport (GLUT1), cell proliferation, and migration, which eventually leads to
carcinogenesis (Figure 1) [13,14]. VEGF plays a vital role in tumor angiogenesis, and is a key target of
anti-cancer therapeutic agents. Regulation of the HIF pathway is vital for cellular homeostasis.
Figure 1. Inhibitors of the hypoxia-inducible factor (HIF) pathway currently being evaluated in clinical
trials. VHL: von Hippel–Lindau; HIF: hypoxia-inducible factors; HDAC: histone deacetylase; VEGF:
vascular endothelial growth factor; LDH: lactate dehydrogenase; GLUT1: glucose transporter 1.
3. Regulation of HIF Pathway by VHL Gene
Von Hippel–Lindau (VHL) is a tumor suppressor gene located on the short arm of chromosome
3 that is commonly mutated in both hereditary and sporadic renal cell carcinoma. The VHL gene
encodes two isoforms of VHL proteins (pVHL) that play a crucial role in cellular oxygen sensing and
regulation of HIFs. In normoxic conditions, the pVHL form a ubiquitin ligase complex and bind to
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the hydroxylated HIF1α and HIF2α, which subsequently undergoes ubiquitination and proteasomal
degradation. However, in cellular hypoxic conditions, the pVHL ubiquitin ligase complex cannot bind
to HIFα and lead to its degradation, as they are not hydroxylated (an oxygen-dependent process).
Hence, this leads to HIFα accumulation and formation of heterodimer complex with HIF1β and
subsequent induction of several target genes in the nucleus [15,16]. In ccRCC, a wide range of
intragenic mutations, deletions (complete or partial) and splicing defects have been identified that
derange normal function of the VHL gene, which creates a situation similar to cellular hypoxia and the
accumulation of HIFs [17].
In addition to the VHL gene, multitudinous genetic and enzymatic derangements have been
identified that predispose a region to various histologies of renal cell carcinoma. These include
folliculin (FLCN; chromophobe RCC/oncocytoma in Birt–Hogg–Dubé syndrome), papillary type 1
RCC (MET), fumarate hydratase (FH; papillary type 2 RCC in hereditary leiomyomatosis and renal
cell cancer syndrome), SDHB/SDHD/SDHC/SDHA (succinate dehydrogenase subunit-related RCC),
chromosome 3 translocations-associated clear cell RCC, papillary RCC (PTEN), and BAP1 (clear cell
RCC) [18].
This interdependency on biological pathways by cancer cells has laid the foundation for the
development of several targeted therapeutic agents for the treatment of advanced renal cell carcinoma.
4. Angiogenesis (Vascular Endothelial Growth Factor Pathway) Inhibitors
Current first-line therapy for stage IV, unresectable, or relapsed disease of clear cell histology
includes the oral VEGF tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib [9]. Additionally, for
intermediate to poor risk groups, based on the international metastatic renal cell carcinoma database
consortium (IMDC) criteria [19], either the combination of ipilimumab and nivolumab or cabozantinib
are options.
Sunitinib is a multi-kinase inhibitor targeting several tyrosine kinase receptors, including
platelet-derived growth factor receptors (PDGFR-α and -β), VEGF receptors (VEGFR-1, -2, and -3),
stem cell factor receptor (c-KIT), FMS-like tyrosine kinase (FLT-3), colony-stimulating factor (CSF-1R),
and neurotropic factor receptor (RET) [9]. In the landmark phase III, multicenter clinical trial by Motzer
et al., sunitinib was compared with interferon-α in patients with previously untreated metastatic
renal-cell carcinoma [20]. Progression-free survival (PFS) in the sunitinib arm was 11 months, and in
the interferon-α arm the PFS was 5 months. The overall survival (OS) with sunitinib was 26 months.
Pazopanib is another oral angiogenesis inhibitor targeting VEGFR-1, -2, and -3, PDGFR-α and -β,
and c-KIT. In a phase III, open-label study of pazopanib in patients with no prior treatment or one
prior cytokine-based treatment, PFS was prolonged significantly with pazopanib versus a placebo. For
the treatment naïve group, PFS was 11.1 months, compared to 2.8 months for pazopanib and placebo,
respectively [21]. In a phase III non-inferiority trial, pazopanib was compared to sunitinib in patients
with advanced renal cell carcinoma. The study was positive for non-inferiority, with a progression-free
survival of 8.4 and 9.5 months for pazopanib and sunitinib, respectively [22]. In addition, the median
OS with pazopanib was 28.3 and 29.1 months for sunitinib. In subgroup analysis for patients with
favorable-risk disease, the median OS for pazopanib and sunitinib was found to be 52.5 and 43.6
months, respectively [23]. Both of these medications had similar rates of adverse events that led to
dose reduction, and had no differences in grades 3/4 adverse events. Symptoms associated with
discomfort, such as fatigue, hand–foot syndrome, and mouth sores occurred more frequently with
sunitinib, while pazopanib was associated with elevations in liver-function tests, weight loss, and
changes in hair color. The study also showed lower monthly use of medical resources with pazopanib
than with sunitinib [22].
Cabozantinib is a small molecule inhibitor of tyrosine kinases, which include VEGF receptors,
MET, and AXL [9]. Cabozantinib was compared to sunitinib in a phase II study of intermediate to poor
IMDC risk, treatment naïve patients with metastatic RCC [24]. In this study, PFS was 8.6 months versus
5.3 months for cabozantinib and sunitinib, respectively, and the median OS was found to be 34.5 months
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and 26.6 months, respectively. Based on these results, cabozantinib has been approved by the United
States Food and Drug Administration (FDA) as a first-line agent. Cabozantinib has also been studied
in a phase III trial (METEOR trial) of patients with disease progression after previous TKI therapy [25].
The study compared second-line therapy with cabozantinib versus everolimus. The results showed
a median PFS of 7.4 months compared to 3.8 months for cabozantinib and everolimus, respectively.
Thus, in addition to first-line therapy, cabozantinib is a viable option as a second-line therapy for
patients with disease progression after other TKI therapy.
Axitinib is a selective, second-generation tyrosine kinase inhibitor targeting VEGFR-1, -2, and -3 [9].
The phase III AXIS trial compared axitinib and sorafenib as second-line therapy, following other
systemic therapy. PFS was 6.7 for axitinib versus 4.7 months for sorafenib. PFS was favored in both
subgroups of patients treated with axitinib whose prior systemic therapy was sunitinib or cytokine
therapy. Median OS was 20.1 months with axitinib, as compared to 19.2 months with sorafenib,
although this was not statistically significant [26].
Bevacizumab along with interferon (IFN) α-2b also has a category 1 level of evidence for first-line
therapy. It is a recombinant humanized monoclonal antibody that binds to circulating VEGF-A.
A double-blind phase III trial (AVOREN) compared bevacizumab plus IFN-α-2b versus placebo
plus IFN-α-2b [27]. With the addition of bevacizumab, PFS was significantly increased (10.4 versus
5.4 months), with a tumor response rate of 30.6% in the bevacizumab group compared to 12.4% in the
placebo group. This was achieved without significant increase in adverse events. OS was improved in
the bevacizumab group versus the placebo group (23.3 versus 21.3 months); however, this was not
statistically significant.
5. Mechanistic Target of Rapamycin Inhibitors
Mechanistic target of rapamycin (mTOR) proteins are known to regulate cellular metabolism,
growth, apoptosis, and angiogenesis through protein expression. Cellular growth factors stimulate the
PI3K/Akt/mTOR pathway and eventually lead to HIF accumulation [28]. These discoveries led to
the evaluation of temsirolimus and everolimus, which are both mTOR inhibitors in the management
of renal cell carcinoma. Temsirolimus was compared to interferon-α in previously untreated patients
with poor risk prognostic risk factors per, the MSKCC prognostic model [29]. The group receiving
temsirolimus alone demonstrated significant improvement in median OS compared to IFN-α alone
(10.9 versus 7.3 months, respectively). Similarly, PFS was shown to have improved from 3.1 months
with IFN-α to 5.5 months with temsirolimus. Based on these study results, temsirolimus was the
first FDA-approved mTOR inhibitor for patients with advanced renal cell carcinoma [30]. Currently,
temsirolimus is the only mTOR inhibitor that is FDA-approved as a monotherapy.
Everolimus in combination with lenvatinib, a TKI, is utilized in patients who progress after
prior therapy. In a phase II clinical trial, lenvatinib plus everolimus was compared to single-agent
everolimus in previously-treated metastatic RCC (mRCC) patients [31]. The combination therapy
showed increased median OS of 25.5 months, compared to 15.4 months for the monotherapy. Similarly,
median PFS improved to 14.6 months in the combination group, compared to 5.5 months for the
everolimus-only group [31].
6. Immunotherapy
Until late 2005, medical treatment options for RCC involved cytokine-based immunotherapy
with the use of high-dose interleukin-2 (IL-2) and IFN-α. Though high-dose IL-2 is associated
with significant toxicity, long-term durable response rates were seen in a small fraction of patients.
High-dose IL-2 therapy is utilized in highly selected patients with excellent performance status and
normal organ function [32]. IFN-α as a monotherapy has fallen out of favor, as a phase III multinational
trial between sunitinib and IFN-α demonstrated a strong trend toward a median overall survival
advantage of sunitinib over IFN-α [33].
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Checkmate-214, a randomized phase III clinical trial, evaluated the combination of two immune
checkpoint inhibitors, nivolumab and ipilimumab, in comparison to sunitinib in treatment-naïve
patients with metastatic ccRCC. In patients with IMDC intermediate and poor risk, PFS was found
to be 11.6 and 8.4 months for the nivolumab/ipilimumab combination and sunitinib, respectively.
However, discontinuation due to adverse events was 24% in the combination group, as compared
to 12% in the sunitinib group. The median OS with sunitinib was 26 months, whereas the median
OS was not reached with the combination therapy [34]. Nivolumab was also shown to be effective as
second-line therapy. In a phase III trial that studied patients previously treated with at least one line
of therapy excluding mTOR inhibitors, nivolumab demonstrated an increase in OS of 5.4 months in
comparison to everolimus monotherapy (25 versus 19.6 months, respectively). Median PFS, however,
was not statistically significant, with 4.6 months for nivolumab and 4.4 months for everolimus [35].
7. Strategies to Inhibit the Hypoxia-Inducible Factor Pathway: A Plausible Therapeutic Avenue
VEGF inhibitors target one of the myriad oncogenic pathways that are activated by HIF. Hence,
the cancer eventually develops resistance and progresses, despite an initial good response to various
oral TKIs. Inhibiting the HIF pathway and subsequently its translational activity is an attractive
treatment modality, as it blocks the activation of all downstream genes. The mTOR inhibitors inhibit
HIF activation, but the responses are limited, as noted above. Recently, further strategies have been
explored targeting the HIF pathway in combination with VEGF inhibitors, with variable success.
HIF regulation, either by blocking its production, antagonizing it effects, or by enhancing its
degradation, has provided multiple opportunities to expand the current therapeutic armamentarium
of renal cell carcinoma. In a small study of mRCC, HIF expression was predictive of increased response
to sunitinib treatment [36]. In this study, 26 of 49 patients had high HIF1α and HIF2α expression on
the tumor cells (based on immunoblot analysis). These patients had a higher rate of complete or partial
response when compared to patients with low or absent HIF1α/HIF2α expression.
8. Role of Selenium in Cancer Therapeutics and the Hypoxia-Inducible Factor Pathway
Selenium is an essential micronutrient; in the human body, it is involved with the regulation of cell
metabolism, DNA, and RNA, as well as protein synthesis, and is at the active site of several enzymes
of the antioxidant network [37]. Inorganic forms of selenium, such as selenide and selenite, are
converted by plants into organic forms, such as selenomethionine (SLM) and Se-methylselenocysteine
(MSC), which are retained in the human body [37]. Epidemiologic studies have suggested that dietary
selenium intake is a protective factor for some forms of cancers, such as colorectal, prostate, lung, and
bladder cancer [38,39]. However, additional studies in healthy men did not show benefit of selenium
in the prevention of prostate cancer [40].
SLM and MSC are forms of selenium that are currently being investigated as possible anti-tumor
agents. In their natural form, these agents have a relatively low toxicity profile. They are converted
via β-lyase into the active form methylselenol (MSA). HIF1α appears to be a target of selenium.
In pre-clinical studies of head and neck squamous cell carcinoma cells that express HIF1α, it was
found that in the setting of hypoxia, where HIF1α expression is increased, the cytotoxicity of SN38,
the active metabolite of irinotecan, was enhanced with the addition of MSA [41]. This is possibly due
to the inhibition of HIF1α by MSA, and demonstrates the potential for reversal of chemoresistance
by MSA. Moreover, selenium has been found to target β-catenin, and increases drug cytotoxicity
through the reduction of β-catenin’s drug-resistant effects [42]. Selenium compounds may also
improve efficaciousness of other anti-tumor agents through a reduction in treatment-induced toxicities,
allowing for higher tolerated doses. In one study of A253 and HT 29 xenografts, coadministration of
MSC with irinotecan at two to three times the maximum tolerated dose of irinotecan led to a response
without intolerable toxicity [43].
Selenium can also affect the tumor microenvironment (TME), and may be able to stabilize the
TME to improve drug delivery. MSC has an anti-vascular effect, and can increase the antitumor effect
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of irinotecan through the inhibition of HIF1α, which leads to decreased microvessel density, lowered
tumor interstitial pressure, and increased pericyte coverage of blood vessels [41].
Selenium may also be able to act through its effects in the expression of miRNAs. Non-coding
miRNAs are small molecules involved in post-transcriptional regulation of genes, which are often
associated with increased angiogenesis and drug resistance.
9. Base-Line Transcription and Translation Biomarkers Expressed in Clear Cell Renal Cell
Carcinoma Cell Lines with Disentail Expression of HIF1α and HIF2α
The expression levels of oncogenic, tumor-suppressor miRNAs, as well as hypoxia-inducible
factors 1α and 2α, and program death ligand1 (PD-L1), are altered in many advanced cancers and
implicated in multi-drug resistance, angiogenesis, and tumor growth and metastasis. Specifically,
the oncogenic miRNA-155 and miRNA-210 are highly expressed in ccRCC tumors with differential
expression of HIFs [44,45].
We demonstrated that these miRNAs and HIF proteins are targets of therapeutic doses and a
schedule of selenomethionine and methylselenocysteine (selenium). It was not fully understood,
however, whether selenium exerts its effects at the transcription or at the translation levels. Studies
were carried out in ccRCC cell lines expressing differential levels of HIFs. We have determined that
the base-line expression of three genes and the two oncogenic miRNAs in four cell lines: 786-O,
RC2, RCC4, and RCC4-VHL. The three genes are HIF-1α, HIF-2α, and PD-L1. The two miRNAs are
hsa-miR-155 and hsa-miR-210, Figure 2A. Results shown in Figure 2B indicate that there is robust
mRNA transcription of each locus in all four of the cell lines. Note that lower normalized transcription
levels (ΔCt) indicate higher expression levels. In general, the 786-O cell line expressing HIF2α displays
the highest transcription. However, translation of these messages into a protein, as shown in Figure 2C,
reveals a very different pattern. For example, in the 786-O cell line, both HIF-1α and HIF-2α are equally
expressed at the RNA level, but reveal very different protein levels. Similarly, the RC2 cell line has
consistently lower levels of RNA transcripts than 786-O, but higher levels of protein for HIF-2α and
PD-L1. These inconsistencies suggest that there may be post-transcriptional targeting of these mRNAs
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Figure 2. Base-line levels of constitutively expressed miRNAs (A), mRNAs (B), and HIFs and PD-L1
proteins (C) in normoxic clear cell renal cell carcinoma (ccRCC) cell lines. These cell lines show minimal
differences in mRNA levels of PD-L1, HIF-1α, and HIF-2α (B), but express differential levels of the
PD-L1, HIF-1α, and HIF-2α proteins (C). Ave ΔCt: average cycle threshold change compared to the
reference sequence.
In normal cells, selenium has been shown to have a selective protective effect against
chemotherapy-induced DNA damage via p53 mediated DNA repair. However, it did not confer
a similar benefit to cancer cells [46].
SLM has been FDA-approved for clinical trials. A phase Ib dose-escalation trial in patients with
metastatic ccRCC after failure of prior treatment is ongoing (NCT02535533). Preliminary results of
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nine evaluable patients demonstrated two patients achieving complete response, and three patients
achieving partial response. No dose-limiting toxicities have been noted. The most common side
effects included anorexia, fatigue, cough, diarrhea, and proteinuria. There were no grade 4 toxicities
or deaths associated with this combination therapy. The phase II part of the clinical trial with SLM
and axitinib 5 mg twice daily is planned [47]. The multiple avenues in which selenium interacts with
other chemotherapies, the tumor microenvironment, and its interaction with miRNA and transcription
factors make it a very favorable target for further research.
10. Studies on Hypoxia-Inducible Factor Inhibitors in Advanced Renal Cell Carcinoma
PT2385 is an HIF-2α antagonist that was evaluated in a phase I, standard “3 + 3” dose escalation
study of heavily pretreated metastatic ccRCC [48]. In this study, 51 patients were treated with oral
PT2385 twice a day, and the recommended phase-II dose (RP2D) was 800 mg BID. One patient had
complete response (2%), six had partial responses (12%), and the rest had either stable disease or
progression. No dose-limiting toxicities were noted. The most common treatment-related side effects
included anemia, peripheral edema, fatigue, and nausea. Considering the promising response signals
of a single agent in a heavily pretreated patient population, further studies are ongoing, with a
combination of PT2385 with nivolumab and cabozantinib, respectively (NCT02293980).
In a multi-institutional, phase I/II clinical trial, vorinostat (histone deacetylase inhibitor) was
evaluated in combination with bevacizumab in ccRCC patients [49]. HDAC inhibitors modulate
the HIF pathway by affecting Hsp90 acetylation and HIF-α nuclear translocation [50,51]. In this
study, 33 evaluable patients were treated with vorinostat 200 mg orally, twice daily for two
weeks, in combination with bevacizumab 15 mg/kg administered intravenously every three weeks.
There were no dose-limiting toxicities. Two patients had grade 4 thrombocytopenia. The most common
adverse events included fatigue, nausea, pain, anorexia, diarrhea, and elevated creatinine. About 10
patients discontinued therapy due to toxicities, but there were no treatment-related deaths. One patient
achieved complete response, and five patients had partial responses. Currently, a phase I/Ib study
of pembrolizumab with vorinostat is in progress for patients with advanced renal or urothelial cell
carcinoma (NCT02619253).
The safety and efficacy of another HDAC inhibitor, abexinostat, as an epigenetic downregulator
of HIF-1α and VEGF expression was evaluated in combination with pazopanib by Aggarwal and
colleagues, in a study of advanced solid tumor malignancies [52]. The RCC cohort included 22 patients.
The dosing schedule of abexinostat was modified, due to five dose-limiting toxicities that included
grade 3 thrombocytopenia (n = 2), grade 3 fatigue (n = 2), and grade 3 AST/ALT elevation (n = 1).
There were no treatment-related deaths. The objective response rate in the RCC cohort was 27%,
including patients who were previously refractory to pazopanib.
Bortezomib is a proteasome inhibitor currently approved for the treatment of multiple myeloma
and mantle cell lymphoma. It is a reversible inhibitor of the chymotrypsin-like activity of the 26S
proteasome in mammalian cells. By inhibiting proteasomes, it causes protein buildup and then leads
to cell cytotoxicity. In preclinical models, Shin and colleagues have shown its role in HIF-1α repression
by inhibiting the recruitment of the p300 coactivator [53]. In a phase II clinical trial of treatment-naïve,
metastatic ccRCC, 17 patients were treated with sorafenib 200 mg orally twice daily, in combination
with bortezomib 1 mg/m2 intravenously administered on days 1, 4, 8, and 11, and then every 21
days [54]. The combination was safe, but the study was negative, as it did not meet the pre-specified
endpoint of median progression-free survival of 70 weeks. Further studies are not planned with
this combination.
The clinical efficacy of bortezomib in combination with bevacizumab was evaluated in 91
patients with treatment-refractory advanced cancers [55]. In the RCC cohort, 5 of 20 patients had
a partial response or stable disease. No treatment-related deaths were noted. Common toxicities
included thrombocytopenia, fatigue, nausea/vomiting, diarrhea, neuropathy, anemia, neutropenia,
and hypertension. Table 1 summarizes the concluded clinical trials.
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11. Conclusions
Insights into the molecular pathogenesis of ccRCC, especially the HIF pathway, have led to
discovery of several therapeutic agents that have improved the treatment landscape. However,
new strategies, which are durable and eventually a step closer to potential cure, are needed to further
improve responses. HIF inhibition, either as monotherapy or in combination with other VEGF
inhibitors, mTOR inhibitors, or immunotherapeutic agents, is promising. Numerous studies are
underway evaluating these potentially synergistic combinations. (See Table 2). The preliminary results
of SLM in early phase clinical trials of ccRCC are encouraging.
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Abstract: Selenium (Se) acts as an essential trace element in the human body due to its unique
biological functions, particularly in the oxidation-reduction system. Although several clinical trials
indicated no significant benefit of Se in preventing cancer, researchers reported that some Se species
exhibit superior anticancer properties. Therefore, a reassessment of the status of Se and Se compounds
is necessary in order to provide clearer insights into the potentiality of Se in cancer prevention and
therapy. In this review, we organize relevant forms of Se species based on the three main categories
of Se—inorganic, organic, and Se-containing nanoparticles (SeNPs)—and overview their potential
functions and applications in oncology. Here, we specifically focus on the SeNPs as they have
tremendous potential in oncology and other fields. In general, to make better use of Se compounds in
cancer prevention and therapy, extensive further study is still required to understand the underlying
mechanisms of the Se compounds.
Keywords: selenium species; Se-containing nanoparticles; anticancer; chemotherapeutics; epigenetics
1. Introduction
Selenium (Se) is an essential micronutrient for the human body that is mainly obtained through
diet and/or nutritional supplement [1]. Trace amounts of Se are required for maintaining optimal
health as Se is a component of the selenoproteins (mostly in the form of amino acid selenocysteine) that
participate in a wide range of cellular physiological processes. These processes include, but are not
limited to, thyroid hormone regulation [2], redox homeostasis [3–5], inflammatory and immunological
responses [6–8], carbohydrate metabolism [9], cardiovascular [10] and reproductive [11,12] health,
and brain function maintenance [13–15]. Se deficiency is associated with numerous human diseases
with various degrees of illnesses [16,17]. For instance, the Keshan disease (fatal cardiomyopathy due
to viral infection) [18] and Kashin-Beck disease (chronic osteochondropathy) [19] are a few typical
examples of Se deficiency-related diseases, which often occur endemically in the population living
in regions with Se-poor soil. Excessive Se can be toxic and may lead to selenosis [17,20]. Currently,
the recommended dietary allowance of Se for adults is set at 55 μg (0.7 μmol)/day [21]. Individuals
with daily Se intake less than ~15 μg appear to be at risk of Se deficiency-related diseases, whereas
those who consume over 400 μg/day are prone to Se toxicity, although some studies have shown that
safe levels of Se intake may be much lower than anticipated [16,21].
The relationship between Se and cancer, particularly in gastrointestinal and prostate cancer,
was discovered in the middle of the 19th century, which then raised interest in the contribution of
Se supplements to cancer prevention and therapy [22–24]. During half a century of exploration,
many novel forms of Se compounds have been discovered and tested, and some have shown
promising anticancer activity [25,26]. A double-blind, placebo-controlled, and randomized clinical
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trial carried out in the 1990s, the Nutritional Prevention of Cancer (NPC) trial, has provided us the
early evidence supporting Se as a potential chemopreventive agent [27–29]. However, to date, none of
the Se compounds have been clinically recognized as anticancer drugs, partly because, over the
years, researchers have obtained conflicting results within and between epidemiological, clinical,
and laboratory studies [30,31]. Notably, in contrast with the NPC trial, subsequent clinical trials such
as the Selenium and Vitamin E Cancer Prevention Trial (SELECT) failed to demonstrate the anticancer
effects of Se [32–34]. Some of these conflicting results showed that Se compounds not only failed to
exert their cancer prevention or anticancer ability as anticipated but, in some cases, may even promote
cancer [35]. Recent epidemiologic evidence suggests that chronic exposure to inorganic Se may increase
cancer risk [36]. As a result, the dual role of Se compounds in carcinogenesis, especially in relation to
the aspects of oxidative stress and angiogenesis, has been proposed and recently summarized [31].
So far, there is no clear conclusion on the circumstances under which a particular Se compound
prevents or enhances carcinogenesis, perhaps due to the wide variety of Se speciations and their
diverse effects at different concentrations on different metabolic pathways of cells and tissues [37,38].
Se or Se-containing compounds can be grouped into three main categories: inorganic, organic (also known
as the organoselenium compounds), and Se-containing nanoparticles (SeNPs). In order to better utilize
the anticancer properties of Se species, it is necessary to thoroughly evaluate the current status of Se
species. Here, we systematically organize the relevant forms of Se species, with slightly more emphasize
on SeNPs, and review their recent developments and potential in cancer prevention and therapy.
2. Anti- or Pro-Cancer?
Several Se compounds derived from all the three groups of Se (inorganic compounds,
organoselenium compounds, and SeNPs) have shown possible anticancer ability. It is generally
accepted that Se compounds exert their anticancer ability mainly through their direct or indirect
antioxidant properties that intracellularly maintain the redox status and protect healthy cells from
reactive oxygen species (ROS)-induced oxidative damage [39]. ROS are free radicals with unpaired
electrons generated during normal biophysiological function. The evidence is strong that excessive ROS
promotes carcinogenesis via elevated oxidative stress and increased DNA mutation [40]. Cancer cells
are often characterized by their ability to produce and cope with an increased amount of ROS [41].
In other words, increased dependence on an antioxidant defense system is one of the principal
characteristics of cancer cells. Despite the links between ROS and cancer formation, however,
optimal (usually low) levels of ROS are actually beneficial as they play important roles in regulating
many biological functions. Some enzymes and cells (e.g., white blood cells) can deliberately produce a
range of superoxide radicals to kill invading pathogens [39,42]. ROS can also destroy damaged cells by
promoting cellular senescence and apoptosis and thus eliminate the formation of cancer [41,42].
Such a dual role of ROS may explain why conflicting results for Se species, as “antioxidants”,
are often observed in cancer research. To further complicate the situation, other research found
that some selenoproteins could actually behave as prooxidants instead of antioxidants, demonstrating
both cancer-inhibiting and -promoting features in a cell type-, genotype-, and dosage-dependent
manner [43–47]. For example, thioredoxin reductase 1, an essential redox regulating selenoprotein,
can change from an anti- to a pro-oxidant and can both inhibit or promote carcinogenesis [44,46].
In addition to oxidative stress regulation, the duality of Se compounds on angiogenesis has been
discovered [31,38]. Angiogenesis refers to the physiological process responsible for the formation and
growth of micro-blood vessels from pre-existing vasculature, which is one of the most important
mechanisms for cells to obtain oxygen and nutrients. The roles of angiogenesis in relation to
cancer development and metastasis have been studied extensively, and therapy explicitly targeting
angiogenesis has become a promising approach for cancer treatment [48]. In vitro and in vivo studies
showed that some Se compounds, such as the monomethylated Se amino acid methylselenocysteine
(MSC), could inhibit cancer growth through its antiangiogenic properties [49–51]. MSC might also
normalize the blood vessels and thus enhance delivery of a range of chemotherapeutic drugs and
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simultaneously reduce their toxicity [52–56]. Conversely, opposite results in which pro-angiogenic
responses of Se-selenoproteins/compounds in normal or cancer cells have also been reported [57,58].
Thus, the dual role and narrow window between the beneficial and toxic effects of Se compounds
often limit their potential for clinical application.
The dual effect of Se mentioned in this section is often restricted to the inorganic and organic
Se compounds, and so far, research on anticancer activity of SeNPs, the emerging special form of
Se species, appears to be positive. The use of SeNPs has had a revolutionary impact on cancer
therapy, and they have shown tremendous potential compared to “ordinary” inorganic and organic Se
compounds [59–62]. However, knowledge regarding the cytotoxicity and other possible adverse effects
of these SeNPs in humans is still lacking, and further extensive research is required [63,64]. So far, all Se
compounds are considered non-carcinogenic with the exception of selenium sulfide, which is categorized
as a probable human carcinogen. Overall, in order to determine the potential of Se compounds in cancer
prevention and therapy, multiple factors (e.g., speciation, concentration, targeting cell type, and cell
state/condition) must be considered. In the following sections, we organize relevant forms of Se species
and discuss their potential roles in cancer treatment based on recently published data.
3. Se-Containing Compounds and Their Usage in Oncology
All three main categories of Se (inorganic, organic, and SeNPs) contain compounds with potential
anticancer properties. For inorganic and organic Se compounds, research has found that they are both
metabolized differently and have varied mechanisms of action in diverse bio-physiological processes,
including their roles in cancer [65]. Both forms of Se compounds can be readily absorbed by the human
body, but only organic Se compounds, usually in the forms of amino acids (e.g., selenomethionine
(SeMet) and selenocysteine), can be better retained and used [65]. The cancer prevention ability of a
range of inorganic and organic Se compounds has been supported by a large number of publications
from a wide range of studies under different settings, including biochemical, epidemiological, clinical,
and animal studies [38,44,46,66–68]. However, toxicity risks accompanied by the use of these Se
compounds have also been recorded. Although organic forms of Se may have lesser toxic effects than
inorganic Se compounds [69], in reality, the toxic effects of Se are determined by multiple factors,
with the forms of Se and dosage exposure being two of the most important parameters [26]. Despite
the greater toxic effects, inorganic Se compounds may have an advantage in certain aspects of cancer
therapy as described below.
3.1. Inorganic Se Compounds
Se exists in four natural valence states: elemental Se (0), selenide (−2; Se2−), selenite (+4; SeO32−),
and selenate (+6; SeO42−). In Figure 1, we display the chemical structures of some of the representative
Se compounds. A more detailed list of classification of Se compounds based on their structural features
is summarized by Sanmartín et al. [70]. The functional and toxic effects of inorganic Se compounds
differ according to their valence states. In Choi et al. [71], various concentrations of sodium selenate
(Na2SeO4) (5, 10, 30, and 50 μM for 48 h) and sodium selenite (Na2SeO3) (0.1, 0.25, and 0.5 μM
for 48 h) along with three other organic Se compounds (SeMet, MSC, and methylseleninic acid
(MSA)) were tested for their ability to sensitize human oral squamous carcinoma (KB) cells resistant
to chemotherapeutic drug vincristine (KBV20C). They found that although all five Se compounds
appeared to be able to sensitize KBV20C to the same extent as the sensitive parent KB cells, only selenate
produced a higher sensitizing effect on the KBV20C cells by arresting the cell cycle at G2-phase and
activating apoptotic pathways. However, opposite results were obtained by Takahashi et al. [72],
where they showed that human oral squamous carcinoma (HSC-3) cells were more sensitive to
Na2SeO3 and selenium dioxide (SeO2), but not sodium selenate at concentrations ranging from 1 to
1000 μM (72 h). Pronounced anti-proliferative effect of selenite (5–100 μM for 2–5 days) against three
oral cancer cell lines (HSC-3, HSC-4, and SAS) was reported [73]. This study also suggested that selenite
had a better anticancer effect than the two other organoselenium compounds (SeMet and MSC) tested.
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Figure 1. Chemical structures of selected representative inorganic and organic Se compounds discussed
in this review.
Selenite is the most studied form of inorganic Se compounds as it exhibits excellent chemopreventive
and anticancer features [74]. Selenite could effectively inhibit cell proliferation of various types of
cancer cells, including lung cancer, which is the most common and deadliest cancer worldwide [75].
Among different human cancer cell lines tested, lung cancer cells, in general, appeared to be especially
sensitive to selenite [76–79]. Olm et al. [80] indicated that selenite cytotoxicity (5 μM for 5 h) was
correlated with Se uptake of three lung cancer cell lines (H157, H611, and U2020) and that high
concentrations (>1 mM) of selenate were non-toxic for these cell lines. Selenite was suggested to play a
role in natural killer (NK) cell-based anticancer immunotherapy where it could increase the susceptibility
of cancer cells to CD94/NK group 2A-positive NK cells, and has possible clinical applications in
lung cancer patients [81]. The synergistic effect of selenite and thioredoxin reductase inhibitors (e.g.,
ethaselen and auranofin) was detected in human ovarian and lung cancer cell lines [82,83]. These results
demonstrated the potential of Se compounds to enhance the activity and reduce the toxicity of anticancer
drugs including those commonly used in chemotherapy (e.g., cisplatin, docetaxel, 5-FU, oxaliplatin, and
irinotecan) [84–86]. Se compounds appear to be more effective in inhibiting the growth of anticancer
drug-resistant cancer cells compared with drug-sensitive cancer cells via deactivating various resistance
mechanisms used by the cancer cells. Chemotherapeutic drug-resistant lung cancer cells were revealed
to be generally more sensitive to selenite (ranging from 0.1 to 100 μM for 48 h and up to 4 days)
compared to drug-sensitive cancer cells [82,87,88]. In addition to the above-mentioned in vitro studies,
a phase I clinical trial published demonstrated the beneficial effects of selenite in cancer patients,
especially in lung cancer patients who were resistant to cytostatic drugs [76].
Notably, the above results, however, do not necessarily mean that selenite is superior to other
inorganic Se compounds in terms of cancer prevention and therapy. For instance, selenate might be
more effective than selenite under certain circumstances as described earlier, even in the same type of
cancer albeit different cell lines [71,72]. Inorganic Se such as selenosulfate (SeSO3−) was reported to
have generally greater cytotoxic effects on cancer cells but was less toxic in healthy cells than selenite,
depending on the cell types and the presence or absence of supplement amino acids that may affect the
uptake of selenite [89]. Both SeSO3− and selenite might have the potential to work as a remedy against
chemotherapy toxicity [76,84]. It was shown that hydrogen selenide (H2Se), a common intermediate
100
Int. J. Mol. Sci. 2019, 20, 75
of dietary Se metabolism produced by reduced selenite, could trigger the apoptosis of cancer cells
(HepG2, HeLa, and MCF-7 cells) via accumulation in mitochondria induced by selenite, which would
subsequently damage mitochondrial function and structure and lead to cell death [90].
3.2. Organic Se Compounds
Organic Se compounds attract considerable attention in the field of cancer research mainly
due to their lower toxicity risk and ability to deliver significant anticancer activity, comparable
or sometimes even better than inorganic Se compounds [69]. Organic Se compounds can be
classified into different families based on their functional chemical structures: Selenides/diselenides,
selenocyanates, selenoaminoacid derivatives (e.g., SeMet and MSC), methylseleninic acid (MSA;
CH3SeO2H), Se-heterocyclic compounds, and other miscellaneous Se-containing compounds (Figure 1).
These organoselenium compounds exhibit anticancer and chemopreventive activity through
diverse mechanisms of action, including reduction of oxidative stress [91], induction of apoptotic
events [92–94], and enhancement of chemotherapeutic drug activity [95–97]. To date, many scientific
studies on organoselenium compounds is available, many of which investigated their roles in
cancer prevention and therapy. Several excellent reviews have listed a range of organoselenium
compounds based on different classifications and summarized their functions in oncology [31,38,70,98].
Additionally, the potential anticancer and chemopreventive activity of selenides/diselenides [99] and
selenocyanates [100] have been extensively reviewed.
Organoselenium compounds have the potential to be used as anti-neoplastic agents against
solid tumors. Since necrosis of cancer cells is linked to host inflammatory response and may lead to
treatment complications, the anti-necrotic and pro-apoptotic feature of some organic Se compounds is
therefore largely preferred in cancer therapy [101]. Selenoaminoacid derivatives, such as SeMet and
MSC, at low concentrations (as low as 0.113 μM), were shown to be able to promote apoptosis in solid
tumors of various types of human cancer, whereas the control non-tumorigenic mammary epithelial
cells (MCF-10A) required substantially high concentrations (up to 87.9 μM for 72 h) of organic Se to
display sensitivity to apoptosis [92]. Owing to the ability of organoselenium compounds to induce
apoptosis, their synergistic effects on chemotherapeutic drugs against cancer were observed [53,95–97].
MSC may also provide additional protection from the toxicity of anticancer drugs [54,56].
MSA is an oxidized form of methylselenol (CH3Se−) converted from selenoaminoacids (e.g.,
SeMet and MSC) [43]. In vivo and in vitro studies have indicated that MSA is an excellent anticancer
agent comparable to SeMet or selenite against a range of cancer models, including lung [102],
breast [103,104], melanoma [105], and prostate cancer in particular [106–108]. In a recent study,
MSA showed significant cytotoxic effects toward monocytic leukemia cells (THP1) compared with
the healthy peripheral blood mononuclear (PBM) cells [109]. MSA also enhanced the anticancer
activity of radiation and chemotherapeutic drugs (cytosine arabinoside and doxorubicin) in the
malignant THP1 cells in a dose-dependent manner (2.5, 5, and 15 μM for 48 h) [109]. At lower
concentrations, MSA protected normal PBM cells from radiation and chemotherapeutic drugs, whereas
at higher concentrations, MSA was considered toxic and could increase the cytotoxicity of radiation
but not chemotherapy [109]. In another study, MSA was able to inhibit the proliferation, migration,
and adhesion of HeLa cells more effectively than SeMet and MSC, and it showed synergistic anticancer
activity with S-adenosyl-methionine—a universal methyl group co-substrate involved in multiple
intermediary metabolites [110]. MSA was shown to be able to reverse the tamoxifen resistance of
breast cancer cells when used in combination with tamoxifen through the activation of caspase-9
and then caspase-8, resulting in the induction of the intrinsic, mitochondrial apoptotic pathway [111].
A novel programmed cell death mechanism (entosis) induced by MSA and methylselenoesters was
identified in pancreatic cancer Panc-1 cells [112]. Entosis is characterized by the invasion of a living cell
to another cell’s cytoplasm resulting in endophagocytosis and the formation of cell-in-cell structures.
Other groups of selenocompounds, such as the selenocynates and Se-containing heterocycles,
also contained several Se compounds with promising chemopreventive or anticancer properties,
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ranging from the well-studied p-xylene selenocyanate and benzyl selenocyanate to the recently
reported novel active compounds that combine the selenocyanate moiety with different heterocycles,
quinones, or steroids [100]. Heterocyclic organoselenium compounds, such as ebselen and ethaselen
(also known as BBSKE) are small molecules that have potential in cancer therapy [113,114].
A list of these heterocyclic compounds and their anticancer ability is summarized in Fernandes
and Gandin [38] and Sanmartíin et al. [70]. The selenophene-based triheterocyclic derivative
2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole (D-501036) has received
increasing attention due to its broad-spectrum anticancer activity against several human cancer
cells in a dose- and time-dependent manner [115–117]. D-501036 selectively induces apoptosis
and double-strand DNA breaks in cancer cells, and is especially effective against chemotherapeutic
drug-resistant cancer cells with overexpression of P-glycoprotein/multidrug-resistant protein [116].
Further study has suggested that enhanced non-homologous end-joining DNA repair activity
was involved in the development of D-501036-resistance in cancer cells [117]. Previously in a
cisplatin-resistant prostate cancer model, the degree of drug-resistance was found to be associated
with the oxidative system in the cells [118]. Thus, it was likely that cancer cells, and in particularly
drug-resistant cancer cells, have higher Se uptake compared with benign cells due to the redox state of
Se and the oxidative system of the cancer cells [118,119].
Previous clinical trials (e.g., NPC) have shown that dietary Se supplements (Se-enriched yeast)
could reduce the risk of multiple cancers [27–29]. However, subsequent trials (e.g., SELECT
and Southwest Oncology Group (SWOG) S9917), tested using SeMet, showed no such beneficial
effects [32,33]. In a clinical trial, it was indicated that SeMet did not improve quality of life or
survival outcomes of patients with head and neck squamous cell cancer undergoing concurrent
chemoradiation [35]. These conflicting results may be partially explained by the selection of the Se
compound administered: 200 μg/day of Se-enriched yeast in the NPC trial and 200 μg/day of SeMet
in SELECT and SWOG S9917. Although SeMet is the major component of Se-enriched yeast, it is
possible that other components in Se-enriched yeast (e.g., MSC) may be contributing to the overall
chemopreventive effect of Se observed in the NPC trial. This speculation, however, cannot be verified
since there were substantial batch-to-batch variations in specific organoselenium compounds in the
samples of NPC yeast [32]. Additionally, no significant benefit in the prevention of second primary
tumors was detected in a phase III clinical trial (ECOG 5597) that administrated 200 μg/day of Se-enriched
yeast to patients with completely resected stage I non-small-cell lung cancer [34]. Despite these negative
findings, most of these trials suggested that Se supplement was safe to consume. Thus, organic Se may be
useful in cancer therapy but appears to confer no significant benefit in the prevention of cancer.
3.3. SeNPs
Since the late 1990s, application of nanotechnology in the bio-medical field has received extensive
attention. Owing to their biocompatibility, biodegradability, and designability, nanomaterials are
increasingly utilized in cancer therapy and diagnosis as pharmaceutical products, drug carriers,
imaging agents, and diagnostic reagents to overcome some limitations of the traditional materials [120].
SeNPs, as emerging Se species, are considered to be promising medical materials, according to their
reported chemotherapeutical properties [121,122], nutritional effects [123], and relatively low toxicity
compared with some other Se compounds [3,124]. The chemotherapeutical potency of SeNPs and their
proposed anticancer mechanisms have been reviewed by Menon et al. [125]. Here, we systematically
tabulated a list of SeNPs based on data published in 2017 and the first half of 2018 and arranged
them according to their reported functions: chemotherapy (Table 1), drug delivery (Table 2), diagnosis
(Table 3), and SeNPs with multiple functions (Table 4). The potential of these SeNPs in cancer
prevention and treatment, along with their synthesis methods, are discussed below.
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Many methods have been reported for SeNPs preparation, which are generally classified
into three broad categories based on different producing principles: chemosynthesis, biosynthesis,
and physical synthesis [159]. Among them, chemosynthesis is considered the most common method
to prepare SeNPs. In chemosynthesis, Se in the +4-valence state, such as selenite, selenious acid,
or SeO2, is frequently employed as precursors, whereas reducing agents (e.g., ascorbic acid and
glutathione [GSH]) and stabilizing agents (e.g., chitosan and pectin) are used for SeNPs formation
and maintenance [131,141,159,160]. SeNPs synthesized in the Na2SeO3-GSH redox system tended
to gather in cancer cells and presented stronger pro-oxidant activity comparing to selenite [134].
However, to optimize their function in cancer therapy and prevention, chemosynthetic SeNPs are
usually decorated with specific molecules, which endow them with ideal features to meet the
demands of practical applications. For example, decorating SeNPs with other bioactive molecules
can enhance the therapeutic effects upon certain types of cancers when compared with non-decorated
SeNPs [128,129,161]. Aside from direct therapeutic effects, chemically modified SeNPs can function
as vehicles that endow the carried objects with favorable properties like tumor targeting [150,157],
high efficacy [137,144], and low toxicity [139]. Notably, chemosynthetic SeNPs were also examined
as diagnostic agents [145,147,149], imaging agents [146,153], and radiosensitizers [130,158]. Overall,
chemosynthesis is the most common method used to obtain and modify SeNPs, because the process
is easy to implement and control. Nevertheless, environmental pollution and accumulation of
chemosynthetic materials in the body should also be considered.
In contrast to chemosynthetic SeNPs, biosynthetic SeNPs appear to be environmentally friendlier
and biologically safer. Thus, there has been increased focus upon biosynthetic SeNPs, partly also
due to their extraordinary biocompatibility, sustainability, and economy [162]. These organismal
materials mediating SeNPs are extracellularly or intracellularly manufactured with selective plants [64],
bacteria [4], fungi [163], and other organisms [163,164]. Taking biological extracts as ingredients,
researchers have successfully synthesized some chemical pollution-free SeNPs that display diverse
biological effects, such as UVB-induced DNA damage prevention [165] and cancer cells proliferating
inhibition [126]. So far, bacteria are the most important source of biosynthesized SeNPs. Bacteria
such as Bacillus licheniformis JS2 [127], Ochrobactrum sp. MPV1 [166], Streptomyces minutiscleroticus
M10A62 [167], and Acinetobacter sp. SW30 [126] have been employed to fabricating SeNPs.
These bacteria-based SeNPs are synthesized by culturing bacterial strain with sodium selenite
(0.5–2 mM). Zonaro et al. [166] demonstrated that, under the stress of Na2SeO3 (0.5 or 2 mM),
Ochrobactrum sp. MPV1 was capable of converting selenite to elemental Se and synthesizing SeNPs
intracellularly; however, medical applications of these SeNPs remain underexploited. The synthesizing
protocol of bacteria-based SeNPs is now gradually developing; however, SeNPs should always be
purified to avoid the toxicity caused by bacteria. Similar to bacteria, fungi with properties such as large
output, easy accessibility, and economic feasibility could be used as candidates for biosynthesizing
SeNPs [168]. However, the investigation into the practicability of fungi synthesized SeNPs in medical
fields is relatively deficient. In Vetchinkina et al. [163], fungus-based spherical SeNPs were obtained
from the medicinal basidiomycete Lentinula edodes cultured with inorganic selenium (10−2 mol) or
organoselenium (10−7 to 10−3 mol). The reduction in selenium (SeIV to Se0) was observed, and the
synthesis mechanism of L. edodes based SeNPs was revealed by transmission electron microscopy,
electron energy loss spectroscopy, and X-ray fluorescence [163]. Overall, bacteria and fungi are expected
to be competent media for SeNPs assembling, given their capability of producing a hypotoxic form of
Se by stepwise transforming Se oxyanions to elemental Se [169,170]. Intracellular synthesis of SeNPs
could be achieved under ideal experimental conditions that usually require Se-involved culture [171],
so that Se oxyanions would be transported into cells for downstream reduction and reassembly. In
a study carried out by Sonkusre et al. [127], SeNPs synthesized in Bacillus licheniformis strain JS2
were able to initiate necroptosis in PC-3 cell by the ROS-mediated activation regulated by a RIP1
kinase, thus taken as undeveloped anti-cancer substances with high producing efficiency. Plant-based
SeNPs are another interesting aspect of biosynthetic SeNPs [168]. For instance, Sharma et al. [64]
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synthesized selenium nanoballs with uniform size (3–18 nm) and shape using dried Vitis vinifera
(raisin) extracts and selenous acid, with a simple refluxing method. Although the extract mechanism
of plant-based SeNPs and the pharmaceutical applications remain largely underexplored, SeNPs
synthesized with/in plants are likely to have vast potential for future development due to the variety
of plants and their cleanliness.
As for the physically synthesized functional SeNPs, approaches such as pulsed laser ablation [172]
and γ-radiation [173] have been used for their generation. For instance, Guisbiers et al. [174] obtained
pure SeNPs by pulsed laser ablation in liquids and showed that these SeNPs were able to disturb
the biofilm formation of a human pathogen Candida albicans, highlighting the potential for medical
application of physical synthesis SeNPs. However, the application of physical-synthetic SeNPs in
cancer treatment and prevention is still immature, which may be due to the equipment requirements.
From the above and Tables 1–4, SeNPs have great potential not only in cancer treatment but
also as diagnostic/imaging agents and more. Among all, the chemotherapeutic effects of SeNPs
could be easily considered the most promising application of SeNPs. So far, results from laboratories
regarding the anticancer property of SeNPs have mainly been positive. SeNPs showed anticancer
effects in a range of cancers, including hepatocarcinoma [128,140], breast cancer [122,129,141],
colon adenocarcinoma [124,132], lymphoma [133], esophageal cancer [143], prostate cancer [136,147],
ovarian cancer [137], and glioma [148]. Further studies and clinical trials are needed to elucidate
the possible applications of SeNPs in oncology. Also, concerns such as toxicity of nanoparticles
accumulation in the human body and the environment should be cautiously addressed.
4. Se and Epigenetics: Possible Roles in Cancer Prevention and Therapy
Epigenetic refers to the study of heritable changes in gene expression that do not involve changes
to the underlying DNA sequence [1,75]. These changes are controlled by epigenetic factors such
as epimodifications of DNA, post-translational modification (PTM) of histone, and expression of
non-coding RNA (ncRNA) [1]. Epigenetics plays a vital role in cancer development, and currently,
therapy targeting epigenetic changes is considered one of the most promising approaches in cancer
treatment [175,176]. The epigenetic effects of Se and their implications for human health, including
cancer, have been reviewed [1,177,178]. Studies have revealed that Se and Se compounds could
affect the epigenome of a cell through all three major epigenetic controls: DNA methylation, histone
modifications, and ncRNA expression [1]. In regards to cancer therapy, inorganic and organic Se
compounds, such as MSA, SeMet, MSC, Se-allylselenocysteine, and selenite, could effectively inhibit
the activities of histone deacetylases and DNA methyltransferases, which expressions are usually
up-regulated in various types of cancer cells [179–182]. Notably, the epigenetic inhibition mechanisms
of Se compounds appear to be quite distinctive depending on their chemical forms [180,183].
A genome-wide epigenetic analysis indicated that both inorganic (selenite) and organic (MSA) Se could
epigenetically affect distinct gene sets in human chronic myeloid leukemia K562 cells: selenite affected
genes involved in response to oxygen and hypoxia, whereas MSA affected genes associated with cell
adhesion and glucocorticoid receptors [184]. So far, the epigenetic effects of SeNPs and mechanism of
their action on gene expression remain largely unknown.
5. Other Potential Applications of Se Compounds
Se is an essential trace element required for the maintenance of human health. In addition to
its potential roles and use in cancer prevention and therapy, Se compounds have many other useful
non-cancer-related features. Among them, one of the most interesting features of Se is the antimicrobial
and antiviral activity observed in specific Se compounds. Previous studies demonstrated the
relationship between selenocompounds and the immune system and showed that Se supplementation
could enhance the activity and cytotoxic response of NK cells [6–8,38,81]. Specifically, sufficient intake
of dietary Se is crucial for handling viral infections and for preventing Se deficiency-related diseases
caused by bacteria and viruses (e.g., Keshan disease) [6,18]. Researchers have also discovered the
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antibacterial, antifungal, and antiviral properties of SeNPs, and have demonstrated how SeNPs can
be potentially used in various settings [168,185,186]. For example, Nguyen et al. [63] examined the
antimicrobial activity of SeNPs against foodborne pathogens and indicated the possible use of SeNPs
for food safety applications. Overall, it is anticipated that new and novel applications of Se compounds
in various fields of life sciences will be extensively investigated and explored due to rapid advancement
in nanotechnology and further understanding of the mechanisms underlying Se compounds at the
nano-scale level.
6. Conclusions
Although several clinical trials indicated no significant benefit of Se in preventing cancer,
overwhelming evidence has demonstrated that Se and many Se compounds, under certain
circumstances, are potent anticancer agents. In vivo and in vitro studies have hinted that the Se
compounds exert their anticancer ability through multiple mechanisms. However, further research and
clinical trials are still required before these Se compounds can be clinically recognized as anticancer
drugs. In addition to cancer therapy, Se compounds have been proven to be quite useful in other
cancer-related fields such as chemoprevention, diagnosis, and imaging, as well as in non-cancer-related
fields as described in this review and summarized in Tables 1–4. Among the Se compounds, SeNPs,
as the emerging form of Se species, have attracted considerable attention. Judging from the current
positive results of SeNPs against a range of cancers, SeNPs will play more critical roles in cancer
prevention and therapy in the near future, especially in the era of precision medicine, where patients
are provided with personalized and tailored treatment based on individual conditions and needs [75].
To conclude, in order to fully determine the potential of Se compounds, in particular the SeNPs,
in cancer prevention and therapy, extensive further studies are required to better understand the
underlying mechanisms behind the biophysiological effects of Se.
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NPC Nutritional prevention of cancer
PBM Peripheral blood mononuclear
PTM Post-translational modification
ROS Reactive oxygen species
Se Selenium
SELECT Selenium and vitamin E cancer prevention trial
SeMet Selenomethionine
SeNPs Se-containing nanoparticles
SWOG Southwest Oncology Group
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Abstract: Combination radiation and chemotherapy are commonly used to treat locoregionally
advanced head and neck squamous cell carcinoma (HNSCC). Aggressive dosing of these therapies
is significantly hampered by side effects due to normal tissue toxicity. Selenium represents an
adjuvant that selectively sensitizes cancer cells to these treatments modalities, potentially by
inducing lipid peroxidation (LPO). This study investigated whether one such selenium compound,
methylseleninic acid (MSA), induces LPO and radiation sensitivity in HNSCC cells. Results from
4,4-difluoro-4-bora-3a,4a-diaza-S-indacene (BODIPY) C11 oxidation and ferric thiocyanate assays
revealed that MSA induced LPO in cells rapidly and persistently. Propidium iodide (PI) exclusion
assay found that MSA was more toxic to cancer cells than other related selenium compounds; this
toxicity was abrogated by treatment with α-tocopherol, an LPO inhibitor. MSA exhibited no toxicity
to normal fibroblasts at similar doses. MSA also sensitized HNSCC cells to radiation as determined
by clonogenic assay. Intracellular glutathione in cancer cells was depleted following MSA treatment,
and supplementation of the intracellular glutathione pool with N-acetylcysteine sensitized cells to
MSA. The addition of MSA to a cell-free solution of glutathione resulted in an increase in oxygen
consumption, which was abrogated by catalase, suggesting the formation of H2O2. Results from this
study identify MSA as an inducer of LPO, and reveal its capability to sensitize HNSCC to radiation.
MSA may represent a potent adjuvant to radiation therapy in HNSCC.
Keywords: head and neck cancer; selenium; methylseleninic acid; radiation; lipid peroxidation;
glutathione; tocopherol
1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is a diverse group of cancers that originate
from the mouth, nose, throat, or other nearby areas. Over 50,000 new cases of HNSCC are anticipated
to arise in the US in 2018; the five-year survival rate is ~64% [1]. Locoregionally advanced HNSCC is
often treated with combination radio- and chemotherapy. However, side effects from primary therapy
can be debilitating. Radiation and chemotherapy can result in oral mucositis, which can significantly
reduce tolerable doses [2]. Even with these aggressive therapy options, about 40% of HNSCC deaths
will occur due to the development of therapy resistance [3]. Additional options to sensitize HNSCC
cells to current therapies are sorely needed.
Selenium administration shows great promise as a sensitizer to radio- and chemotherapy. Sodium
selenite, an inorganic selenium derivative, induces toxicity and radiation sensitization in various
cancer cell types with limited effects on normal fibroblasts [4–6]. A recent metastudy reported that
Int. J. Mol. Sci. 2019, 20, 225; doi:10.3390/ijms20010225 www.mdpi.com/journal/ijms123
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selenite supplementation in patients receiving radiation therapy reduced deleterious side effects with
no protective effects noted in tumors, supporting the use of selenium as an adjuvant to therapy [7].
These studies and others suggest that selenium may sensitize tumors to intervention, while potentially
protecting normal tissue. Unfortunately, sodium selenite exhibits toxicity at relatively low doses,
with a reported maximum tolerable dose of 10.2 mg m−2 [8]. Organoselenium derivatives, such as
selenomethionine (SLM) and methylselenocysteine (MSC), are much less toxic than their inorganic
counterparts while maintaining the selective effects noted with selenite [9,10]. Organoselenium
derivatives exert their anticancer activities through the formation of a common active metabolite,
methylselenol [11,12]. SLM and MSC require the action of specific lyase enzymes, such as methionine
gamma-lyase (MGL), to release methylselenol [13]. MGL expression is reported to decline in a number
of cancer types, suggesting that the formation of methylselenol in tumor tissue by SLM may be slow,
limiting its efficacy [14–17].
Methylseleninic acid (MSA) is an organoselenium derivative that generates methylselenol through
its spontaneous reaction with free thiols, such as glutathione [18]. Because the activity of MSA is not
reliant upon the expression of lyases, such as MGL, it may represent a more effective antitumor agent
than other organoselenium compounds. Previous studies have reported that MSA more effectively
reduces TM2H and TM12 hyperplastic mammary cell accumulation than MSC, even at 10-fold lower
doses [12]. Additionally, oral administration of MSA reduced the size of PC-3 xenografts in mice
by approximately 40%, while administration of SLM, MSC, or sodium selenite exhibited no effects,
indicating that MSA is more effective both in vitro and in vivo than other selenium compounds [19].
A combination of MSA and paclitaxel reduced the size of MDA-MB-231 xenografts in mice by about
50%, compared to paclitaxel alone, suggesting that MSA may be an effective adjuvant to current
therapies [20]. In these studies, no change in body weight was observed, suggesting that MSA was
well tolerated.
Although methylselenol has been identified as the active antitumor metabolite of organoselenium
compounds, the mechanism of action following its generation is poorly understood. The combination
of MSA and glutathione has been demonstrated to increase lucigenin-based chemiluminescence, which
was abrogated by the presence of superoxide dismutase, suggesting the generation of superoxide
(O2•−) [18]. Superoxide may be protonated to form hydroperoxyl radical (HO2•) or dismutated to
form hydrogen peroxide (H2O2), both of which may contribute to the initiation of lipid peroxidation
(LPO) [21,22]. Selenium administration has been associated with elevated markers of LPO, suggesting
that these initiating effects occur in vivo [23–25]. Because end products of LPO can be highly toxic,
MSA-generated methylselenol could, therefore, exhibit toxicity through the superoxide-mediated
initiation of LPO. Furthermore, HNSCC patients exhibit higher levels of plasma markers of LPO than
matched healthy subjects, suggesting that HNSCC may be particularly susceptible to LPO [26,27].
Results presented herein reveal that MSA exhibits toxicity and radiation sensitization of Cal27
and SCC25 HNSCC cells. Cal27 cells were found to be much more sensitive to MSA compared to
SLM or MSC, while normal human fibroblasts were resistant to MSA-induced toxicity. Initiation of
oxidative distress via lipid peroxidation appears to be the underlying mechanism for toxicity. Our
data suggest that the toxic effects of MSA are mediated by a glutathione-dependent formation of an
initiator of LPO. MSA may be a useful adjuvant to radiation therapy.
2. Results
2.1. MSA is More Toxic to HNSCC Cells than Other Organoselenium Derivatives, and Causes Cell Death in a
Dose- and Time-Dependent Manner
Organoselenium derivatives SLM and MSC require enzymatic action to generate methylselenol,
the common active metabolite. Therefore, methylselenol generation from SLM and MSC will be
less in situations where these enzymes are poorly expressed. MSA requires no enzymatic activity to
generate methylselenol [18]. To determine if MSA exhibits greater toxicity than other organoselenium
compounds, Cal27 cells were treated with MSA, MSC, or SLM for 72 h, and viability was assessed
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with propidium iodide (PI) exclusion assay. MSC and SLM exhibited no toxicity at doses up to 10 μM,
Figure 1A. Treatment with 1 μM MSA resulted in a small but significant increase in PI positive cells,
while 10 μM MSA resulted in about 30% PI-positive cells. To ensure that MSA toxicity was not cell-line
dependent, the effects of MSA treatment on SCC25 cells were also examined. A dose-dependent
increase in PI positive SCC25 cells was observed with MSA treatment, with approximately 30% of the
cells staining positive at 10 μM, Figure 1B. These results indicate that Cal27 cells are more sensitive to
MSA than other organoselenium derivatives and that MSA-induced toxicity is dose-dependent in both
Cal27 and SCC25 cell lines.
The sensitizing effects of organoselenium compounds on cancer cells have been reported to
occur as early as 24 h following the beginning of treatment [28]. To determine the temporal aspects
of the toxicity resulting from exposure to MSA, Cal27 and SCC25 cells were treated with MSA for
varying durations and the toxicity was examined by measuring changes in cell numbers as well as
flow cytometry measurements of the percentage of PI-positive (non-viable) and PI-negative (viable)
cell populations. SCC25 and Cal27 cells both showed a marked decline in cell number as early as
24 h after initiation of treatment with MSA, with a reduction in cell number of about 75% and 95% in
Cal27 and SCC25, respectively, Figure 1C. Cal27 cell numbers continued to decline up to 72 h, while
SCC25 cell number appeared to begin to recover at 72 h. The rapid onset of a reduction in cell number
correlated with an increase in the percentage of PI-positive Cal 27 cells at 48 h of treatment, Figure 1D.
SCC25 cells exhibited significant toxicity as early as 24 h. SCC25 maximal toxicity (45% PI-positive
cells) was reached by 48 h in the period examined, while Cal27 reached similar levels at 72 h. Together,
these results indicate that the MSA treatment exhibits greater toxicity to HNSCC than treatments with
MSC and SLM and that this toxicity is dose- and time-dependent. Furthermore, treatment with MSA
appears to be more toxic to SCC25 compared to Cal27 cells.
 
Figure 1. Methylseleninic acid (MSA) is toxic to Cal27 and SCC25 HNSCC cells in a dose- and
time-dependent manner. (A) PI exclusion assay of Cal27 cells treated with the shown concentrations of
Se-methylselenocysteine (MSC), seleno-L-methionine (SLM), or MSA for 72 h. (B) Propidium iodide
(PI) exclusion assay of SCC25 cells treated with 0 to 10 μM MSA for 72 h. (C) Cell counts of Cal27 and
SCC25 cells following treatment with 10 μM MSA for 0 to 72 h. (D) PI exclusion assay of Cal27 and
SCC25 cells after treatment with 10 μM MSA for 0 to 72 h. *, statistical significance relative to 0 μM
MSA controls; p < 0.05, n = 3.
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2.2. MSA Treatment Sensitizes HNSCC Cells to Radiation
Selenium compounds, such as sodium selenite and seleno-L-methionine, sensitize cancer cells
to radiation [4,5,10,29]. Furthermore, this sensitization is frequently noted to be selective for cancer
cells [29]. Fibroblasts are often thought to make up the majority of the non-cancer cellular fraction
in the tumor stroma [30,31]. To determine if normal human fibroblasts (NHF) were resistant to MSA
toxicity, a PI exclusion assay was utilized. PI-positive (non-viable) NHF population did not increase
following MSA treatment, Figure 2A. MSA (1 μM) treatment more than doubled non-viable Cal27 and
SCC25 populations, Figure 1A,B, demonstrating the selective effects of MSA to HNSCC over NHF. To
determine if MSA sensitizes HNSCC to radiation, Cal27 cells were treated with MSA for 48 h before 2
or 4 Gy irradiation, and toxicity was analyzed by using a clonogenic assay. Irradiated cells without
MSA treatment showed a surviving fraction of 0.75 and 0.28 at 2 and 4 Gy, respectively, Figure 2B.
Treatment with 0.1 μM MSA did not significantly alter surviving fraction of Cal27 cells: 0.66 and 0.22
at 2 and 4 Gy, respectively. Interestingly, prior treatment with 1 μM MSA significantly reduced the
surviving fraction to 0.3 and 0.03 at 2 and 4 Gy compared to a surviving fraction of 0.75 and 0.28
without MSA treatment.
Radiation response is frequently dependent upon the support of the tumor stroma. To determine
if the tumor stroma impacts the ability of MSA to sensitize Cal27 cells to radiation, a co-culture
clonogenic assay was utilized. Cal27 cells were plated on lawns of quiescent normal human fibroblasts
(NHF), and co-cultures were treated with 1 μM MSA for 48 h before irradiation. Even with NHF
present, MSA treatment resulted in a 40% decline of surviving fraction following 2 Gy radiation,
Figure 2D. Additionally, the lawn of NHF was not disturbed by MSA, further indicating that MSA
was not toxic to NHF even in combination with radiation, Figure 2C. These results indicate that MSA
treatment potently and selectively sensitizes Cal27 cells to radiation in co-cultures of NHF.
 
Figure 2. MSA selectively sensitizes head and neck squamous cell carcinoma (HNSCC) cells to radiation.
(A) PI exclusion assay of normal human fibroblasts (NHF) treated with MSA 24 h. (B) Clonogenic
assay of Cal27 cells treated with MSA 48 h before irradiation with γ-rays. (C) Representative images of
Cal27 cells in co-cultures with NHF that were treated with MSA 48 h before irradiation with γ-rays.
Black arrows: Cal27 colonies; white arrows: quiescent NHF. (D) Quantitation of Cal27 clonogenic
survival in co-cultures of Cal27 and NHF that were treated with MSA 48 h before irradiation with
γ-rays. *, statistical significance relative to 0 μM MSA controls; p < 0.05, n = 3.
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2.3. MSA Treatment Induces Lipid Peroxidation in HNSCC Cells
Organoselenium compounds are theorized to be metabolized through a multitude of pathways
to a central active metabolite, methylselenol, which exerts toxicity. Due to the highly reactive nature
of methylselenol, studies concerning its mechanism of toxicity are sorely lacking. However, markers
of lipid peroxidation have been found to rise in patients treated with selenium [24], suggesting that
high dose selenium may induce lipid peroxidation. To determine if MSA treatment induces lipid
peroxidation in HNSCC cells, MSA-treated Cal27 cells were labeled with the dye BODIPY C-11. This
dye integrates into membranes and emits maximally at 590 nm. Upon oxidation by an initiator or
propagator of lipid peroxidation, the maximal emission shifts to 510 nm. By reading both channels
simultaneously, a ratio of oxidized to reduced dye can be calculated, providing a snapshot of lipid
peroxidation initiation and propagation. Lipid peroxidation was found to be up to 30% elevated
in Cal27 cells treated with MSA for 72 h, Figure 3A. An elevation was noted at a dose as low as
0.1 μM MSA, suggesting a powerful potential for initiation. Examination of lipid peroxidation at very
early time intervals indicated that lipid peroxidation was initiated as early as 2 h, and maintained at a
relatively stable level up to 72 h, Figure 3B. To determine if these increases in initiation and propagation
events resulted in elevated lipid hydroperoxides, the Cayman Lipid Hydroperoxide Assay kit was
utilized. Cal27 cells treated with 10 μM MSA for 72 h were found to have 1.16 fmol lipid hydroperoxide
per cell, nearly 40 times as much as untreated cells, Figure 3C. These data indicate that treatment
with MSA induces lipid peroxidation potently and persistently and that this induction results in a
significant accumulation of lipid hydroperoxides.
Figure 3. MSA induces lipid peroxidation in HNSCC cells. (A) Lipid peroxidation in Cal27
cells assessed by 4,4-difluoro-4-bora-3a,4a-diaza-S-indacene (BODIPY) C-11 staining following 72 h
treatment with 0 to 10 μM MSA. (B) Lipid peroxidation in Cal27 cells following treatment with 10 μM
MSA. (C) Lipid peroxides in Cal27 cells as assessed by the Cayman Chemical LPO Kit following
treatment with 0 to 10 μM MSA for 72 h. (D) PI exclusion assay of Cal27 and SCC25 cells treated with
20 μM α-tocopherol acetate (TOH) for 24 h, 10 μM MSA for 72 h, or pre-treatment with TOH for 24 h
followed by treatment with MSA. *, statistical significance relative to 0 μM MSA controls; #, statistical
significance relative to MSA alone; p < 0.05, n = 3.
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Lipid peroxidation is a deleterious oxidative chain reaction that can form toxic products, such
as MDA or 4-HNE. Induction of uncontrolled lipid peroxidation can damage critical biomolecules
resulting in cell death. To determine if MSA-induced toxicity is caused by lipid peroxidation, Cal27
and SCC25 cells were pre-treated with a lipid peroxidation chain terminator, α-tocopherol acetate
(TOH), before MSA treatment. Treatment with TOH alone did not impact the percentage of PI-positive
cell populations in either cell line, Figure 3D. However, treatment with TOH before MSA treatment
reduced the percentage of the PI-positive cell population in Cal27 from 26% to 15%, and in SCC25
from 20% to 12%, an approximate 40% decline in the PI-positive populations. These results show that
lipid peroxidation is an essential step in MSA-induced toxicity of HNSCC cells.
2.4. N-Acetyl-L-Cysteine Exacerbates MSA Toxicity in HNSCC
MSA spontaneously reacts with glutathione (GSH) to form its active metabolite, methylselenol,
and GSH disulfide (GSSG), see below [18]. As the principal intracellular redox buffer, GSH is critical to
normal cellular function. GSSG may be cytotoxic; it can be recycled to GSH by glutathione reductase,
exported from the cell, or form mixed protein disulfides. To determine if MSA treatment influences
GSH levels in HNSCC cells, the intracellular GSH content was measured in MSA-treated Cal27 cells
using a biochemical assay [32]. Results indicate a dose-dependent decrease of total GSH in MSA-treated
Cal27 cells, Figure 4A. Untreated Cal27 cells exhibited a total GSH concentration of about 17 nmol
(mg protein)−1. Treatment with MSA lowered this to below 10 nmol (mg protein)−1, a 40% decline.
Despite this marked decline, intracellular GSSG was not found to increase following MSA treatment,
but rather also declined, Figure 4B. The decline in GSH levels suggests that GSH may have a significant
role in the MSA-induced toxicity of HNSCC. This premise is further supported by results showing
N-Acetyl-L-Cysteine (NAC) treatments exacerbating MSA-induced toxicity in Cal27 cells, Figure 4C.
NAC is a membrane permeable precursor to GSH, stimulating its production; its effects are detectable
within 4 h [33,34]. Cal27 cells were treated with 5 mM NAC for 24 h, washed, and treated with 10 μM
MSA for 72 h. Cell number declined from 3 × 105 in cultures treated with MSA alone, to 0.5 × 105 cells,
Figure 4C. A PI exclusion assay revealed that the combination of NAC and MSA resulted in a 30%
non-viable cell population, while MSA alone resulted in only 25%, Figure 4D. Although NAC alone
reduced cell number from 11 × 105 to 0.6 × 105, it had no effect on viability. This is consistent with
prior reports from our lab that NAC treatment induces a cell cycle arrest [33,34]. These results indicate
that GSH facilitates MSA-induced free radical chemistry (see below), leading to lipid peroxidation and
HNSCC cytotoxicity.
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Figure 4. MSA exhibits toxicity in a glutathione (GSH)-dependent manner. (A) Total GSH in Cal27
cells treated with 0 to 10 μM MSA for 72 h. (B) Percent of GSH existing as glutathione disulfide (GSSG)
in Cal27 cells treated with 0 to 10 μM MSA for 72 h. (C) Cell counts of Cal27 cells following treatment
with 5 mM N-Acetyl-L-Cysteine (NAC) for 24 h, and/or 10 μM MSA for 72 h. The NAC + MSA group
received 5 mM NAC for 24 h before treatment with MSA. (D) PI exclusion assay of Cal27 cells treated
with 5 mM NAC for 24 h, and/or 10 μM MSA for 72 h. The NAC + MSA group received 5 mM NAC for
24 h before treatment with MSA. *, statistical significance relative to 0 μM MSA controls; #, statistical
significance relative to NAC alone; p < 0.05, n = 3.
2.5. MSA Treatment Enhances GSH-Dependent O2 Consumption
MSA can be reduced by free thiols, such as GSH, to form its active metabolite, methylselenol,
Figure 5C. Because the pKa of the selenohydryl group is 5.2, it primarily exists in biological systems
as its conjugate base, the highly reactive methylselenolate anion (MeSe−) [35]. This reactive species
may initiate a cyclic reaction with molecular oxygen and GSH to cycle between a methylselenyl radical
intermediate and methylselenolate anion, forming O2•− (which is rapidly dismuted to H2O2) and GSH
to GSSG as products. This cyclic reaction is anticipated to account for the toxicity of organoselenium
compounds [18,36]. In support of this chemistry, a previous study demonstrated the involvement
of oxygen to the cyclic reaction between a related compound, selenocystamine, and GSH [36]. To
determine if MSA may also undergo a similar reaction, O2 consumption was monitored in a cell-free
system containing MSA and GSH, Figure 5A. This system was held at pH 9.2, as this is the reported
optimum pH for selenium-catalyzed O2•− generation [18]. O2 was observed to disappear from the
buffer at a rate of approximately 3 nM s−1. Addition of MSA to buffer did not change the rate
of consumption of O2 (data not shown). Addition of GSH in the absence of MSA resulted in the
disappearance of O2 at a rate of approximately 15 nM s−1, Figure 5B. Interestingly, the addition of
MSA (250 μM) following GSH doubled the rate of O2 consumption to approximately 32 nM s−1.
Furthermore, the addition of 500 IU catalase caused the rate of O2 consumption to return to 13 nM
s−1, approximately the same as GSH alone. These results indicate an O2-dependent reaction occurring
between MSA and GSH that may result in the formation, but not accumulation, of H2O2. H2O2
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may also contribute to another O2-dependent reaction between GSH and MSA. The resulting flux
of H2O2 may facilitate lipid peroxidation through the iron-dependent generation of HO•, resulting
in MSA-induced toxicity of HNSCC. Previous reports indicate elevated markers of LPO in HNSCC
patients [26,27], suggesting that MSA-induced selective cytotoxicity may be due to higher baseline
levels of LPO in HNSCC compared to normal cells.
 
Figure 5. MSA enhances the consumption of O2 by glutathione. (A) Representative trace of O2
concentration in 3.00 mL pH 9.2 50 mM borate buffer at 37 ◦C. GSH and MSA added to a final
concentration of 2 mM and 250 μM, respectively, at indicated time points. (B) Rate of O2 consumption
in 3.00 mL pH 9.2, 50 mM borate buffer at 37 ◦C. (C) Schematic of metabolism of MSA. MSA is reduced
by GSH to methylselenol (MeSeH) through a methylselenenic acid (MeSeOH) intermediate. MeSeH
may cycle with O2 and GSH through a methylselenyl radical intermediate (MeSe•) to generate H2O2,
potentially through an O2•− intermediate. MeSeH may also exhibit peroxidase activity, consuming
H2O2. (D) Schematic of the process of lipid peroxidation. The process is initiated by abstraction of a
hydrogen atom from a lipid, forming a carbon-centered lipid radical (L•). The reaction is propagated
by the addition of O2, followed by abstraction of another hydrogen atom from a neighboring lipid,
forming LOOH and a new L•. The chain can be terminated by a donor antioxidant, such as tocopherol
(TOH). The resulting tocopheroxyl radical (TO•) radical does not efficiently further oxidize lipids. *,
statistical significance relative to buffer alone; #, statistical significance to GSH alone; p < 0.05, n = 3.
3. Discussion
Results presented here show that MSA treatment results in toxicity and enhanced radiation
sensitivity in HNSCC cells and that this toxicity may be facilitated by glutathione and oxygen-mediated
reactions resulting in toxicity. BODIPY C-11 oxidation data indicate that lipid peroxidation is associated
with this oxidative process, can be detected within 2 h of the initiation of MSA treatment, and
persists for at least 72 h. Lipid hydroperoxides were detected in a dose-dependent manner following
treatment with MSA, consistent with a role for lipid peroxidation and corroborating BODIPY C-11
oxidation experiments. In a cell-free system, MSA doubled the rate of GSH-dependent O2 consumption.
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Consistent with results from the cell-free experiments, intracellular GSH levels decline in Cal27 cells
following exposure to MSA. Supplementation of the intracellular GSH pool by pre-treatment with
NAC further sensitized, rather than protected, the cells from MSA-induced toxicity. These results
suggest that MSA reacts with intracellular GSH, yielding reactive oxygen species capable of inducing
lipid peroxidation and cell death.
MSA exhibited significant toxicity to Cal27 and SCC25 HNSCC cells, Figure 1. Similar
organoselenium compounds SLM and MSC did not show any toxicity at doses up to 10 μM, while
10 μM MSA resulted in a nearly 30% PI-positive (non-viable) population of cells, Figure 1A. The
active metabolite of all three of the examined compounds is methylselenol [11,12]. SLM and MSC
release methylselenol following processing by lyase enzymes, such as MGL [13]. Several reports have
identified MGL as a tumor suppressor gene, suggesting that its expression is reduced in tumors [14–17].
Overexpression of MGL in ovarian cancer cells resulted in up to 1000-fold sensitization to SLM [37].
Furthermore, hepatoma xenografts treated with the combination of adenovirus-delivered MGL and
SLM (1 μmol d−1, IP) exhibited a drastic decline in tumor size compared to SLM alone, indicating
the necessity of MGL for SLM to generate methylselenol [37]. MSA generates methylselenol by a
direct and spontaneous reaction with GSH, obviating the need for MGL, Figure 5C [13,18]. Previous
studies have identified MSA as more effective than MSC at inducing apoptosis and inhibiting cell
growth in murine mammary cell cultures [12]. MSA also more effectively reduced prostate cancer
xenograft size than SLM or MSC with no change in body weight [19]. Our results indicate that HNSCC
is also more sensitive to MSA than SLM or MSC. MSA was also found to render Cal27 HNSCC cells
sensitive to radiation, Figure 2B. Although other selenium compounds have been reported to induce
sensitivity of cancer cells to radiation, the ability of MSA to do so has not yet been reported [4,10]. The
increased toxicity of MSA compared to other selenium compounds suggests that it may also more
effectively sensitize cancer cells to radiation. Additionally, the cytotoxic and sensitizing effects appear
to be selective to cancer cells, as NHF were relatively resistant to MSA-induced toxicity, Figure 2A, and
quiescent lawns of NHF were undisturbed by a combination of MSA and radiation, Figure 2C.
MSA treatment increased BODIPY C11 oxidation in Cal27 cells, Figure 3A,B. BODIPY C11
may be oxidized by LPO initiators, such as hydroperoxyl radical, and propagators, such as lipid
peroxyl radical [38]. The dye is insensitive to LOOH and aldehydic end products of LPO, such
as malondialdehyde (MDA) or 4-hydroxynonenal (4-HNE). A dose-dependent increase of BODIPY
C11 oxidation was not observed at 72 h of MSA treatment. However, MSA treatment did result in
a dose-dependent increase in the accumulation of LOOH, as determined by the Cayman LPO Kit,
Figure 3C. Additionally, BODIPY C11 dye oxidation was found to stabilize as early as 2 h of MSA
treatment, Figure 3B. These results suggest that MSA induces LPO rapidly and persistently and that
this results in an accumulation of toxic lipid hydroperoxides. Furthermore, LPO appears essential
to the toxicity of MSA, as pre-treatment with α-tocopherol acetate, an inhibitor of LPO, protected
the cells from MSA-induced toxicity, Figure 3D. Previous studies have mainly focused on selenium
administration as an inhibitor of LPO, presumably due to the induction of the glutathione peroxidase
system [39]. However, evidence exists to suggest that selenium may initiate rather than inhibit LPO.
Pre-treatment with sodium selenite (single dose 2 mg kg−1, IP) in a murine model of heavy metal
poisoning found a 4-fold increase of liver MDA content over metal alone [23]. Administration of
ebselen, a synthetic organoselenium compound, increased liver MDA content in rats by approximately
20% [25]. Serum MDA levels were elevated in ovarian cancer patients following the administration of
50 μg of selenium as selenized yeast (4.8 μM compared to 3.9 μM) [24]. These reports and others suggest
that in some circumstances, selenium administration may induce LPO, although the mechanisms are
yet unclear. Because MSA more effectively generates methylselenol, the active metabolite, than similar
selenium compounds, it may also more potently induce LPO.
MSA treatment of Cal27 cells resulted in a depletion of total intracellular GSH content, Figure 4A,B.
MSA has been reported to deplete GSH in A549 lung cancer and HepG2 hepatoma cells [40,41]. In
HepG2 cells, a biphasic response was noted: A 10 μM treatment of MSA for 24 h caused intracellular
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GSH to increase by about 75%, while 25 μM MSA resulted in an approximate 20% decline in GSH,
with no change in GSSG. This biphasic response was not noted in Cal27 cells; total GSH content was
unchanged or declined at all doses tested, Figure 3A. Furthermore, treatment with MSA (10 μM) for
24 h decreased cell numbers of Cal27 and SCC25; a significant increase in the non-viable population,
Figure 1C,D. Apoptosis of HepG2 cells as detected by LDH was not noted at 10 μM MSA for 24 h,
suggesting that HepG2 cells are more resistant to MSA than HNSCC [41]. This concentration coincides
with elevated GSH in HepG2, which suggests that the biphasic response may play a role in resistance
of MSA. Interestingly, despite a decline in intracellular GSH levels following MSA treatment, no
change was noted in GSSG, Figure 4B. This may be due to increased GSSG efflux through membrane
transporters, such as MRP1 [42]. GSH may also be consumed without GSSG formation through
conjugation, suggesting that MSA treatment may induce increased GSH conjugation forming mixed
disulfides. Supplementation of the intracellular thiol pool by pre-treatment with NAC sensitized
Cal27 cells to MSA, Figure 4C,D. Similar results were reported with MSA treatment of HepG2
cells [41]. These results suggest that a reaction between MSA and a thiol, such as GSH, is essential for
MSA-induced cytotoxicity.
Oxygen consumption by GSH was doubled in the presence of MSA in a cell-free system,
Figure 5A,B. Furthermore, the addition of catalase to this system returned the rate of O2 consumption
to those similar to GSH alone. These results suggest the formation, but not accumulation, of H2O2.
Had H2O2 accumulated, the addition of catalase would have returned O2 to the system, i.e., an
increase in the concentration of O2 would have been observed. Selenol species may exhibit peroxidase
activity, as evidenced by the active site selenol of selenium-containing glutathione peroxidases [36].
Methylselenol may, therefore, exhibit peroxidase activity, yielding a methylselenenic acid, which may
again react with GSH to regenerate methylselenol, Figure 5C. Previous reports indicate the potential for
the formation of O2•− in systems containing selenium and GSH. The addition of MSA to a solution of
GSH is reported to increase lucigenin-based chemiluminescence [13,18]. This effect was abrogated by
the presence of superoxide dismutase, suggesting the formation of O2•−. Additionally, an examination
of the reaction kinetics of GSH and selenocystamine, an organoselenium compound similar to MSA,
suggests a cyclic reaction yielding superoxide [36]. Following O2•− generation, methylselenol may
be regenerated by an additional reduction by GSH, yielding a cyclic reaction capable of generating
large amounts of O2•− [18,36]. These reactions are summarized in Figure 5C. Following its formation,
O2•− can dismute to H2O2, either spontaneously or through the action of superoxide dismutase [43].
H2O2 may contribute to LPO initiation through the generation of hydroxyl radical by iron-mediated
Fenton chemistry [44,45]. Superoxide can also be protonated to form hydroperoxyl radical, which is
a powerful LPO initiator [21,22]. The contribution of O2•− to selenium-based cytotoxicity has been
further demonstrated by the protective effects of a superoxide dismutase mimetic [46]. Methylselenol
may, therefore, initiate lipid peroxidation chain reactions through superoxide-mediated products.
Overall, results from this study indicate that MSA sensitizes HNSCC cell to radiation and exhibits
toxicity through a GSH-dependent induction of LPO. LPO occurs more readily in cells with higher
polyunsaturated fatty acid content [47]. Many types of cancer exhibit greater lipid content than their
respective normal counterparts, including colon, prostate, pancreatic, and clear cell renal carcinoma [48–52].
MSA may, therefore, exhibit selective cytotoxicity in cancer cells on the basis of altered lipid content. A
pre-clinical study examining the efficacy of MSA (4 mg kg-1 d−1, PO) in treating prostate cancer xenografts
found a nearly 40% reduction in tumor size following MSA treatment, with no change in body weight [19].
Similarly, MSA (4.5 mg kg−1 d−1, PO) combined with paclitaxel (10 mg kg−1 week−1, IP) reduced breast
cancer xenograft tumor size with no change in body weight [20]. These studies suggest that MSA is
selectively toxic to cancer cells. The work presented herein suggests that this selectivity may be in part due
to a differential sensitivity to LPO in cancer compared to normal cells.
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4. Materials and Methods
4.1. Cell Culture and Reagents
Head and neck squamous carcinoma cell lines Cal27 (tongue origin, CRL-2095) and SCC25 (tongue
origin, CRL-1628) were purchased from ATCC (Manassas, VA, USA). Both lines have mutated p53,
are epidermal growth factor receptor (EGFR) positive, and human papillomavirus (HPV) negative.
Normal human fibroblasts (NHF) were obtained from the Coriell cell repository (AG01522D). Cells
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific, Waltham,
MA, USA), supplemented with antibiotics and 10% bovine calf serum (HNSCC cells, Thermo Fisher
Scientific, Waltham, MA, USA) or 10% fetal bovine serum (NHF, Sigma-Aldrich, St. Louis, MO, USA).
All cells were grown in humidified incubators set to 37 ◦C, 5% CO2, and atmospheric oxygen.
Seleno-L-methionine (SLM, S3132), N-acetylcysteine (NAC, A9165), glutathione (GSH, G4251),
glutathione disulfide (GSSG, G4376), glutathione reductase (GR, G3664), 2-vinylpyridine (2-VP,
132292), 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB, D8130), and 5-sulfosalicylic acid (SSA, S2130) were
purchased from Sigma-Aldrich. Reduced nicotinamide adenine dinucleotide phosphate (NADPH)
(481973) was purchased from EMD Millipore (Burlington, MA, USA). Methyl-Se-selenocysteine (MSC)
and methylseleninic acid (MSA) were generous gifts of the laboratory of Youcef Rustum (Roswell Park
Cancer Institute, Buffalo, NY, USA). BODIPY 581/591 C-11 (D3861) and CellTracker Green CMFDA
(C7025) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Lipid Hydroperoxide
(LPO) Assay Kit (705002) was purchased from Cayman Chemical Company (Ann Arbor, MI, USA).
4.2. Irradiation
Exponentially growing cells were irradiated at the Free Radical and Radiation Research Core
Facility at The University of Iowa. All irradiated cells received a single dose of γ-rays from a cesium-137
irradiator (JL Shephard, San Fernando, CA, USA) at a dose rate of 0.65 Gy min−1. Cell survival was
measured using a clonogenic assay following a previously published method [53].
4.3. Propidium Iodide Exclusion Assay
Following treatment, cultures were trypsinized, washed, and resuspended in cold phosphate
buffered saline (PBS). The suspended cultures were filtered and labeled with 1 μg mL−1 propidium
iodide for 5 min on ice. Flow cytometry was completed on a Becton-Dickinson FACScan at the
University of Iowa Flow Cytometry Core. Data from 10,000 events were collected in list mode. The
population of PI-positive (non-viable) and negative (viable) cells were calculated with FlowJo software
(FlowJo, LLC, Ashland, Oregon, USA).
4.4. BODIPY C-11 Assay
Following MSA treatment, adherent cells were washed and labeled with 5 μM BODIPY C-11
in DMEM lacking serum and antibiotics for 15 min at 37 ◦C. Following labeling, cultures were
collected by trypsinization, washed, resuspended in cold PBS and filtered. Samples were read on a
Becton-Dickinson LSR II flow cytometer using channels for Texas Red (reduced dye) and fluorescein
isothiocyanate (FITC, oxidized dye) simultaneously at The University of Iowa Flow Cytometry
Core. Populations were gated and analyzed with FlowJo software (version 7.6.5), and ratios of
oxidized:reduced dye were calculated.
4.5. Total Lipid Hydroperoxide Determination
A Cayman Lipid Hydroperoxide Assay Kit was used to determine total lipid hydroperoxides in
cell samples. Cal27 cells were treated with MSA for 72 h. Following treatment, cells were collected by
trypsinization and counted. Total lipid extracts were obtained and analyzed as recommended by the
manufacturer in glass cuvettes on a Beckman DU650 spectrophotometer. Lipid hydroperoxides per
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cell was quantified by construction of an appropriate standard curve and normalized to cell number,
as determined by a Z1 Coulter Counter (Beckman-Coulter, Brea, CA, USA).
4.6. Glutathione Determination
Following treatment, cells were collected by trypsinization, washed, and pellets were lysed in ice
cold 5% sulfosalicylic acid. Extracts were stored at −80 ◦C until analysis. Following centrifugation, the
supernatant was removed and used for the glutathione assay; protein precipitate was dissolved in 1%
SDS, 0.1 M NaOH for protein determination. Total glutathione was determined as described previously
on a Beckman DU-650 spectrophotometer [54]. Glutathione disulfide (GSSG) was determined using the
method of Griffith and Anderson [32]. Rates of reaction were compared to glutathione or glutathione
disulfide standard curves and normalized to protein content as determined by bicinchoninic acid
(BCA) (Thermo Fisher Scientific, Manassas, VA, USA).
4.7. Oxygen Consumption
Involvement of oxygen in the reactions of glutathione and MSA was investigated by recording
oxygen consumption during reaction progress in a cell-free system with an ESA BioStat Multi Electrode
System and YSI Oxygen Probe (Yellow Springs Instrument Co., Yellow Springs, OH, USA) at the Free
Radical and Radiation Research Core Facility at The University of Iowa. Measurements were conducted
in 3.00 mL of 50 mM pH 9.2 borate buffer at 37 ◦C. Initial oxygen concentration was assumed to be
188 μM, as reported previously [55]. The reactants glutathione, MSA, and catalase were introduced
sequentially to final concentrations of 2 mM, 250 μM, and 167 IU mL−1, respectively.
4.8. Statistical Analysis
Statistical analysis was completed using Prism (GraphPad Software, San Diego, CA, USA).
Two-way ANOVA with post-hoc analysis was completed to determine statistical significance.
Homogeneity of variance was assumed at a 95% confidence interval. Results from at least three
biological replicates with p < 0.05 were considered significant.
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Abstract: The prognosis for patients with metastatic melanoma remains very poor. Constitutive
signal transducer and activator of transcription 3 (STAT3) activation has been correlated to metastasis,
poor patient survival, larger tumor size, and acquired resistance against vemurafenib (PLX-4032),
suggesting its potential as a molecular target. We recently designed a series of isoseleno- and
isothio-urea derivatives of several biologically active heterocyclic scaffolds. The cytotoxic effects
of lead isoseleno- and isothio-urea derivatives (compounds 1 and 3) were studied in a panel of
five melanoma cell lines, including B-RAFV600E-mutant and wild-type (WT) cells. Compound 1
(IC50 range 0.8–3.8 μM) showed lower IC50 values than compound 3 (IC50 range 8.1–38.7 μM) and
the mutant B-RAF specific inhibitor PLX-4032 (IC50 ranging from 0.4 to >50 μM), especially at a
short treatment time (24 h). These effects were long-lasting, since melanoma cells did not recover
their proliferative potential after 14 days of treatment. In addition, we confirmed that compound 1
induced cell death by apoptosis using Live-and-Dead, Annexin V, and Caspase3/7 apoptosis assays.
Furthermore, compound 1 reduced the protein levels of STAT3 and its phosphorylation, as well as
decreased the expression of STAT3-regulated genes involved in metastasis and survival, such as
survivin and c-myc. Compound 1 also upregulated the cell cycle inhibitor p21. Docking studies
further revealed the favorable binding of compound 1 with the SH2 domain of STAT3, suggesting it
acts through STAT3 inhibition. Taken together, our results suggest that compound 1 induces apoptosis
by means of the inhibition of the STAT3 pathway, non-specifically targeting both B-RAF-mutant and
WT melanoma cells, with much higher cytotoxicity than the current therapeutic drug PLX-4032.
Keywords: selenium; isoselenourea; melanoma; STAT3; apoptosis
1. Introduction
Melanoma is originated from the malignant transformation of melanocytes. Its incidence has
been rapidly increasing, with a 5-fold increase in the last three decades [1]. The American Cancer
Society’s estimates for melanoma in the United States for 2018 are: About 91,270 new melanomas
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will be diagnosed (about 55,150 in men and 36,120 in women) and about 9320 people are expected to
die of melanoma (about 5990 men and 3330 women). Nearly 1,330,300 new cases of melanoma and
about 126,000 deaths are estimated to occur worldwide in 2018. The regions more affected are those
with white population, highest incidences being in Australia, New Zealand, Northern America, and
Northern and Western Europe [2]. If diagnosed in early stages, melanoma can be easily removed by
surgical excision but in metastatic form, it is one of the most aggressive malignancies with low survival
rates [3].
The mitogen-activated protein kinase (MAPK) signaling cascade is a key pathway in melanoma
survival and proliferation. Constitutive activation of B-RAF kinase due to B-RAFV600E mutation occurs
in nearly 50% of cutaneous melanomas [4]. Moreover, constitutive activation of signal transducer and
activator of transcription 3 (STAT3) has been implicated in many oncogenic features, as it regulates
the transcription of a variety of genes involved in cell proliferation, apoptosis, angiogenesis, and
metastasis. The constitutive activation of STAT3 has been reported in melanoma patients [5]. The high
expression of STAT3 has been correlated to large tumor diameter and depth, lymph node metastasis,
high expression of MMP-2 and -9, and poor patient survival [6–8].
Traditional treatments for melanoma have shown low response rates and are associated with
severe adverse effects. The introduction of agents that specifically target the MAPK pathway, such as
vemurafenib (PLX-4032), dabrafenib, and trametinib, has significantly improved the overall survival
of patients bearing the B-RAFV600E mutation [9]. Although treatment with these inhibitors induces a
quick initial response, the effect is not durable because of the rapid development of drug resistance [10].
The acquired resistance against vemurafenib is implicated in the activation of STAT3 and its signaling
pathways [11]. Importantly, suppression of STAT3 activity disrupts B-RAFV600E-mediated induction
of anti-apoptotic proteins and reduces melanoma cell survival [12]. In addition, these treatments are
ineffective in patients without the B-RAFV600E mutation [10]. Therefore, there is an urgent need to
develop novel agents for melanoma treatment.
In the last decade, selenium-containing compounds have emerged as promising anticancer
agents due to their efficacy and selectivity [13]. Several studies, including those from
our laboratories, have reported the role of different selenium-containing compounds in
the prevention and treatment of melanoma, including its metastasis [14–20]. Of these,
Se,Se′-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe), an isoselenourea derivative, has been
found to inhibit proliferation and promote apoptosis in melanoma cells in cell culture models [19].
It should be noted that PBISe was over 10-fold more effective than its isosteric sulfur analog
S,S’-1,4-phenylenebis(1,2-ethanediyl)bisisothiourea (PBIT). Furthermore, the topical application of
PBISe significantly delayed xenografted melanoma tumors growth [21].
In continuation of our pursuits towards developing novel organoselenium compounds as
anticancer agents, we recently reported the synthesis and screening of a series of novel isoselenourea
and corresponding isothiourea analogs [22]. This series consisted of new hybrid compounds containing
an isoselenourea or an isothiourea group and different carbo- and hetero-cyclic scaffolds which
have been traditionally included in anticancer agents [22]. Considering the encouraging results
of PBISe in melanoma, we decided to evaluate the potential of the novel analogs as potential
melanoma therapeutics. For this purpose, we selected an isoselenourea and an isothiourea derivative
which showed the highest activity against a melanoma cell line (1205Lu) in our previous screening
(compounds 1 and 3, respectively) [22]. The corresponding sulfur analog of compound 1, i.e.,
isothiourea compound 2, was also tested in order to determine if the compound selenium-containing 1
was more active than the sulfur compound 2 against melanoma cells, similar to what observed in the
case of PBISe. This study examines the effects of these compounds on various melanoma cell lines and
further evaluates the underlying mechanisms of action of compound 1.
139
Int. J. Mol. Sci. 2019, 20, 521
2. Results
2.1. Synthesis of Compounds 1, 2, and 3
The structures of quinoxaline-2,3-diylbis(methylene)dicarbamimidoselenoate dihydrobromide
(compound 1), its sulfur analog quinoxaline-2,3-diylbis(methylene)dicarbamimidothioate dihydrobromide
(compound 2), and (9,10-dioxo-9,10-dihydroanthracen-2-yl)methyl carbamimidothioate hydrochloride
(compound 3) are depicted in Figure 1A. These derivatives were synthesized as previously reported [22].
Briefly, compound 1 was synthesized by treating 2,3-bis(bromomethyl)quinoxaline with selenourea
(molar ratio 1:1.1) in absolute ethanol at room temperature for 2 h, and compound 2 by treating
2,3-bis(bromomethyl)quinoxaline with thiourea in absolute ethanol for 3.5 h at reflux. Compound 3
was obtained from 2-(chloromethyl)anthraquinone and thiourea (1:1.1 molar ratio) in absolute ethanol,
stirring for 3 h at reflux. The purity of compounds was ≥ 99%.
 
Figure 1. Compounds 1 and 3 were effective at reducing cell viability of different melanoma cancer cell
lines. (A) Structures of the compounds, (B) Screening of the three agents in melanoma cells (1205Lu)
for 24, 48, and 72 h using the MTT (cell viability) assay (C) Cell viability (MTT) results for compounds 1
and 3 in four different melanoma cancer cell lines at three different time points. Graphs were obtained
by performing non-linear regression analysis using variable slope. Error bars represent mean ± SD.
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2.2. Compounds 1 and 3 Reduced the Viability of Different Melanoma Cancer Cells
All the compounds were tested against a melanoma cell line (1205Lu) for their effect on cancer
cell viability. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was
performed in order to measure cancer cell viability, as previously described [22]. The anti-cancer effect
of each agent was tested at seven different concentrations between 0.1 and 50 μM and three time
points (24, 48, and 72 h). As shown in Figure 1B, compounds 1 and 3 potently inhibited the cancer
cell viability of melanoma cells, while the isosteric sulfur analog (compound 2) of 1 was essentially
ineffective up to the maximum concentration (50 μM) used. These results were in accordance with
many of our previous reports [14,16,22–24] where isosteric replacement of sulfur by selenium in a
small molecule significantly enhanced the anticancer activity. Therefore, compounds 1 and 3 were
further screened against a panel of four melanoma cancer cell lines (WM2664, A375M, UACC903, and
CHL-1) using the MTT assay. We compared the results with those obtained with PLX-4032, a B-RAF
kinase inhibitor used currently in the clinic for melanoma treatment. The results are summarized in
Table 1, expressed as IC50, the concentration that produces 50 % of growth inhibition.
Table 1. Effects on cell viability of compounds 1 and 3 and PLX-4032 in five different melanoma cell lines.
The results are expressed as mean values for IC50 with their respective standard deviation (± SD).
Comp. Time (h)
Cell Lines
WM2664 1205Lu A375M UACC903 CHL-1
1
24 1.8 ± 0.4 2.6 ± 0.3 2.6 ± 1.0 3.8 ± 1.6 2.9 ± 0.4
48 1.1 ± 0.3 1.9 ± 0.3 1.9 ± 0.1 0.8 ± 0.2 3.1 ± 0.4
72 2.0 ± 0.2 2.0 ± 0.6 1.1 ± 0.2 0.3 ± 0.6 2.5 ± 0.2
3
24 32.7 ± 3.6 33.7 ± 10.1 38.7 ± 1.0 32.6 ± 1.9 29.3 ± 10.6
48 21.0 ± 2.9 11.3 ± 3.0 21.3 ± 0.8 24.7 ± 2.3 12.3 ± 2.2
72 22.8 ± 7.0 8.3 ± 0.9 8.1 ± 4.2 22.3 ± 5.6 13.6 ± 1.7
PLX-4032
24 >50.0 >50.0 >50.0 38.5 ± 7.2 >50.0
48 32.1 ± 14.2 31.4 ± 8.0 3.5 ± 1.1 10.3 ± 2.6 21.2 ± 3.4
72 3.6 ± 1.5 9.3 ± 3.4 0.4 ± 0.3 17.9 ± 1.3 12.2 ± 1.5
Compound 1 was more cytotoxic across all cell lines compared to compound 3 and PLX-4032
(Figure 1, Table 1). Interestingly, while PLX-4032 was more effective when the B-RAFV600E mutation
was present, compounds 1 and 3 also reduced cell viability in the B-RAF wild-type cell line CHL-1,
compound 1 being the most potent. It should be noted that PLX-4032 showed no effect at 24 h in four
out of the five lines tested, whereas both compounds 1 and 3 produced a reduction of cell viability in
the five cell lines at that time point (Figure 1, Table 1). Compound 1 exhibited an IC50 lower than 4 μM
in all the cell lines tested at 24 h. Furthermore, this compound was more potent than the reference
drug in all cell lines at the three time points, with the exception of A375M cell line after 72 h of
treatment. Overall, the isoselenourea derivative (compound 1) exhibited much higher potency than the
isothiourea analog (compound 3) and, therefore, we selected compound 1 for further in vitro efficacy
and mechanism of action elucidation.
2.3. Compound 1 Suppressed the Proliferative Ability of Melanoma Cells (1205Lu and UACC903)
In order to evaluate the long-term effects of compound 1 on melanoma cells, a colony formation
assay was employed. For this assay, the cells were treated with either compound 1 or dimethyl
sulfoxide (DMSO, control) for 24 h, and then 500 live cells were counted and re-seeded in new plates in
the absence of compound 1 or DMSO and allowed to form colonies over a period of 14 days. As shown
in Figure 2, compound 1 effectively inhibited the colony formation ability of both 1205Lu and UACC903
melanoma cell lines. At the dose of 1 μM, the ability of melanoma cells to form colonies was reduced
to less than 50%, and when cells were treated with 2.5 μM, this percentage was dramatically reduced
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at levels lower than 20% and 5% for 1205Lu and UACC903 cells, respectively. These studies clearly
indicate that the effects of compound 1 on the inhibition of melanoma cells replication are long-lasting.
Figure 2. Compound 1 dramatically reduced the colony formation ability of melanoma cells. 1205Lu
(A) and UACC903 (B) cells were treated with 1 or 2.5 μM of compound 1 or dimethyl sulfoxide (DMSO)
(control) for 24 h. Subsequently, 500 cells were re-seeded with free compound 1 or DMSO medium
for 14 days and stained with 0.5% alcoholic crystal violet. The results are expressed as mean ± SD.
*** p < 0.001.
2.4. Compound 1 Increased Melanoma Cell Death in Vitro
In order to study whether the reduction of cell viability caused by compound 1 was due to cell
death and not cell growth inhibition, 1205Lu cells were subjected to the Live-and-Dead assay. As
shown in Figure 3, compound 1 increased the number of cells positive for ethidium homodimer
staining (dead cells, upper left quadrant) and reduced the cells stained with calcein AM (live cells,
lower right quadrant) compared to control cells. After treatment with 1 μM compound 1, no difference
was observed between control and treated cells. However, when the dose of compound 1 was increased
to 5 μM, the percentage of dead cells increased dramatically up to 25 %. These results suggest that
compound 1 was able to induce cell death in vitro in melanoma cells.
Figure 3. Compound 1 induced cell death in melanoma cells. 1205Lu cells were incubated with 1, 2.5,
or 5 μM of compound 1 or DMSO (control) for 24 h and stained with ethidium homodimer and calcein
AM. Live and dead cells were quantified by flow cytometry.
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2.5. Compound 1 Induced Apoptosis in Melanoma Cells
With the aim of investigating whether the increase in cell death induced by compound 1 was due
to apoptosis induction, the MuseTM Annexin V & Dead Cell assay was carried out. Annexin V was
employed in this assay to detect the externalization of phosphatidylserine to the cell surface, a process
occurring in apoptosis but not in necrosis [25]. A dead cell marker (7-ADD) was also included in the
kit as an indicator of cell membrane structural integrity. Therefore, cells negative for both markers
(lower left quadrant) were healthy cells, cells positive for Annexin V only (lower right quadrant) were
in early apoptosis, and cells positive for both Annexin V and 7-ADD were undergoing apoptotic death
(upper right quadrant). Cells positive for 7-ADD only were undergoing necrosis (upper left quadrant).
Compound 1 was tested at three concentrations: 1.75, 2.5, and 5 μM. The dose of 1 μM was
not tested because we observed no significant effect at this dose in the previous assay. As shown
in Figure 4A, after the treatment with compound 1 at 1.75 μM concentration, 15% of cells were in
early apoptosis (lower right quadrant). At 5 μM of compound 1, less than 50% of cells were healthy
cells and 25% of cells died by apoptosis (upper right quadrant). Less than 1% of cells died without
externalization of phosphatidylserine (upper left quadrant), indicating that compound 1 induced cell
death through apoptosis.
 
Figure 4. Compound 1 induced apoptotic cell death. After 24 h of incubation with the indicated
concentration of compound 1 or DMSO (control), the apoptotic status of 1205Lu cells was analyzed
using the MuseTM Annexin V & Dead Cell Kit according to the manufacturer’s instructions.
(A) Analogous independent experiments were analyzed with MuseTM Caspase 3/7 Kit to confirm the
results. (B) The results of both experiments were analyzed by flow cytometry.
In order to confirm these results, the MuseTM Caspase-3/7 kit was also employed. The kit includes
a reagent with a DNA binding dye. In non-apoptotic cells, this reagent is linked to an effector caspase
recognition sequence which does not bind to DNA. However, when caspases are active, the dye is
released by caspase cleavage and translocated to the nucleus, where it binds to DNA, producing
high fluorescence. This kit also includes the dead cell marker 7-ADD. Hence, cells negative for both
dyes were healthy cells (lower left quadrant), cells only positive for Caspase 3/7 reagent (lower
143
Int. J. Mol. Sci. 2019, 20, 521
right quadrant) were supposed to be in early apoptosis, cells positive for both dyes (upper right
quadrant) were undergoing apoptotic death, and cells only positive for 7-ADD (upper left quadrant)
were undergoing caspase-independent death. The results (Figure 4B) showed the same tendency
observed in the Annexin V assay. The doses of 1.75 and 2.5 μM increased the amount of early apoptotic
cells (lower right quadrant), and, after treatment with 5 μM compound 1, more than 60% of the cells
were positive for caspase 3/7 activity (lower and upper right quadrants). Less than 0.5% of cells died
through caspase-independent mechanisms. Overall, our results confirmed that compound 1 is a potent
apoptosis inducer.
2.6. Compound 1 did not Inhibit the Phosphorylation of Akt and ERK1/2
The dysregulated expression of Akt and ERK1/2 is associated with cell proliferation and
melanoma cell survival [26,27]. Hence, we decided to evaluate whether compound 1 affected
the expression and phosphorylation status of these proteins. Interestingly, as shown in Figure 5A,
compound 1 did not affect the expression or phosphorylation of Akt or ERK1/2. These observations
suggest that the cell inhibitory response to compound 1 is not mediated through the inhibition of Akt
and ERK1/2; therefore, other pathways might be implicated.
Figure 5. Compound 1 downregulated STAT3 and its downstream target proteins expression. 1205Lu
cells were incubated with either DMSO (control) or compound 1 for 24 h. Whole cell lysates were
subjected to western blot analysis. Expression of different proteins related to STAT3 and its downstream
targets (A–D) were monitored. ß-actin was used as a loading control.
2.7. Compound 1 Inhibited STAT3 and Related Proteins Expression
To further examine the mechanism of action of compound 1, its effects on proteins implicated
in cancer survival and metastasis were studied. STAT3 is highly upregulated in melanoma, and
its activation by phosphorylation contributes to cancer progression and survival [12]. Hence, we
decided to establish whether compound 1 affected the expression and phosphorylation status of
the transcription factor STAT3. As shown in Figure 5B, compound 1 reduced protein levels and
phosphorylation of STAT3. At the dose of 2.5 μM, the expression and phosphorylation of STAT3 were
dramatically reduced.
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STAT3 controls the expression of proteins involved in proliferation, survival, and metastasis
formation, such as XIAP, survivin, and c-myc [28–30]. As observed in Figure 5C, compound
1 also downregulated these proteins at the doses at which STAT3 inhibition was observed. In
addition, the inhibition of these anti-apoptotic proteins was accompanied by PARP (poly(ADP-ribose)
polymerase) cleavage (Figure 5D), which is traditionally employed as a marker of apoptosis [31]. These
results suggest that compound 1 has the ability to inhibit STAT3 signaling pathway. Moreover, the
induction of apoptosis and cell proliferation inhibitory response of compound 1 may be mediated by
STAT3 inhibition.
2.8. Compound 1 Induced the Cell Cycle Inhibitor p21
Recent studies have shown a correlation between the cell cycle inhibitor p21 and transcription
factor STAT3 [32]. These studies revealed that p21 is part of a feedback network controlling the
down-modulation of STAT activity [32]. Thus, we sought to investigate whether compound 1 activated
the expression of this cell cycle inhibitor. As shown in Figure 6, compound 1 induced the expression
of p21. These results suggest that the cell inhibitory activities of compound 1 may be mediated by
activation of p21.
Figure 6. Compound 1 induced p21 expression. After 24 h of treatment with either compound 1 or
DMSO (control), 1205Lu cells were collected, and the expression of p21 was analyzed by western blot
analysis. ß-actin was used as a loading control.
2.9. Compound 1 Inhibited the Phosphorylation of STAT3, Increased the Expression of p21, and Induced
Apoptotic Cell Death in Different Melanoma Cell Lines
The data above demonstrate that compound 1 effectively decreased p-STAT3 levels and increased
the expression of p21 and apoptotic cell death in 1205LU cells. However, to rule out cell line-dependent
effects of compound 1, we tested all the above biological activities of compound 1 in two additional
melanoma cell lines (UACC903 and SK-Mel-8). As shown in Figure 7A, compound 1 inhibited cell
proliferation of both melanoma cell lines, with UACC903 cells being more sensitive than SK-Mel-8.
As suggested by our Annexin V and Caspase 3/7 activity assay (Figure 7B,C), compound 1 induced
apoptotic cell death. Additionally, compound 1 also decreased the phosphorylation of STAT3
(Figure 7D,E) and induced p21 expression similar in both cell lines, to what observed in 1205Lu
cells. Hence, the biological activities of compound 1 were consistent across a variety of human
melanoma cell lines.
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Figure 7. Compound 1 inhibited the phosphorylation of STAT3, increased the expression of p21, and
induced apoptotic cell death in UACC 903 and Sk-Mel-8 melanoma cell lines. (A) Cell viability (MTT)
results for compound 1 in two different melanoma cell lines at 72 h. The graphs were obtained by
performing non-linear regression analysis using variable slope. Error bars represent mean ± SD. (B,C)
Human melanoma cells UACC 903 and SK-Mel-8 were treated with compound 1 (2.5 μM) for 24 h, and
an apoptotic assay was performed using the MuseTM Annexin V & Dead Cell (B) and Caspase 3/7
Kit (C) according to the manufacturer’s instructions. (D) Melanoma cells (UACC 903 and SK-Mel-8)
cells were treated with the mentioned concentrations of Compound 1. After 24 h, cells were collected
and lysed, and the expression of p-STAT3, STAT3, and p21 was analyzed by western blot. GAPDH
was used as a loading control; (E) Quantification of protein expression was performed using Image
J software, and graphs represent the relative expressions of proteins. The relative expressions were
determined using either STAT3 or GAPDH as mentioned.
2.10. Docking
In order to substantiate our experimental findings and to investigate the binding propensities
of compound 1 to the SH2 domain of STAT3, docking simulations were employed. The molecular
structure [33] of STAT3 (pdb id: 1BG1, resolution 2.25 Å) was retrieved from the protein data bank
(www.rcsb.org). CDocker [34], a CHARMm force field-based algorithm embedded in DS version 4.0
(Accelrys; San Diego, CA, USA), was used to flexibly dock compound 1 within the conservative SH2
domain of STAT3. The docking analysis revealed favorable binding of compound 1 with STAT3, based
on the computed scoring function (CDocker energy = −23.8 kcal/mol), where the most negative value
of CDocker energy indicates good binding affinity of a ligand for a protein. The visualization of the
complex (Figure 8A) further revealed that compound 1 penetrated deep inside the STAT3 cavity and
settled well by establishing a network of hydrogen bonding and electrostatic forces with the protein.
Specifically, compound 1 utilized its nitrogen atom (proton acceptor) of the quinoxaline moiety to form
two strong concurrent hydrogen bonds (2.2 Å, 2.8 Å) with the amine (proton donor) functionalities of
Arg609 (Figure 8B). This amino acid contributed significantly to STAT3 and SH2 peptide binding, as
the mutation of Arg609 has been reported to abolish the peptide-binding ability of this domain [35,36].
Several anticancer agents targeting the same amino acid residue (Arg609) in STAT3 SH2 domain
have already been documented in the literature [37,38]. Additionally, a hydrophobic interaction and
two electrostatic forces (cation-type) between the –NH3 group of Lys591 and the aromatic network
of compound 1 also facilitated locking its conformation in the binding domain of STAT3. Overall,
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the docking results revealed compound 1 as a good inhibitor of STAT3 protein and supported our
experimental observations.
 
Figure 8. Docked complex of compound 1 with STAT3. (A) The surface representation of STAT3
showing deep penetration of compound 1 into the SH2 domain of STAT3 (pdb id: 1BG1), generated
by DS (Accelrys). (B) Docked conformation of compound 1 in the SH2 domain of STAT3 (pdb id:
1BG1), viewed by DS (Accelrys). Carbon atoms of compound 1 (in sticks format) are colored green.
The interacting amino acids of the SH2 domain of STAT3 are colored in red. All other amino acids of
STAT3 are depicted in violet (flat ribbon format). Hydrogen bonds are shown in green, electrostatic
interactions in black, and hydrophobic interactions are shown as magenta dotted lines.
3. Discussion
In this work, we tested the effects of an isoselenourea derivative and an isothiourea compound on
cell viability in a panel of five melanoma cell lines bearing different mutations. The sulfur analog of
compound 1 (compound 2) was inactive at the studied doses. This was in accordance with a previous
report showing the isoselenourea derivative PBISe, an isosteric selenium analog of PBIT, to be over
10-fold more effective in inhibiting the viability of melanoma cells [19]. However, our recent report [22]
also indicates that replacing the isothiourea functionality by an isoselenourea may not always lead
to a more potent compound, suggesting that the potency depends on the overall structure of the
molecule. For example, the isothiourea analog compound 3 was more effective than its corresponding
isoselenourea analog [22]. Compounds 1 and 3 were active against both B-RAF mutant and wild-type
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(CHL-1) cells lines, whereas PLX-4032 is only effective against the altered form [39]. In addition,
our compounds were also more effective in reducing cell viability at 24 h in all the tested cell lines,
compound 1 being at least 10-fold more potent than PLX-4032. In general, as reported in previous
works [14,22,23], the selenium-containing derivative was much more active than the isothiourea one
in reducing cancer cell growth.
The results from Annexin V and Caspase3/7 assays, as well as the observation of cleaved PARP
in western blot, indicated that compound 1 induced apoptotic cell death. Apoptosis is a typical
mechanism for selenium compounds to induce cell death [13]. However, the underlying mechanism
of apoptosis induction could be remarkably different between distinct selenium-containing small
molecules. Activation of caspases, modulation of anti-apoptotic proteins, alteration of oxidative
stress-related proteins, cell cycle arrest, or kinases regulation are some of the described mechanisms
associated with apoptosis [40]. This fact could explain the different mechanism of action between
PBISe and compound 1. Although PBISe inhibited the phosphorylation and total protein levels of
Akt in melanoma cells [41], compound 1 did not regulate this protein. We conclude that compound
1 is not effective against either Akt or ERK1/2 and indeed we found that compound 1 inhibits the
expression of STAT3. In silico docking simulations conducted on compound 1 using STAT3 as a
molecular target also suggested the compound to be a good inhibitor for this target protein. Hydrogen
bonding and electrostatic and hydrophobic forces were found to be accountable for their host–guest
relationship. Moreover, just like other known STAT3 inhibitors, compound 1 also interacted with
Arg609, an essential amino acid for STAT3 function, suggesting its anti-melanoma activity may well be
through inhibition of STAT3, in agreement with the experimental results.
STAT3 is a member of the signal-transducer-and-activators-of-transcription family. When
phosphorylated, STAT3 dimerizes and translocates to the nucleus, where it modulates the transcription
of genes involved in cell survival and proliferation [42]. Constitutive activation of STAT3 has been
reported in several tumor types and has been proved to be involved in proliferation, survival,
inflammation, invasion, metastasis, and angiogenesis [7]. Several in vitro and in vivo studies have
demonstrated that the inhibition of STAT3 leads to tumor growth inhibition [5]. Thus, STAT3
is considered a valid therapeutic target for cancer therapy. STAT3 also has an important role
in melanoma development and survival. This protein was found to be constitutively activated
in numerous melanoma cell lines and tumor specimens [5]. Furthermore, inhibition of STAT3
signaling led to apoptosis of melanoma cells. Besides, STAT3 upregulation has been associated
with acquired resistances to PLX-4032. Melanoma cells resistant to PLX-4032 showed increased
STAT3 pathway activity [43], and in vitro silencing of this signaling inhibited the growth of cells
resistant to PLX-4032 [11]. Moreover, a combination treatment with WP1066 (a STAT3 inhibitor)
and PLX-4032 resulted in more significant growth inhibition of both resistant and sensitive cells to
PLX-4032. The downregulation of other proliferative and anti-apoptotic proteins which are under
transcriptional regulation of STAT3, such as XIAP, survivin, and c-myc, supports that compound 1
induces apoptosis through STAT3 inhibition. A previous study also reported a relationship between
selenium-containing compounds and STAT3 inhibition [44]. The studies by Zuazo et al. demonstrated
that imidoselenocarbamate derivatives blocked hypoxia-induced STAT3 phosphorylation [44].
4. Materials and Methods
4.1. Chemistry
All the chemicals were obtained from Sigma Aldrich (Alcobendas, Madrid, Spain) and Acros Organics
(Janssen Pharmaceuticalaan, Geel, Belgium). Quinoxaline-2,3-diylbis(methylene)dicarbamimidoselenoate
dihydrobromide (compound 1), quinoxaline-2,3-diylbis(methylene)dicarbamimidothioate dihydrobromide
(compound 2), and (9,10-dioxo-9,10-dihydroanthracen-2-yl)methyl carbamimidothioate hydrochloride
(compound 3) were synthesized and characterized as previously described [22]. Briefly, the corresponding
alkyl halide (1 mmol) was added to a mixture of selenourea (2.2 mmol; compound 1) or thiourea (2.2 mmol
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for compound 2 and 1.1. mmol for 3) in absolute ethanol (20 mL). The mixture was stirred 2 h at r.t. for
compound 1 or 3 hat reflux for 2 and 3. The precipitate was filtered and washed with 50 mL of ether (1
and 2) or with dichloromethane and ether (3).
4.2. Reagents and Antibodies
All the chemicals were obtained from Sigma Aldrich (Alcobendas, Madrid, Spain) and Acros Organics
(Janssen Pharmaceuticalaan, Geel, Belgium). Quinoxaline-2,3-diylbis(methylene)dicarbamimidoselenoate
dihydrobromide (compound 1), quinoxaline-2,3-diylbis(methylene)dicarbamimidothioate dihydrobromide
(compound 2) and (9,10-dioxo-9,10-dihydroanthracen-2-yl)methyl carbamimidothioate hydrochloride
(compound 3) were synthesized and characterized as previously described [22]. Briefly, the corresponding
alkyl halide (1 mmol) was added to a mixture of selenourea (2.2 mmol; compound 1) or thiourea (2.2 mmol
for compound 2 and 1.1. mmol for 3) in absolute ethanol (20 mL). The mixture was stirred 2 h at r.t.
for compound 1, or 3 h at reflux for compounds 2 and 3. The precipitate was filtered and washed with
50 mL of ether (1 and 2) or with dichloromethane and ether (3). Rabbit anti-phospho-Akt (Cat # 4060),
rabbit anti-Akt (Cat # 4685), rabbit anti-phospho-STAT3 (Cat # 9145), rabbit anti-STAT3 (Cat # 12640),
rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Cat # 4370), rabbit anti-p44/42 MAPK (Erk1/2) (Cat # 4695),
rabbit anti-XIAP (Cat # 14334), rabbit anti-survivin (Cat # 2803), rabbit anti-c-Myc (Cat #9402), rabbit
anti-p21waf1/Cip1 (Cat # 2947), and rabbit anti-PARP (Cat # 9542) were obtained from Cell Signaling
(Danvers, MA). Antibodies against GAPDH, β-actin, goat anti-rabbit, and goat anti-mouse horseradish
peroxidase conjugates, and MTT were purchased from Sigma-Aldrich (St. Louis, MO, USA).
4.3. Cell Culture
Human melanoma cell lines were grown in DMEM medium supplemented with 10 % fetal bovine
serum (FBS) and 100 units/mL of penicillin and streptomycin (Corning; Corning, NY, USA). The cells
were maintained at 37 ◦C and 5% CO2.
4.4. Cell Viability
A total of 3000 cells/well were grown in 96-well plates for 12 h and then treated with either
DMSO (control) or increasing concentrations (0.5–50 μM) of compound 1, 3, or PLX-4032 for 24, 48, and
72 h. Three hours before the termination point, 20 μL of MTT were added to measure cellular viability.
The resultant formazan crystals were dissolved in 50 μL of DMSO, and absorbance was measured at
570 nm and 630 nm wavelengths. IC50 values were calculated using GraphPad Prism version 6.01.
4.5. Colony Formation Assay
Melanoma cells (UACC903 and 1205Lu) were treated with DMSO or compound 1 (1 and 2.5 μM)
for 24 h. The cells were then trypsinized and counted, and 500 live cells were seeded in new 10 cm
tissue culture plates separated by treatments. The cells were allowed to form colonies for 14 days
in DMEM without compound 1 or DMSO in a 5% CO2 incubator. After 14 days, the medium was
removed, and the formed colonies were stained with 0.5% alcoholic crystal violet. The percentage
plating efficiency (PE) was calculated by using the following formula:
%PE =
number o f colonies
number o f cells plated
× 100 (1)
The results correspond to the mean ± SD of three independent experiments. Differences
between control and treated cells were determined by one-way ANOVA tests, using GraphPad
Prism version 6.01.
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4.6. Live-and-Dead Assay
The LIVE/DEAD viability/cytotoxicity kit for mammalian cells (Molecular Probes, Invitrogen;
Carlsbad, CA, USA) was employed for this experiment. A total of 7.5 × 105 1205Lu cells/well were
plated in a 6-well plate and treated with DMSO (control) or increasing amounts of compound 1.
After 24 h of incubation, both floating and attached cells were collected and re-suspended in PBS.
Further, cells were stained with a calcein AM and ethidium homodimer solution according to the
manufacturer’s instructions. The number of live and dead cells was determined by flow cytometry
(BD FACSCalibur; Heidelberg, Germany).
4.7. Annexin V Assay
1205Lu, UACC903, and SK-Mel-8 (4 × 105 cells/well) were pleated and treated with DMSO
(control) or compound 1 at the given concentrations. After 24 h of treatment, both floating and attached
cells were collected and stained with the MuseTM Annexin V & Dead Cell Reagent (Millipore; Bedford,
MA, USA) for 20 min at room temperature in the dark. The results were collected by MuseTM Cell
Analyzer (Millipore).
4.8. Caspase-3/7 Assay
The MuseTM Caspase 3/7 kit (Millipore) was employed for this experiment according to the
manufacturer’s instructions and our previously published method [22]. 1205Lu, UACC903, and
Sk-Mel-8 cells were seeded at a density of 4 × 105 cells/well and treated with DMSO or the indicated
amounts of compounds 1 and 3 for 24 h. Next, both floating and attached cells were collected, out of
which 50 μL of cells were stained with 5 μL of MuseTM Caspase-3/7 working solution and incubated
for 30 min at 37 ◦C with 5 % CO2. After incubation, 150 μL of MuseTM Caspase 7-AAD working
solution were added to each sample, and the samples were incubated in the dark for 5 min more. The
samples were analyzed by MuseTM Cell Analyzer.
4.9. Western Blotting
1205Lu, UACC903, and SK-Mel-8 cells (7 × 105 cells/well) were plated in 6-well plates and
treated with compound 1 or DMSO for 24 h. The cells were then collected, and whole cell lysates
were prepared in RIPA buffer (Thermo Scientific #89900; Rockford, IL, USA) supplemented with 1%
phosphatase inhibitor cocktail 2 (Sigma #P5726-5ML), 1% protease inhibitor (Complete mini, Roche
#11836170001; Branchburg, NJ, USA), and 0.5 % of 200 mM phenylmethanesulfonyl fluoride (PMSF)
(Sigma #P7626-250 mg). The cell lysates were spun at 15,000× g for 10 min to remove any insoluble
cell debris. The resultant supernatants were collected and stored at −80 ◦C until use. The whole cell
lysates were resolved by SDS-PAGE. The proteins were transferred to Immobilon®-P PVDF membranes
(Millipore # IPVH304F0) and blotted with the indicated antibody overnight at 4 ◦C. The dilution for
primary antibodies was 1:1000, with the exception of p-STAT3 (1:2000), STAT3 (1:200), and β-actin
(1:3000). Further, the membranes were incubated with the corresponding peroxidase-linked secondary
antibodies (dilution 1:3000) for 1–4 h at room temperature. The antibodies were detected by an
enhanced chemiluminescence reagent (Thermo Scientific #1856135 and #1856136).
4.10. Docking Methodology
Different 3D conformations of compound 1 were generated and energetically minimized using
the “Generate Conformations” tool in Discovery Studio (DS) 4.0 client (Accelrys). The lowest energetic
conformation thus obtained was subjected to the “Prepare Ligands” module to generate its isomers at
physiological pH. The CHARMm force field was employed to develop the partial atomic charges on
each atom of the isomer. The isomer with the lowest CHARMm energy was used for the docking study.
The X-ray co-ordinates of STAT3 (pdb id: 1BG1, resolution 2.25 Å) were retrieved from the protein
data bank (www.rcsb.org). The “Prepare Protein” tool in DS was used to add missing atoms/chains
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and remove water molecules in the protein structure. The “Prepare Protein” algorithm was employed
to protonate amino acid residues according to the physiological conditions. Prior to docking, a binding
sphere covering the SH2 domain of STAT3 was generated. CDOCKER [34], a grid-based docking
program, was used to dock compound 1 in the SH2 domain, considering the default parameters. The
most favorable pose of compound 1 was identified based on the CDOCKER energy (-CDE).
5. Conclusions
In conclusion, compound 1, a quinoxaline-isoselenourea, showed promising efficacy in vitro
against melanoma cells. Compound 1 was more effective than the isothiourea derivative 3 and the
reference drug PLX-4032, especially at short times of treatment (24 h). As demonstrated by the colony
formation assay, the effects of compound 1 in inhibiting cell proliferation were long-lasting. Overall,
we demonstrated for the first time that the cell growth inhibitory response of compound 1 may be
mediated through the STAT3 pathway as it does not inhibit other pro-survival signaling pathways
such as Akt and ERK1/2. On account of the fact that compound 1 inhibits STAT3, it could also
be employed in combination therapy with PLX-4032 to overcome acquired resistance to the latter.
Interestingly, the response to compound 1 was not dependent on the mutation status of BRAF. Only
about half of all melanomas have a mutation in the BRAF gene, and, therefore, compound 1, targeting
both BRAF-mutant and WT melanoma cells, may have a broader clinical impact. However, more
preclinical studies examining in vivo efficacy, Absorption, Distribution, Metabolism and Excretion
(ADME), toxicity, and mechanism of action are required to determine the therapeutic properties and
future clinical potential of compound 1.
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Abbreviations
AKT Protein kinase B
c-myc Avian myelocytomatosis virus oncogene cellular homolog
ERK1/2 Extracellular signal-regulated kinases 1 and 2
FBS Fetal bovine serum







STAT3 Signal transducer and activator of transcription 3
XIAP X-linked inhibitor of apoptosis protein
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